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Foreword 
Highly innovative products resulting from emerging technologies are usually 
accompanied by the generation of new terms, concepts and definitions, which may be 
used ambiguously by various stakeholders having diverse interests, coming from 
different backgrounds and/or various regions in the world. A typical example of 
generation of a new and complex terminology is the application of nanotechnology in 
health. Such nanotechnology based products - often called nanomedicines - can be 
based on a variety of materials, are unique in their design and can have specific size 
related physicochemical properties and biological effects. In recent years, the growing 
number of submissions of nanomedicines to regulatory bodies has led to the 
development of a new vocabulary in the regulatory domain which has not yet been 
harmonised between the various competent authorities worldwide. This can cause 
difficulties regarding the mutual acceptance of data requiring a clear understanding of 
the scientific/technical vocabulary by the various parties.  
The Nanomedicines Working Group of the International Pharmaceutical Regulators Forum 
(IPRF) acknowledged the relevance of terminology in the field and the need to map and 
compile the most relevant terms used in the regulatory domain. As a member of the 
working group, the European Commission's Joint Research Centre (JRC) has taken the 
lead to identify and describe the most relevant keywords used by various stakeholders. 
In order to obtain a bigger picture of currently used keywords in the field of 
nanomedicine, the JRC has applied automated text and tech mining tools for the 
identification of the relevant terms before manually extracting and compiling the most 
relevant terms used by the partners of the IPRF Nanomedicines Working Group in 2016. 
The present report aims to provide a useful basis for discussion among experts and 
efforts towards terminology harmonisation in the field of nanomedicine. It is outside the 
scope of this report to present an official terminology or glossary for nanomedicine.   
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Abstract 
A common terminology is essential in any field of science and technology for a mutual 
understanding among different communities of experts and regulators, harmonisation of 
policy actions, standardisation of quality procedures and experimental testing, and the 
communication to the general public. It also allows effective revision of information for 
policy making and optimises research fund allocation. 
In particular, in emerging scientific fields with a high innovation potential, new terms, 
descriptions and definitions are quickly generated, which are then ambiguously used by 
stakeholders having diverse interests, coming from different scientific disciplines and/or 
from various regions. The application of nanotechnology in health -often called 
nanomedicine- is considered as such emerging and multidisciplinary field with a growing 
interest of various communities.  
The Nanomedicines Working Group of the International Pharmaceutical Regulators Forum 
(IPRF) has been established in 2009 in order to discuss key issues related to the 
regulation of nanomedicines such as the definition of nanotechnology, standards, 
biocompatibility, risk/safety assessments and labelling. Since these objectives are also of 
interest for the European Commission's Joint Research Centre (JRC), the JRC has joint 
the group in 2015.  
In order to support a better understanding of terms used in the regulatory domain, the 
IPRF has prioritised the need to map, compile and discuss the currently used terminology 
of regulatory scientists coming from different geographic areas. The JRC has taken the 
lead to identify and compile frequently used terms in the field by using web crawling and 
text mining tools as well as the manual extraction of terms. Websites of 13 regulatory 
authorities and clinical trial registries globally involved in regulating nanomedicines have 
been crawled. The compilation and analysis of extracted terms demonstrated sectorial 
and geographical differences in the frequency and type of nanomedicine related terms 
used in a regulatory context. Finally 31 relevant and most frequently used terms deriving 
from various agencies have been compiled, discussed and analysed for their similarities 
and differences. These descriptions will support the development of harmonised use of 
terminology in the future. 
The report provides necessary background information to advance the discussion among 
stakeholders. It will strengthen activities aiming to develop harmonised standards in the 
field of nanomedicine, which is an essential factor to stimulate innovation and industrial 
competitiveness. 
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Glossary 
Term Definition 
Author keywords Author keywords are the keywords attributed by the authors to their 
publications and retrieved by the Tool for Innovation Monitoring 
(TIM) technology. 
Automatic 
keyword  
Automatic keywords are terms generated automatically by natural 
language processing algorithms from a bibliographic dataset created 
by the Tool for Innovation Monitoring (TIM) technology. 
Automatic Term 
Recognition 
Automatic Term Recognition focuses on the extraction of words and 
multi-word expressions that are significant for a given domain. The 
roots of Automatic Term Recognition date back to late 80s when 
the need for automatic extraction of terminological units from 
specialized texts became acute in various fields [4]. 
Bibliographic 
metadata 
Bibliometric study involves the analysis of bibliographic metadata 
linked to scholarly publications. Such metadata, which include 
authors' affiliations, associated keywords, funding and citation 
information, can be used to monitor trends in the scientific 
development of a research domain, determine the impact of 
research funding, compare research performance across different 
institutions, document changes in the research workforce, identify 
emerging areas of research focus and predict future research 
success [7]. 
Bibliographic 
search engine 
A bibliographic search engine is an information retrieval 
system designed to help find information stored on a bibliographic 
database. 
Expanded lexical 
query 
Expanded lexical query can help to identify records lying near the 
boundaries of emerging and legacy technologies. This step makes 
substantial use of precision and recall indicators rather than relying 
solely on expert judgment. 
Natural Language 
Processing (NPL) 
Natural Language Processing is a theoretically motivated range of 
computational techniques for analysing and representing naturally 
occurring texts at one or more levels of linguistic analysis for the 
purpose of achieving human-like language processing for a range of 
tasks or applications [3].  
Publications 
dataset 
Publications dataset is the name given in this report for the 
construction of a dataset of different types of publications (including 
article papers, grant reports and patents) related to a specific topic, 
e.g. nanomedicine, using the "Tools for Innovation Monitoring" 
(TIM) tool, developed by JRC. 
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Search string A search string is a combination of keywords, truncation symbols, 
and Boolean operators you enter into the search box of a library 
database or search engine [6].  
Term 
discrimination 
The term discrimination value of an index term has been proposed 
as a quantitative measure of the extent to which that term can 
discriminate between documents in bibliographic databases. 
Indicates to what degree a set of terms can aid to distinguish one 
scientific domain from others. 
Tech mining Tech mining is the application of text mining tools to science and 
technology information, informed by understanding of technological 
innovation process. Tech mining has roots in content analysis, 
bibliometrics and text mining [2]. 
Text mining Text mining is defined as the automatic discovery of new, previously 
unknown, information from unstructured textual data. This is often 
seen as comprising of three major tasks: information retrieval 
(gathering relevant documents), information extraction (extracting 
information of interest from these documents), and data mining 
(discovering new associations among the extracted pieces of 
information) [1]. 
Unstructured text  While structured data is readily available for information and 
knowledge extraction, unstructured information, for example 
obtained from a collection of text documents cannot be directly 
utilized for such purposes. Most text documents are written in an 
unstructured manner, so classification has to be done on the basis 
of attributes such as presence or absence of keywords and their 
frequency of occurrence [8]. 
Wildcard 
character 
It is a term modifier that allows the user to introduce flexibility in 
the terms used for a search. The character for wildcard is an 
asterisk ("*") and it is used to substitute any other character(s) in a 
string. 
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1 Introduction 
The application of nanotechnology in the health sector impressively demonstrates how 
new technologies can have an impact on society. The opportunities provided by 
nanotechnology in medicine were already envisaged by Richard Feynman in his lecture 
"There's Plenty of Room at the Bottom" given to the American Physical Society meeting 
at Caltech on December 29, 1959 [9]. Nanotechnology is now seen as an emerging tool 
in the health sector that offers many possibilities to revolutionize the healthcare sector 
through nanotechnology-enabled formulations in imaging, diagnostics, therapeutics, 
regenerative medicine and medical devices. There is an increasing trend of 
nanomedicines seeking for approval of clinical trials and market authorisations. 
Currently, the regulatory community is building expertise on how to best evaluate the 
next generation of nanomedicines and various regulatory bodies have published specific 
guidance. However, the terminology used in the various documents deriving from 
various regions is not always harmonised and as such can contribute to 
misunderstandings regarding the mutual acceptance of data in different countries [10]. A 
harmonisation of the regulatory practice for this new product class requires a common 
understanding of the terminology used by the various parties. 
In 2013, the OECD published the results of a survey aiming to provide information on 
regulatory approaches, legislative regimes and government-sponsored regulatory-
science research in food and medical products that involve the application of 
nanotechnology [11]. The report elucidates that nanotechnology based medical products 
are generally covered under existing national and/or regional legislative and regulatory 
frameworks for medical products. None of the 12 responding international regulatory 
authorities reported to have specific regulations for nanotechnology based medical 
products. However, some regulatory agencies, including the European Medicines Agency, 
have started to tailor the regulatory practice by publishing a variety of guidance for 
product developers addressing the evaluation of nanospecific properties in 
nanomedicines [12]. In addition, some regions are facing a substantial increase in the 
submission of nanotechnology based products aiming to enter into clinical applications or 
seeking market authorisation [13]. A harmonised terminology would facilitate the 
sharing of experiences and the development of common practices between authorities.  
Moreover, a mutual understanding of terms is essential for the communication between 
various stakeholders in order to enable information sharing, collaborative scientific work 
and common standards, as well as to assist industry in the translation of research in 
nanotechnology into clinical applications [14]. Satalkar et al. (2015) concluded that a 
clear and consistent definition of terminology in this area would contribute to generate a 
trusted environment among stakeholders (researchers, industry, clinicians, regulators 
and patients) and would be critical to foster an ethical research and transparent 
translational nanomedicine [14]. Tinkle et al. (2014) explained how regulatory 
communities are challenged by a confusion of definitions for nanomaterials and 
nanotechnology-enabled products and by limited standard nomenclature and lack of 
reference materials, also highlighting the importance of a common terminology in a 
harmonised regulatory approach [15]. However, there are only few regulatory relevant 
documents available which consider the application of nanotechnology for medical 
products, and most of the available glossaries refer to technical terms. Several national 
and international organisations have contributed to the terminology and standards for 
the application of nanotechnology in the health care sector e.g. British Standards and 
ISO (see section 2.2.3). These terminologies, harmonised or not, are intended to be 
used in broad contexts by the health sector, but definition of general terms, which may 
be needed in the regulatory landscape, may be lacking and may not always reflect the 
increase of terms and synonyms, and diversity of descriptions that regulators may 
encounter. 
 
 
 10 
 
 
The International Pharmaceutical Regulatory Forum (IPRF) has established a working 
group on nanomedicine to provide a platform for exchanging information and advance 
the regulatory science in this field. One objective of the IPRF working group is to 
establish a common understanding of the current terminology used by the involved 
regulatory bodies. The European Commission's Joint Research Centre has taken up the 
task to compile and map the terminology currently used by different stakeholders.  
Usually the construction and expansion of terminology in emerging scientific fields, such 
as nanomedicine, begin in scientific publications with terms that represent basic 
elements of knowledge concepts, followed by other areas needing terminology for 
communication, such as manufacturing, marketing, clinical research, regulatory practice 
or information to the general public [16][17]. The multidisciplinary nature and rapid 
evolution of nanomedicine also lead to the continuous generation of new terms, which, 
however, leads to ambiguity and confusion for existing definitions, both in the scientific 
and regulatory landscape. 
The aim of the JRC work was i) to develop an unbiased methodology allowing to monitor 
the growing terminology of an innovative field such as nanomedicine; ii) to describe in 
an unbiased manner the growing terminology in the emerging field of nanomedicine used 
by different stakeholders (scientists, regulators, industry) and iii) to select and describe 
the most frequently used terms by the various regulatory bodies.  
This information may provide a basis for future discussion of a harmonised or convergent 
terminology.  
In order to avoid any bias in the selection of the most relevant terms, tech and text 
mining methods, including the automatic extraction of terms used in the regulatory, 
clinical and patent landscape have been explored in this report. In addition, the report 
builds on previously developed methodologies, such as the use of modular keyword sets. 
These keyword1 sets have been used in the field of bibliometrics to analyse emerging 
trends of nanotechnology, to identify trajectories of nanotechnology publications and 
research funding sponsorships, as well as active nanotechnology research in the 
scientific literature [7]. The established keyword training set that is specific to 
nanomedicine, is covering two categories of terms: 1) general terms describing the field, 
and 2) specific terms1, describing scientific/technical terms for materials or final products 
used in the research or application of nanomedicine. The keywords were used as the 
main tool to identify the implementation of specific terminology and information on 
nanomedicine in relevant information sources, such as the regulatory authorities' 
websites.  
Aims and Objectives of this compilation 
Aims:  
- Development of an unbiased methodology allowing the extraction of terms with 
regulatory relevance in the innovative field of nanomedicine 
- Selection and description the most frequently used terms in regulatory documents 
Objectives:  
- Construction of a keyword set based on specialised scientific literature 
- Mapping the nanomedicine keyword set in information sources of regulatory relevance 
- Compilation of descriptions for a selection of terms from relevant documents 
 
                                           
1
The words keywords and terms are interchangeably words throughout this report. 
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2 Methodology 
2.1 Information sources 
2.1.1 Bibliographic databases  
Scientific literature and related documents, such as scientific articles and project reports 
are an excellent source of data and knowledge to describe any given scientific field, and 
therefore to be used in a first attempt to identify and retrieve a field-related terminology. 
The following databases were analysed: 
Scopus from Elsevier, a large bibliographic database of peer-reviewed 
scientific publications including scientific articles, reviews, book chapters and 
conferences proceedings (https://www.scopus.com/). This database was 
automatically and manually queried using a specific bibliometric program and 
the website search engine, respectively. 
PubMed, a large citation database specialised in biomedical literature from the 
U.S. National Library of Medicine (MEDLINE), life science journals, and online 
books. This database was queried using a specific bibliometric program for 
automatic keyword extraction. 
CORDIS, the European Commission's primary portal for results of EU-funded 
research projects published as briefs, report summaries and projects 
factsheets from Horizon 2020, Seventh Framework Programme and earlier 
funding programmes (http://cordis.europa.eu/). This database was queried 
using a specific bibliometric program for automatic keyword extraction. 
2.1.2 Regulatory authorities' websites 
The regulatory authorities' (RAs) websites are usually dedicated means of 
communication from regulators to health professionals and patients with the aim to 
inform on medical products. The medicines RAs websites have been also described as 
tools to contribute to the transparency of their procedures and activities to all 
stakeholders. These RAs websites provide access to diverse information on safety, 
efficacy, and quality of health care products, on regulatory requirements and guidance 
[22]. A complete understanding of the specific terminology used by these different 
organisations involved in the regulation of nanomedicine products is particularly 
important for a future harmonisation exercise, to enhance the discussion on this topic 
and strengthen a potential global regulatory convergence for nanomedicines. 14 
websites of regulatory agencies participating in the IPRF working group Nanomedicine 
have been explored by regulatory authorities in order to analyse the content and the use 
of specialised nanomedicine terminology (Table 1). 
 
 
 
 
 
 
 
 
 12 
 
 
Table 1. Regulatory authorities' websites explored in this study.  
Country 
Regulatory authorities Website 
(English version) 
Regulate or support regulation 
Australia Therapeutic Goods Administration (TGA) www.tga.gov.au Medicines 
Medical devices  
Cosmetics 
Biologicals 
Blood and tissues 
Brazil Brazilian Health Surveillance Agency (ANVISA) portal.anvisa.gov.br/english Medicines 
Medical devices 
Sanitizers 
Pesticides 
Food 
Cosmetics 
Blood, tissues and organs 
Tobacco 
Canada Health Canada, Health Products and Food 
Branch (HC) 
www.canada.ca Drugs 
Health Products 
Food  
European Union  The European Medicines Agency (EMA) 
 
Directorate General for Health and Food 
Safety (DG SANTE) 
www.ema.europa.eu/ 
 
ec.europa.eu/health/location_en 
Medicinal products for 
human and veterinary use 
 Directorate General for Internal Market, 
Industry, Entrepreneurship and SMEs (DG 
GROW) 
ec.europa.eu/growth/index_en Medical devices 
Japan Ministry of Health, Labour and Welfare 
(MHLW) 
www.mhlw.go.jp/english/ Pharmaceuticals 
Medical devices 
Pharmaceuticals and Medical Devices Agency 
(PMDA) 
www.pmda.go.jp/english/ 
Republic of Korea Ministry of Food and Drug Safety (MFDS) www.mfds.go.kr/eng Drugs 
Medical devices 
Food 
Agro-Livestock and Fisheries 
Biologics 
Cosmetics 
Russian Federation Roszdravnadzor (Federal Service for Control 
over Healthcare and Social Development) 
www.roszdravnadzor.ru/en Medicines 
Medical devices 
Singapore Health Sciences Authority (HSA) www.hsa.gov.sg/ Western medicine 
Medical devices 
Complementary Health Products 
Cosmetics 
Tobacco control 
Switzerland Swiss Institute of Therapeutic Products 
(Swissmedic) 
www.swissmedic.ch/swissmedic/
en/home.html 
Medicinal products 
Medical devices 
Taiwan Taiwan Food and Drugs Administration (TFDA) www.fda.gov.tw/EN/index.aspx Human drugs 
Medical devices 
Cosmetics 
Food 
United States of 
America 
U.S. Food and Drug Administration (FDA) https://www.fda.gov/ Drugs 
Medical devices 
Food 
Radiation-emitting products 
Vaccines, blood and biologics 
Animal and Veterinary 
Cosmetics  
Tobacco Products 
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2.1.3 Clinical trial registries database 
Clinical trials are defined as any research study that prospectively assigns human 
participants or groups of humans to one or more health-related interventions to evaluate 
the effects on health outcomes. Interventions include but are not restricted to drugs, 
cells and other biological products, surgical procedures, radiologic procedures, devices, 
behavioural treatments, process-of-care changes, preventive care, etc.2. Clinical trials 
are registered in specifically designed databases that serve as an information platform 
for researchers, clinicians, regulators, industry and patients. This information platform 
aims to improve transparency and data quality, avoid unnecessary duplication of studies, 
and foster collaboration. 
In order to capture the terminology that describes the application of nanotechnology for 
health products in clinical trials, the International Clinical Trials Registry Platform 
(ICTRP) that is hosted by the World Health Organisation (http://www.who.int/ictrp/en/) 
has been analysed. This platform gathers datasets of clinical trials from 17 international 
registries including relevant sources such as ClinicalTrials.gov, the European Union 
Clinical Trials Register and the Japan Medical Association Clinical Trials Register 
(JMACTR) (Table 2). 
Table 2. Registries and number of clinical trials containing nanomedicines 
Registries Websites N° of clinical trials with 
nano-terms 
Australian New Zealand Clinical Trials Registry www.anzctr.org.au 19 
Brazilian Clinical Trials Registry (ReBec) www.ensaiosclinicos.gov.br 4 
Chinese Clinical Trial Register www.chictr.org.cn/abouten.aspx 47 
ClinicalTrials.gov www.ClinicalTrials.gov 464 
Clinical Trials Registry - India www.ctri.nic.in 28 
EU Clinical Trials Register www.clinicaltrialsregister.eu 96 
German Clinical Trials Register www.germanctr.de 9 
Pan African Clinical Trial Registry www.pactr.org 3 
Thai Clinical Trials Registry www.clinicaltrials.in.th 5 
The Netherlands Trial Register (NTR)* www.trialregister.nl/ 23 
Data retrieved in November 2016. *Clinical trials registered under NTR identification have been annotated 
under EudraCT registry after this analysis, where text mining for the prefix "nano*" was performed, 
including using term modifiers such as wildcard characters ("*" or "?") and Boolean operators (AND, OR, 
NOT). 
This database offers information on clinical and interventional trials of several products 
including drugs, cells and other biological products, surgical procedures, radiologic 
procedures, devices, behavioural treatments, process-of-care changes, preventive care 
or environmental epidemiological studies. Also, ICTRP uses an unambiguous trial 
identification to avoid duplication of the registration of results, i.e. trials that are 
registered in more than one registry database. Another reason for the selection of this 
database was the easiness to manually extract information using the website’s search 
engine. ICTRP allows the manual search for the prefix "nano*" using term modifiers such 
as wildcard characters ("*" or "?") and Boolean operators (AND, OR, NOT). This 
facilitates the extraction of nano-prefixed terms and the exclusion of unwanted terms. 
The data from ICTRP was retrieved in November 2016. 
2.1.4  Patent database 
Patent databases are an important source of information as state-of-the-art information 
for the development of new products, for exploring responses to technical problems or 
                                           
2 http://www.who.int/ictrp/en/ 
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for regulators and policy makers to improve their national innovation systems, for 
example investing in new innovation infrastructures or targeting research funding 
programs [18]. The structure of these technical documents are similar to scientific 
publications, including an abstract, background information on the technology patented, 
methodology, and bibliography related with the technology. Patent information on 
nanomedicine products may include description of the composition, production methods, 
targeting, or methods of use [19].  
 
 
  EPO-PATSTAT  
EPO-PATSTAT, a database that contains bibliographic and 
legal status data on published European and Euro-PCT (Patent 
Cooperation Treaty) patent applications launched by the 
European Patent Office (EPO) in 2016 
(https://www.epo.org/searching-for-
patents/business/patstat.html). This database was queried 
using a specific bibliometric program for automatic keyword 
extraction. This database was queried using a specific 
bibliometric program for automatic keyword extraction. 
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Figure 1 Overview of the methodological approach  
 
§Relevance refers not only to the assessment of weight of a given term in the pool of scientific publications but also to terms that are not highly frequent but still considered 
as relevant for the ongoing discussion. The report refers in particular to terms that are mentioned by specific regulatory agencies but not present in others (e.g. 
nanosimilars). RA= regulatory authorities and agencies
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2.2 Data collection and analysis 
The applied methodology consisted of three steps illustrated in Figure 1: 1) building a 
“keyword set” via automatic and manual extraction of keywords relevant to 
nanomedicine from specialised scientific literature (bibliographic databases and European 
patents); 2) applying the identified keyword set for mapping and analysis of the 
nanomedicine keyword set in documents that have relevance in a regulatory landscape, 
such as those available from regulatory authorities’ websites and clinical data registries, 
and 3) manual selection and compilation of descriptions for a selection of relevant terms 
from information sources with regulatory relevance. 
Due to the nature of the methods and tools used to extract and map the nanomedicine 
keyword set, the following types of information sources in the different steps have been 
explored (Figure 1). Information on the time period of the data collection and analysis 
is summarised in Table 3. 
Table 3. Overview of data collection and analysis timeline by source 
2.2.1 Step 1: Keyword extraction and keyword set construction 
The first step in this methodological approach aims to identify a set of keywords related 
with nanomedicine in an unbiased manner, which is used as a tool to explore the impact 
of nanomedicine terminology in the various information sources with regulatory 
relevance. In order to build a reliable keyword set on nanomedicine, a combination of 
techniques and tools used in the field of bibliometrics have been applied [20, 21].  
A specialised dataset of documents has been created by using the Tools for Monitoring 
Innovation (TIM) technology editor and GoPubMed as bibliographic search engines. The 
dataset has taken a 20 years publication period (from 1996 to 2016) into account which 
included scientific publications, EPO patents and project reports from bibliographic 
databases containing the keyword "nanomedicine*" either in the title, abstract, author 
keyword list or in the text corpus. The application of automatic term recognition 
algorithms on the metadata (e.g., title, author keyword list, abstract) and body text of 
the specialised documents aids to harvest a list of the most relevant and frequent 
Source Tool Process Period 
Bibliographic sources: 
Scopus database, 
CORDIS, EPO-PATSTAT 
Tools for Innovation 
Monitoring (TIM): TIM 
technology editor 
Publication dataset creation 
Automatic keyword extraction 
Year of publication 1996-
2016 
October 2016 
Bibliographic sources: 
 PubMed database 
GoPubMed Automatic keyword extraction October 2016 
Bibliographic sources: 
Scopus database 
Website advance search 
engine 
Manual keyword extraction 
from review articles 
October 2016 
Regulatory authorities 
websites 
Web crawlers Web crawling and data 
collection 
June 2016- March 2017 
Text mining Term descriptions collection November 2015- June 2017 
Clinical trials registries Website advance search 
engine 
Semi-automatic keyword 
extraction 
November 2016 
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terminology, that allows to profile this field and create an initial nanomedicine-specific 
keyword set. Ideally, this nanomedicine keyword set should contain specific nano-
prefixed terms, specific non nano-prefixed terms and multiword terms describing 
materials, processes or areas of application of this field. 
Then, to complement this initial keyword set, a literature review and manual extraction 
of keywords from the most cited reviews on the topic (according to the CiteScore3 
function from Scopus) aiming to capture additional terms used to define nanomedicine 
products or materials has been performed.  
2.2.1.1 Automatic keyword extraction 
The automatic keyword extraction is defined as the process of identifying sets of 
keywords (single words or multiword terms) from a document, which can characterise 
the topic addressed in that document. The process of automatic keyword extraction used 
in this study is shown in Figure 2 and is partly based on an expanded lexical query 
methodology as applied in previous works to assess emerging sciences and technologies 
[22]. Using two bibliographic search engines (see below), several bibliographic 
databases (section 3.1.1) with a general search string have been queried (i.e., 
"nanomedicine*", the wildcard "*" was used to capture term variants). By identifying 
this search string in the bibliographic metadata (i.e., title, abstract, author keyword list) 
or in the text corpus of the documents, these tools create a specialised (or topic-
targeted) dataset of documents (1 in Figure 2). On this target document dataset, called 
in this report "publications dataset", these tools apply automatic term recognition 
algorithms on the bibliometric metadata resulting in a list of the most frequent and 
relevant terminology profiling this topic (2 in Figure 2). To generate a reasonable 
representation of the topic terminology, when possible, a cut off of the top 100 keywords 
was applied resulting from the automatic extraction of keywords present in the 
publications dataset (3 in Figure 2).  
Figure 2. Process of automatic keyword extraction 
 
Description of the process for keyword extraction using bibliometric search engines: 1) query of bibliographic 
databases using specific search strings (e.g. nanomedicine*) resulting in a number of topic publications that 
form the publications dataset; 2) application of algorithms to extract topic keywords; 3) manual extraction of 
top 100 frequent (hit counts) or relevant keywords (see 0). 
2.2.1.2 Bibliographic search engines 
One component of the selected methodology was the identification of appropriate 
bibliographic search engines to survey the bibliographic databases listed in section 2.1 
(i.e. Scopus from Elsevier, PubMed, and CORDIS). The selection criteria were: first, the 
search engines should be able to explore databases specialised in the field of interest, 
and second, they should include a tool for automatic extraction of keywords associated 
to the search results as well as provide quantitative data on keyword occurrence (hit 
counts: number of documents including a given keyword in its metadata).  
As a result, two online search engines have been selected: 1) Tools for Monitoring 
Innovation (TIM) technology editor, an online search engine developed by the JRC for 
European Commission staff member that allows its users to create and visualise datasets 
                                           
3 https://www.elsevier.com/solutions/scopus/features/metrics 
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about specific technological issues. This tool gathers together datasets such as patents, 
scientific publications, and EU grants (www.timanalytics.eu); 2) GoPubMed, a public web 
server which allows users to explore information from scientific publications in PubMed 
[23]. Each search engine provided a means of extracting nanomedicine-related terms in 
a distinct way and gave useful information for other components used in this study. Both 
programs combine full text analysis (identification of topic related keywords) and 
traditional bibliometrics methods (quantitative analysis of publications, citation analysis, 
or calculation of keyword frequency in the dataset). TIM also facilitates the visualisation 
of the keyword extraction results through word maps, also called keyword co-occurrence 
networks (KCO). 
The methodology followed to extract keywords was the same for the two search engines 
(Figure 2). The list of keywords is presented either by how frequently they appear in 
these documents (hit counts) and/or, as in the case of TIM, by their relevance 
(estimated weight/importance of some keywords within the pool of the documents in the 
specific dataset). 
Using TIM, also relevant terms for the search string "nano* AND medical devices" in 
addition to "nanomedicine*" were extracted. 
0 contains supplementary information on these bibliographic search engines and the lists 
of keywords extracted with TIM and GoPubMed. 
2.2.1.3 Manual keyword extraction 
A manual keyword extraction was performed to complement the initial keyword set 
resulting from the use of the search engines TIM and GoPubMed, especially to capture 
terms that describe nanomaterials or molecular entities used in the field of 
nanomedicine. The manual extraction of keywords was applied to a number of review 
publications selected through a dedicated literature search. These types of publications 
usually summarise the state-of-the-art on a topic and provides lists of terms and 
descriptions of the type of materials under investigation. They were therefore chosen to 
extract keywords characterising the investigated nanomaterials or the medicinal 
products containing nanomaterials that are used, which are not commonly extracted by 
engines.  
In order to select a list of reviews on nanomedicine, the bibliographic database Scopus 
with the same search string as for the automatic keyword extraction (i.e. 
"nanomedicine*") was queried and 50 review publications were identified. These review 
publications met the following three criteria: i) reviews with the highest number of 
citations; ii) reviews with open access to the full text; iii), publications that provide an 
explicit list of nanoscale materials or molecular entities in the body of the publication 
(e.g., tables or figures containing terms that describe materials, such as dendrimers, or 
liposomes, or terms to describe material classes, such as inorganic nanoparticles, or 
polymer based nanocarriers). The terms of interest were manually extracted from these 
publications, applying expert judgement, and are listed in 0 (Table 18). 
2.2.1.4 Keyword sets construction 
To be able to map the information sources, two keyword sets were constructed and 
applied depending on the type of mapping approach. A comprehensive keyword set was 
constructed for automatically map the regulatory authorities using text mining tools; a 
second reduced keyword set was built to explore those information sources where, due 
to technical limitations, a manual search using search engines had to be performed 
instead. This reduced keyword set was also used for the compilation of descriptions. 
In order to construct the keyword set for automatic mapping, keywords that have been 
automatically extracted from publications datasets with the search engines TIM and 
GoPubMed (List of keywords in 0) were merged with keywords manually captured from 
the literature search on reviews in Scopus (0). 
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The cut off value considered the top 100 most frequently occurring author keywords and 
relevant keywords (0: Table 11 and Table 12, respectively) extracted automatically 
with TIM using "nanomedicine*" as search string and complemented with top 100 author 
and relevant keywords extracted with the search string ("nano* AND medical devices") 
in a 20 years publication range (from 1996 to 2016) (0: Table 13 and Table 14). The 
selection of the 100 top frequent terms cut off was based on results from previous 
bibliometric studies for research domain analysis [16]. These lists of terms were merged 
and complemented with the list of terms extracted from GoPubMed querieng 
"nanomedicine*" as search string (0: Table 15 and Table 16). Then, the terms 
retrieved from the manual extraction were added (0: Table 17). The merged list was 
consolidated eliminating duplicates and particular plural forms (for those cases in which 
the meaning of the terms were not affected by their plural form). Expert judgement was 
applied to eliminate general terms not specific for nanotechnology and to ensure the 
inclusion of some specific terms. 
Although the use of text-mining tools for mapping of regulatory authorities' websites, in 
step 2, allowed easily parsing nano-prefixed terms in a text corpus, the keyword set was 
adjusted including specific nano-prefixed terms to reduce the identification of nano-
prefixed terms that are unspecific to the health sector during the mapping exercise. For 
example, many regulatory agencies surveyed in this study in step 2 also address 
nanotechnology products for applications other than nanomedicine, such as cosmetics or 
foods, and a general search for "nano*" may retrieve many terms that are not specific to 
nanomedicine. General nano-prefixed terms referring to metrics, such as nanometre or 
nanomolar, were excluded from this final keyword set. 
A reduced keyword set, for manual mapping, was built considering the term frequency 
results from the extraction of publications dataset's keywords and from the analysis of 
terminology in the regulatory agencies. These terms were either more frequently 
mentioned in the regulatory authorities' websites analysed in the following Step 2, or 
relevant because their uniqueness, i.e. terms used by only one specific regulatory 
authority. As in the comprehensive keyword set, the reduced keyword set includes nano-
prefixed and non nano-prefixed terms.  
2.2.2  Step 2: Methods for mapping nanomedicine terminology 
In the context of this report, mapping refers to the process of mining, identification and 
analysis (term frequency and/or term relevance) of the use of nanomedicine-related 
terms in various sources of information with regulatory relevance. 
In step 2, text mining and bibliometric methods were applied, such as analysis of 
keyword occurrence frequency and the mapping of selected nanomedicine-related terms 
in different technical documents with regulatory relevance. Raw texts were extracted 
from a selection of regulatory authorities' websites using web crawlers creating a 
websites documents dataset, which was then searched by the keyword set generated in 
step 1 to produce a list of matching documents for each term of the keyword set. In 
addition, keywords from the clinical trials registries database were manually extracted by 
using the advanced search engines offered by the databases, as it was not possible to 
extract raw data from these two databases. This section details the methodology 
followed in each approach. 
It is important to point out that this report does not aim to show a quantitative mapping 
of terminology, but a semi-quantitative representation of the type and use of 
nanomedicine terminology in diverse sources of information.  
In order to map the use of nanomedicine terminology in the regulatory landscape, 
unstructured text were extracted from 14 health-related regulatory authorities' websites 
participating in the Nanomedicine working group of the IPRF. The criteria to select these 
websites were: first, these regulatory agencies either regulate medicinal products, 
medical devices or both, and second, the websites provided information in English. The 
names and links of these authorities were obtained from the IPRF's website 
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(https://www.i-p-r-f.org/index.php/en/members/). In addition, the websites of two 
departments of the European Commission, the Directorate-General for Health and Food 
Safety (DG SANTE) and the Directorate-General for Internal Market, Industry, 
Entrepreneurship and SMEs (DG GROW), were considered as they are responsible for EU 
policies on health products. Table 1 in section 2.1.2 lists the regulatory authorities' 
websites surveyed in this study and the type of products that they oversee and regulate. 
The described two-step approach for exploring the use of nanomedicine terminology in 
the regulatory authorities' websites is based on methodologies applied in previous 
bibliometric studies aimed to understand emerging technologies [24]. First, text-mining 
tools to extract unstructured information from the websites of interest were used. 
Second, the data generated in the previous step was queried with the keyword set 
constructed in step 1 to locate nanomedicine terms as well as calculate their occurrence 
in the text. 
2.2.2.1 Web Crawling and metadata extraction  
Using two different web crawlers, WinHTTrack WebSite Copier and Crawler4j, retrieved 
raw text from several document file formats including HTML, XML, MS Word, MS 
PowerPoint, MS Excel and PDF, posted in the selected regulatory authorities' websites 
were retrieved. 13 regulatory authorities' websites were successfully crawled but the 
crawling tools failed to extract information from the Japan's Pharmaceuticals and Medical 
Devices Agency (PMDA) due to technical problems with the translated English version. It 
cannot be excluded that the web crawlers might have failed to extract clear text from 
other websites in which English was not the official language. 
2.2.2.2 Keyword set matching and analysis  
Once the metadata from the regulatory authorities' websites was extracted, a series of 
analyses were undertaken to evaluate the information on nanomedicine provided by 
these platforms. For the data analysis, the number of documents (referred in this report 
as term frequency or hit counts) were calculated for a given keyword in the keyword set 
for each regulatory authority website as well as the frequency of the term within the 
total number of documents per regulatory authority website. The current report aims to 
describe the amount and the type of information provided on nanomedicine by each 
regulatory authority, capture the most frequently used nanomedicine-related terms, and 
identify those terms that were uniquely used by a particular regulatory authority. To 
assess the quality of the results and the type of information provided, manual text-
mining was performed for relevant terms. This validation was especially appropriate for 
terms that were unique to certain authorities. 
2.2.2.3 Mapping in clinical trials registries 
Due to the technical challenges to crawl the data available from the International Clinical 
Trials Registry Platform (ICTRP) (see section 3.1.1), the ICTRP website's advanced 
search engine was used to explore the use of nanomedicine terminology in the ICTRP. 
Since it was clear that materials, products, or research procedures described in the 
ICTRP would correspond exclusively to the health sector to identify nano-prefixed terms 
the advance search engine was queried with the string nano*. In order to map the use of 
non nano-prefixed terms, a reduced keyword set similar as performed in [25] (see  
Table 5) was manually introduced into the advance search engine. In this case, the 
number of trials found for each term is regarded as hit counts.  
 
Figure 3 shows an example of the mapping approach used for the term liposome. 
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Figure 3. Screenshot of the ICTRP Search Portal results webpage using "liposome" as search 
string 
 
Source: http://apps.who.int/trialsearch/Default.aspx (screenshot taken on February 2018) 
To identify nano-prefixed terms, the database was queried to find terms in the clinical 
trial summaries matching "nano*". The extensive search resulted in many unspecific 
terms, including terms indicating metrics (e.g. nanometre, nanomole, nanogram or 
nanosecond), product names (e.g. NanoKnife®, Nanotube®, NanOss Bioactive, or 
Nanette™), companies' names (e.g. Nanotherapeutics, Inc., Nanos Tim, Inc., Nano Bio 
Corporation, or NanoString Technologies, Inc.) and terms describing methodologies or 
techniques (e.g. Nanofiltration, or Nano-scintillator). These unspecific terms were 
excluded from this analysis. The remaining terms found in this search were analysed and 
the number of clinical trial registrations matching each reported term were calculated. As 
in the analysis of the publications dataset performed in step 1, each clinical trial 
document/registration extracted was considered as a hit count to estimate the term 
occurrence. Particle size description of the material under research is unavailable in most 
of the clinical trials registered; therefore, this analysis was based on the assumption that 
the materials described with a nano-prefixed term were at least smaller than 1,000 nm, 
based on the working definition of nanomedicine used at the European Medicines Agency 
(0: Table 20), the working definition of nanomaterial suggested by the U.S. Food and 
Drug Administration (0: Table 22), and the definition of synthetic nanoparticles present 
in medicinal products suggested by Swissmedic (0: Table 26). 
2.2.2.4 Mapping in patent databases 
The publications dataset extracted with the TIM tool includes also patents from EPO-
PATSTAT which contain the keyword nanomedicine in their information. The analysis with 
TIM also reported the term frequency of the automatically retrieved keywords in these 
specific documents (see section 3.1.1) through language processing algorithms (step 1, 
section 3.2). See results in section 3.2.4. 
2.2.3  Step 3: Methodology for collection of term descriptions  
The compilation of term descriptions or definitions was performed by manually searching 
terms from the reduced keyword set (Table 5) in the regulatory authorities' websites, 
previously mapped, and other relevant sources including specialised glossaries or 
scientific publications.  
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As previously proposed in other glossaries or terminologies4, this report classifies terms 
in two categories: general terms referring to terms that describe the field of 
nanomedicine and specific terms to describe molecular entities, structural entities or 
methodologies used in the application of nanotechnology in medicine. 
2.2.3.1 Manual collection of descriptions from regulatory authorities' websites 
Regulatory authorities' websites are an important source of information to identify terms 
and descriptions within a regulatory context. In addition to mapping the nanomedicine-
related keyword set automatically, descriptions of the selected terms were also manually 
retrieved by using the search function at the same webpages.  
Many regulatory authorities assess and monitor activities related to products other than 
health care products, such as food, cosmetics, or tobacco that also benefit from the 
application of nanotechnology. In this report only those descriptions or definitions that 
apply to the regulation of health products were selected. Care was taken to exclude 
documents and terminology exclusively related to such other topics during the mapping 
and descriptions collection, and, when available, an advanced search engine to refine the 
search was used. Also, when information from English language websites was scarce, a 
search in Google or/and Google Scholar was performed, indicating the regulatory 
authority's name/abbreviation and the term of interest (e.g. search string: "FDA Taiwan 
AND nanomedicine*"). 
2.2.3.2 Manual collection of descriptions from other sources 
Terms describing materials or formulations within the regulatory authorities' websites 
generally lacked descriptive information. To fill this gap, descriptions from existing 
health-related terminologies, vocabularies, glossaries, and scientific ontologies, both 
standardised and not standardised were extracted. Table 4 summarises the information 
about the sources referred in this section. 
2.3 Internationally activities contributing to a standardised 
terminology  
Several national and international organisations are developing terminology and 
standards for the application of nanotechnology in the health care sector. In 2007, the 
British Standards Institution (BSI) published a Publicly Available Specification (PAS) on 
terminology for medical, health and personal care applications of nanotechnology (PAS 
131). A PAS is published to respond to an urgent market need, representing either the 
consensus of the experts within a working group, or a consensus in an organization 
external to ISO. PASs are published for immediate use and also serve as a means to 
obtain feedback for an eventual transformation into an International Standard. PASs 
have a maximum life of six years, after which they can be transformed into an 
International Standard or withdrawn5.  
In 2011, ISO published a new document entitled Nanotechnologies -- Vocabulary -- Part 
7: Medical, health and personal care applications (ISO/TS 80004-7:2011) as part of a 
series of documents on nanotechnology-related vocabulary. This document refers to the 
use of nanotechnologies in medical diagnostics and therapeutics, terms related to the 
exploitation of material features for diagnostic or therapeutic purposes in relation to 
human disease. Aware of the need of a standard terminology in the field of 
nanomedicine, ISO also drafted a technical report on Nanotechnologies-Framework for 
identifying vocabulary development for nanotechnology applications in human healthcare 
that pursued to provide a taxonomic framework for the development of vocabulary for 
clinical applications in human healthcare (ISO/TR 17302, 2015). 
                                           
4 http://www.who.int/ipcs/methods/harmonization/areas/terminology/en/ 
5 https://www.iso.org/deliverables-all.html#PAS 
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2.3.1 Glossaries and non-standardised terminologies  
In recent years, much effort has been undertaken to develop controlled vocabularies6 
and scientific ontologies in biomedical fields. Terminology standardisation and data 
handling are both included as informatics components, which are essential to 
nanotechnology data-sharing and interdisciplinary communication. They enable easier 
data and protocol storage, information retrieval and modelling of data output. 
In nanoinformatics, ontologies can be considered as a semantic framework representing 
also the nanomedical domain. The National Center for Biomedical Ontology has created 
BioPortal (http://BioPortal.bioontology.org), which is an open repository of biomedical 
ontologies that provides web-access to ontologies developed in different computer 
languages (e.g. OWL, RDF, OBO format and Protege frames). As the number of 
biomedical ontologies increases, so does the number of repositories that index and 
organize ontologies. BioPortal has indexed biomedical data sets available online such as 
ClinicalTrial.gov with ontologies in BioPortal. Considering BioPortal’s wealth of 
information on descriptions for nanomedicine-related terms and aiming to complement 
the compilation of descriptions captured in documents relevant for regulatory purposes, 
BioPortal was used to extract descriptions of selected terms. 
Table 4. List of terminologies, scientific ontologies and vocabularies used in Step 3 to manually 
collect term descriptions from other sources than regulatory authorities' websites 
Source 
terminology 
/ontology 
Acronym Website Description 
International 
Organization for 
Standardization 
ISO www.iso.org ISO is developing standards for terminology and nomenclature in the field 
of nanotechnologies under the technical committee ISO/TC 229 
(Nanotechnologies). This TC is developing a series of vocabulary documents 
on nanotechnology, the ISO/IEC 80004 series: Nanotechnologies — 
Vocabulary. This series includes ISO/TS 80004-7:2015, Nanotechnologies — 
Vocabulary — Part 7: Medical, health and personal care applications, 
currently under preparation. 
British Standards 
Institution 
BSI www.bsigroup.com A Publicly Available Specification (PAS) is published to respond to an urgent 
market need, representing either the consensus of the experts within a 
working group or a consensus in an organization external to ISO. As with 
Technical Specifications, PASs are published for immediate use and also 
serve as a means to obtain feedback for an eventual transformation into an 
International Standard. PASs have a maximum life of six years, after which 
they can be transformed into an International Standard or withdrawn. 
NanoParticle 
Ontology 
NPO purl.bioontology.org/
ontology/NPO 
An ontology that represents the basic knowledge of physical, chemical, and 
functional characteristics of nanotechnology as used in cancer diagnosis and 
therapy (description in BioPortal). 
 
 
 
 
 
                                           
6 Controlled vocabularies are list of terms created to facilitate knowledge organisation (indexing) and 
information retrieval, e.g. MeSH (Medical Subject Headings in the U.S. National Library of Medicine: 
https://www.nlm.nih.gov/mesh/) 
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Table 4 (cont.) 
Source 
terminology 
/ontology 
Acronym Website Description 
U.S. National 
Cancer Institute 
Metathesaurus 
NCIm ncim.nci.nih.gov/ncim
browser/ 
Biomedical terminology database that covers most terminologies used by 
NCI for clinical care, translational and basic research, and public information 
and administrative activities (NCIm webpage). 
National Cancer 
Institute 
Thesaurus 
NCIt ncit.nci.nih.gov/ncitbr
owser/ 
Reference terminology for many NCI and other systems. It covers 
vocabulary for clinical care, translational and basic research, and public 
information and administrative activities (NCIt website). 
Computer 
Retrieval of 
Information on 
Scientific 
Projects 
Thesaurus 
CRISP www.nlm.nih.gov/res
earch/umls/sourcerel
easedocs/current/CSP
/ 
A terminology used for indexing biomedical information. It was developed 
by the National Institutes of Health for use in the CRISP database of 
research projects funded by the U.S. Public Health Service (PHS) (Source: 
CRISP website). 
Medical Subject 
Headings 
MeSH www.nlm.nih.gov/me
sh/ 
Hierarchically-organized terminology for indexing and cataloguing of 
biomedical information from various databases including 
MEDLINE/PubMed, other NLM databases as well as RxNorm database, and 
managing the curation of the UMLS and Snomed CT database (Source: 
MeSH website). 
Chemical Entities 
of Biological 
Interest 
Ontology 
CHEBI www.ebi.ac.uk/chebi A freely available dictionary of molecular entities focused on ‘small’ 
chemical compounds (Source: CHEBI webpage). 
Neuroscience 
Information 
Framework (NIF) 
Standard 
Ontology 
NIFSTD purl.bioontology.org/
ontology/NIFSTD 
A set of modular ontologies that provide a comprehensive collection of 
terminologies to describe neuroscience data and resources (Source: NIFSTD 
website). 
Physician Data 
Query 
Terminology 
PDQ www.cancer.gov/publi
cations/pdq 
Online source of cancer information that is developed and maintained by 
the National Cancer Institute (NCI). It contains cancer information 
summaries on a wide range of cancer topics; drug information summaries 
on many cancer-related drugs and drug combinations; and dictionaries of 
general cancer terms, drug terms, and genetics terms (Source: PDQ 
website). 
 
 
In this report, the Medical Dictionary for Regulatory Activities (MEDDRA), a medical 
terminology developed by the ICH [International Conference on Harmonisation] to 
facilitate sharing of regulatory information internationally for medical products used by 
humans7 was consulted; however, this dictionary does not include any of the selected 
terms. Using the MEDDRA search engine from its website, no nano-prefixed terms 
indicating the application of nanotechnology could be identified even if cross-checked by 
querying the MEDDRA ontology displayed in bioportal.org.  
                                           
7 http://www.ich.org/products/meddra.html 
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3 Results 
3.1 Step 1: Construction of a nanomedicine keyword sets 
3.1.1 Bibliometric analysis: capturing keywords in bibliographic 
sources 
Querying TIM datasets using the search string "nanomedicine*" yielded a publications 
dataset of more than 7000 documents (data from 1996 to 2016), in which 98% were 
scientific publications from Scopus, and the remaining 2% were documents retrieved 
from the EU research projects platform (CORDIS) and patents (EPO-PATSTAT) (Figure 
4). When applying algorithms for automatic keyword recognition to this dataset, TIM 
automatically extracted keywords from different sections in these publications (title, 
abstract, author keywords, and full text) resulting in a large pool of emerging 
terminology referring to the field of nanomedicine. 
Figure 4. Screenshot of TIM describing the publications dataset for nanomedicine 
 
The bars represent the yearly distribution of publication records matching the search string "nanomedicine*" 
for the period of 1996 to 2016. The different colours identify the type of documents: scientific articles (green), 
book chapters (orange), conference proceedings (light blue), European granted projects (dark blue) and EPO 
patents (red). The pie chart on the left shows the type of document distribution in the publications dataset. 
Source: http://tech.timanalytics.eu 
3.1.1.1 Terminology expansion 
From the publications dataset, 13084 author keywords were identified. These author 
keywords included spelling variants for each term, for example plurals (e.g., 
nanomedicines), use of capital letters (e.g., Nanomedicine), and use of hyphenation 
(e.g., Nano-medicine), therefore the list of genuinely different keywords would be 
significantly shorter. A general analysis of the use of nano-prefixed author keywords in 
the period 1996 to 2016 in the publications dataset showed that the number of scientific 
articles on nanomedicine increased as did the specialised terminology (Figure 5, blue 
line). This growth of nanomedicine records has been noted in many bibliometric studies 
when studying the evolution of terminology in nanotechnology [17].  
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Figure 5. Number of total scientific articles on nanomedicine and number of nano-prefixed author 
keywords by year of publication 
 
In this period the number of scientific articles records mentioning the term nanomedicine continuously 
increased (blue line). The use of nano-prefixed terms showed a pronounced increase in the years 2006, 2011 
and 2014, growing year by year and contributing to the expansion of a specialised terminology (green bars). 
Source: TIM (search string: "nanomedicine*" information source: Scopus) 
 
This emergence of specialised terminology in the field was also confirmed through the 
term frequency analysis (number of documents with a given term), in which a few terms 
seemed to consolidate across the scientific articles although there was still a consistent 
generation of new terms (Annex2).  
This expansion of terminology in an innovation field can be visualised in the keyword co-
occurrence network (KCO) (Figure 6). This network represents the 13084 author 
keywords (nodes) and 6297 co-occurrences or connections (edges) extracted from the 
publications dataset. Only few keywords, usually well established, general terms 
(nanomedicine, nanotechnology, nanoparticle, or drug delivery, theranostics or 
nanobiotechnology), are highly connected within the network. 
 
Result 1: Frequency of author keywords used in the scientific 
literature 
From more than 7000 scientific documents containing 13084 author keywords: 
— More than 90% were mentioned in less than 5 scientific documents, 
— Approximately 78% of these terms were used only in one scientific article, 
— 2% were present in more than 10 documents, and out of these 20% were nano-
prefixed terms, 
— Only a few terms were used as author keywords in more than 100 scientific articles 
(i.e., drug delivery, nanoparticle, nanotechnology, cancer, and liposomes) (see 
Annex 2) 
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Figure 6. Term map related to the topic of nanomedicine. A. Network representing all author 
keywords extracted with TIM; B. Network of author keywords present in more than 50 scientific 
articles. 
 
Each node represents a different keyword in the publications dataset, and the size of the nodes size is 
proportional to the respective keyword's frequency (number of documents mentioning a given author 
keyword); the edges represent the connection among keywords that are mentioned in the same documents, 
and the thickness of the edges represents the co-occurrence of the linked nodes (number of documents sharing 
keywords). In this case the different colours of the nodes do not reflect clear subtopics. Orange and red nodes 
are keywords that have been listed in at least 2 papers as author keyword; nodes of other colours, and placed 
in the network's outside, are keywords mentioned only in 1 paper. The network on the top (Figure 6, A) 
represents the KCO of all the author keywords extracted from the publications dataset. Keywords present in 
less than 5 documents correspond to the 86% of the total number of connections, which points out the 
expansion of the terminology in this field. Source: TIM (http://tech.timanalytics.eu; search string: 
"nanomedicine*") 
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The list of the most frequently occurring author keywords (source: TIM) indicates the 
direction of the current research activities and can provide some foresight information on 
the nanomedicine field (0).  
The top 50 most frequent author keywords in the publications dataset (Figure 6, B) 
included general terminology (nanomedicine, nanotechnology, or nanoscale) and specific 
terms describing the main applications of nanomedicine, potential targeted diseases, 
types of nanomaterials and nanotechnology-based products. For example, the term drug 
delivery was the most frequent author keyword mentioned in approximately 10% of the 
scientific publications; the terms cancer and cancer therapy were referenced in 5% of 
scientific articles in the dataset. This list also includes keywords related to the type of 
materials already in use or under research such as liposomes, carbon nanotubes, gold 
nanoparticles, silver nanoparticles, quantum dots, magnetic nanoparticles, dendrimers or 
nanocarriers. Other applications of nanomedicine identified in this list were for example 
theranostics, imaging, gene therapy, tissue engineering or regenerative medicine. 
In addition, the 'discrimination' of terms was analysed, i.e. to what degree a set of terms 
can aid to distinguish one scientific domain from others [16]. Discrimination of terms 
identifies words that may have low frequency but still are important to reflect the field's 
innovation. Using Natural Language Processing (NLP) algorithms, "TIM" captured a set of 
automatic keywords present in distinct parts of the documents within the dataset. The 
occurrence-frequency of automatic keywords (see Annex 1 for description) in the 
publications dataset was the basis for the calculation of relevant keywords. These refer 
to a group of concepts in this dataset identified by combining and ranking term 
frequency and discrimination.  
 
Figure 7 shows the list of the 25 most relevant keywords extracted from the metadata 
of this study; 0 shows the extended list of the top 100 relevant keywords. The top 
relevant keywords retrieved from the studie's publications dataset included several 
general terms such as nanomedicine, nanotechnology, nanoparticle, theranostics, or 
nanomaterial, and specific terms such as nanocarriers, liposomes, quantum dots or 
micelles. Other terms listed as relevant were related to biological properties of 
nanomaterials, such as biocompatibility, conjugation, protein corona, self-assembly, or 
EPR effect (Enhanced Permeability Retention).  
The evaluation of the resulting most frequent and relevant terms demonstrated the 
ability of TIM to identify specialised terminology in the field of nanomedicine. Following a 
similar reasoning for calculation as described in van Eck et al. [26] to evaluate emerging 
fields, the retrieval precision8 was calculated in the two sets of the 100 most frequent 
and relevant keywords, resulting in a precision of 90% and 100%, respectively. The 
retrieval recall9 could be not calculated because not every expected list of terms to be 
compared with TIM's results was available. 
 
 
 
 
 
 
                                           
8 Precision is the fraction of retrieved documents that are relevant. It is the number of correctly identified 
terms divided by the total number of identified terms (in a set of 100 terms).  
9 Recall is the fraction of relevant documents that are retrieved. Recall is the number of correctly identified 
terms divided by the total number of correct terms. 
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Figure 7. List of the 25 most relevant keywords in the nanomedicine field  
Relevant keywords have been considered to build the keyword sets used for mapping and compilation of 
descriptions. Source: TIM (search string: "nanomedicine*") 
Beside the use of nanotechnology for medicinal products, the application of 
nanotechnology will be crucial for innovative medical devices. The new medical device 
regulation is in particular referring to classification needs if a medical device has 
incorporated or consist of nanomaterial and an internal exposure is expected (refer to 
rule 19 L117/145). In order to check whether the initial keyword set of this study 
covered the application of nanotechnology in medical devices an alternative publications 
dataset (source: TIM) using the search string "nano* AND medical device" from year 
1996-2016 was created and identified a total of 1548 documents on this topic. The TIM 
tool automatically extracted a list of relevant keywords. Besides specific types of 
nanomaterials with a broad range of applications in nanomedicine, this refined search for 
medical devices showed an enrichment of synonyms given for silver nanoparticles (silver 
nanoparticle, nanosilver, silver, silver ions, AgNPs, and AgNO) and an increased 
relevance score for some terms such as nanocomposites, nanofiber, nanostructure, or 
nanostructured surface nanotube, nanocoating, hydrogel, and block polymer. Although 
these terms were not present in the top 100 relevant keywords using the search string 
"nanomedicine*", they did appear in the complete list of keywords retrieved with TIM 
from the search nanomedicine. The top 100 relevant and author keywords for the 
specific search in the publications dataset for medical devices are also listed in 0. Only 
few keywords (11) from this list were used to complement the nanomedicine keyword 
set based on expert judgement. 
Finally, the literature review (see section 3.2.1.2) revealed a variety of individual terms 
(268) used to describe nanomaterials or nanotechnology-based materials used in 
nanomedicine research and application, expanding significantly the initial set with 111 
keywords, most of them being variants of the keywords extracted using the automatic 
extraction (for example dendrimeric, polymer based nanocarrier, and polymeric micelle). 
0 presents a summary of the terms and categories suggested by several authors for 
nanomaterials and products in the field of nanomedicine. 
The literature review also revealed a variety of general terms used to describe these 
nanomaterials such as nanomedicine, nanomedicines, nanoparticles and nanocarriers. In 
some cases, these terms appeared in combination with others such as polymer-based 
nanomedicine, nanomedicinal products and drug nanoparticles. Other terms identified 
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were nanoplatforms, nanodrugs, nanoformulations, nanopharmaceuticals, nanoscale 
therapies and carrier systems. 
A few reviews provided sub-categories for these formulations or materials, which ranged 
from general categories such as organic nanoparticles, inorganic nanoparticles, carbon 
nanotubes [27], and lipids and polymers [28], to more specific ones such as lipid-based 
nanocarriers, drug-conjugates, polymer-based nanocarriers, inorganic nanoparticles and 
viral nanoparticles [29]. In some reviews, the type of polymer used was also considered 
to derive a different classification such as polymer-based nanomedicine (e.g., 
polyetherimide (PEI), poly(L-lysine) (PLL), and chitosan), polymeric micelles (e.g., 
poly(ethylene glycol (PEG)–poly(amino acid), PEG–polyester and PEG–lipid), polymer–
drug conjugates and others [30]. Other general categories identified were protein 
nanoparticles, base nanoparticles, lipid base nanocarriers, metal based nanocarriers, and 
nanostructured materials. 
This terminology variation was also evident from the number of distinct keywords within 
the categories. The most frequent keywords identified in this review were liposome that 
appears in 82% of the reviews, followed by micelle (37%), polymeric nanoparticle 
(27%), nanoparticle (22%), carbon nanotube (20%), polymeric micelle (20%) and solid 
lipid nanoparticle (18%). Other terms and term variants were mentioned in less than 
10% of the documents, and 162 term variants were mentioned only in 1 review. The list 
of terms contains 25 types of nanoparticles (e.g., albumin bound nanoparticle, carbon 
nanoparticle, gold nanoparticle, and crystalline nanoparticle), 4 types of micelles 
(polymeric micelles, block copolymer micelles, lipid-based micelles and micelleplexes), 
and 21 terms to describe polymer-based nanomedicines (e.g., polymeric nanogels, 
polymeric conjugates, and star block copolymers). 
 
Result 2: Division of final keyword set of 383 terms10 into four 
categories 
- n=79 General terms defining general concepts including nanotechnology, 
nanomedicine, nanomaterial, theranostics and nanosimilars; 
- n=235 Structural entities terms: terms covering nanoscale materials and 
nanotechnology platforms used in the field of nanomedicine including dendrimers, 
liposomes, quantum dots and nanocomposites;  
- n=29 Terms to define chemical processing such as coating, emulsion, functionalization, 
and nanoformulation;  
- n= 41 Terms indicating methodologies, techniques or properties applied to material 
characterisation and relevant to nanotechnology such as particle size, surface 
morphology, dynamic light scattering and dustiness. 
 
3.1.2  Description of the final keyword set for nanomedicine 
By merging the resulting lists extracted in Step 1 (section 2.2.1), a final keyword set 
was built that contained 383 terms including plurals and variants (290 when excluding 
these). This keyword set is composed of nano-prefixed terms and non nano-prefixed 
terms that are relevant to the topic and includes terms describing nanoscale materials 
(e.g., dendrimers, liposome), chemical processes (e.g., conjugation, emulsion and 
functionalization), and various aspects of nanomaterial physicochemical characterisation 
including results and techniques (e.g. aggregation, chemical composition, and dynamic 
light scattering). The keyword set of this study contains single keywords, combined 
keywords (e.g., polymeric nanoparticles, protein polymer conjugate and lipid based 
                                           
10 This list includes term variations such as plurals, or hyphenated variations. 
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micelles) as well as plurals and adjective variants when appropriate (e.g. micellar, 
colloidal, nanosized, and constructions such as nanotechnology-based and nanoparticle-
based). Similarly, as proposed by the BSI terminology11, selected terms were divided in 
four categories to describe the keyword set (see textbox). Figure 8 indicates the 
percentage of terms included in the keyword set for each category. 
Figure 8. Distribution of terms from the nanomedicine final keyword set  
 
 
Finally, the publications set was queried with both search engines TIM and GoPubMed in 
order to validate the simple string search strategy by using a series of alternative search 
strings: "nano* AND medicine", "nanotechnol* AND drug*", "nanomed* AND medical 
device*", and "nanomedicine AND regulatory". The relevant keywords and top terms 
extracted with these searches were already present in the keyword set and therefore this 
search did not contribute to its enlargement. Figure 9 shows the final keyword set 
selected for the mapping of terminology in regulatory authorities' websites in Step 3. A 
reduced keyword set, based on this one, was selected to map the other sources: clinical 
trial registry database (see Figure 5). 
  
                                           
11 British Standards Institution (2007) PAS 131 Terminology for medical, health and personal care applications of 
nanotechnologies 
Characterisation:  
Particle size 
Surface morphology Chemical Processing: 
Nanoencapsulation 
Nanoformulation 
Nanocoating 
General: 
Nanomedicine 
Nanostructure 
Nanomaterial 
Theranostics 
Structural entity: 
Dendrimer 
Micelles 
Nanocrystal 
21% 11% 
7% 
61% 
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Figure 9. List of terms in the nanomedicine final keyword set  
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3.1.3 Selection of a reduced keyword set for manually mapping 
identified sources  
Only the previously described scientific publications lend themselves to a fully automatic 
extraction of keywords and associated frequency of occurrence, and the mapping of the 
regulatory agencies can be done in a semi-automatic way using the terms listed in 
Figure 9. The exercise of mapping of the scientific publications and regulatory agencies 
provided the basis for a refined keyword set that allows easily manual mapping 
information from other sources, such as the clinical trial registry, which did not permit to 
automatically retrieve information. In fact, keywords from these databases were 
manually extracted by querying their website's advanced search engine with the reduced 
keyword set described below.  
For the manual mapping exercise, some of the keywords relating to general terms were 
chosen based on their frequent occurrence and relevance, in text by the regulatory 
authorities on the application of nanotechnology in the health sector. Other general 
terms were selected due to their distinctive use, e.g. by one regulatory authority, and 
therefore their potential implications in global communication among authorities. 
 
Table 5. Selected terms (in random order) for manual extraction  
General terms Specific terms 
Nanotechnology Nanoparticle Dendrimer Nanosuspension 
Nanoscale Metal nanoparticles Carbon nanotube Nanocomposite 
Nanostructure Magnetic nanoparticles (SPIO, 
SPION, USPION) 
Micelle Nanoaerosol 
Nanomaterial Polymer therapeutics Quantum dot Nanobody 
Nanomedicine Polymeric nanoparticles Colloid Virosome 
Nanomedicines polymeric nanoparticle Fullerene  
Nanodevice polymeric micelles Nanocrystal  
Theranostic 
products 
Solid lipid nanoparticles Nanocarrier  
Combination 
products 
Albumin-bound nanoparticles Nanocapsule  
Borderline 
products 
Liposome Nanoemulsion  
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3.2 Step 2: Mapping nanomedicine terminology in information 
sources 
3.2.1 Summary of terminology mapping  
Table 6 summarises the term frequency of all sources explored in this report. The term 
frequency for the scientific literature represents the number of publications, within the 
publications dataset extracted with the search string nanomedicine*, containing each 
term either in the title, abstract, author keywords or in the text corpus. For the 
regulatory authorities' websites, term frequency refers to the number of extracted pages 
containing each term, whereas for the clinical trial registries database the term 
frequency correspond to number of entries with each term listed in the table.  
Detail mapping results and discussion for each is provided in the following subsections. 
Table 6. Summary of term frequency (number of documents) of keyword set in various 
information sources. 
keyword set 
N
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N° of documents from regulatory authorities 
N
° 
o
f 
cl
in
ic
al
 t
ri
al
s 
TG
A
 
Sw
is
sm
ed
ic
 
H
e
al
th
 C
an
ad
a 
 F
D
A
 
TF
D
A
  
EM
A
 
M
H
LW
 
M
FD
S 
H
SA
 
D
G
 S
A
N
TE
 
D
G
 G
R
O
W
 
O
cc
u
rr
en
ce
**
 
Drug delivery system  1815 58 632 229 1087 13 1 9 - 2 3 5 10 121 
Nanoscience 104 - - 4 5 2 - - - - 4 2 5 - 
Nanotechnology  1459 37 235 236 1230 25 730 - - - 121 371 8 14 
Nanomedicine 5958 4 29 5 38 7 10 - - - 1 3 8 - 
Nanomedicines 116§ 1 12 1 2 - 785* - - - - - 5 - 
Nanosimilar 2§ - - - - - 8 - - - - - 1 - 
Nanoparticle 2763 107 112 118 309 74 10 - - 1 39 31 9 239 
Aerosol 22 101 288 91 712 1 6 2 - - 7 49 9 300 
Nanomaterial  757 17 4 584 498 43 2 
 
1 
 
123 373 9 2 
Colloid 98 67 62 98 291 - 18 - - 1 1 1 8 173 
Nanocolloid 4 - - - 1 - 14 - - - - - 2 7 
Emulsions - 91 3651 47 260 22 33 - - - - 21 7 547 
Nanoemulsion - - - - 1 - - - - - - 1 2 10 
Micelle 326 5 1 6 7 37 3 - - - - 1 7 30 
Nanomicelle 28 - - - - - - - - - - - - 2 
Liposome  494 4 - 16 290 8 52 - - - - - 5 886 
Nanoliposome 14 - - - 3 - - - - - - - 1 10 
Nanostructured Materials  98 1 - 2 20 24 - - - - - 7 5 4 
Quantum dot 267 3 - 21 12 6 - - - - - 1 5 - 
Nanotubes  448 - - 8 52 4 - - - - - 1 4 3 
Hydrogel  50 13 189 30 81 
 
- - - - - 
 
4 230 
Nanocapsule 71 - 2 - - 6 - - - - - 1 3 - 
Dendrimer 227 - - - 11 - - - - - - 1 2 1 
Fullerene 77 - - - 14 7 - - - - - - 2 - 
Nanowire 37 - - - 5 - - - - - 1 - 2 - 
Nanocomposite 89 - - - 3 - - - - - - 3 2 1 
Nanocrystals  82 - - 2 3 - - - - - - - 2 21 
Virosome 2 - 25 - - - 3 - - - - - 2 37 
Nanoporous materials  3 - - - 1 - - - - - - - 1 1 
Nanocarrier  557 - - - - 1 - - - - - - 1 5 
Nanorods  44 - - - 2 - - - - - - - 1 - 
Nanosheets 11 - - - 1 - - - - - - - 1 - 
Nanoshells  38 - - - 1 - - - - - - - 1 - 
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Table 6 (cont.) 
keyword set 
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Nanospheres  - - - - 22 - - - - - - - 1 1 
Polymeric nanoparticle 34§ - - - - - - - - - - - - 1 
Polymeric micelle 24§ - - - - - - - - - - - - 7 
Solid lipid nanoparticle 73 - - - - - - - - - - - - - 
Nanopharmaceutical 57 - - - - - - - - - - - - - 
Nanotherapeutics 140 - - - 5 - 6 - - - - - 2 - 
Polymer-drug conjugate 13 - - - - - - - - - - - - - 
Nanoconjugate 40§ - - - - - - - - - - - - - 
Block copolymer 102 - - - - - - - - - - - - 2 
*search string: "nanomedicine*" (extracted automatic keywords hit counts); 
§
author keyword; 
**
calculated by 
number of authorities including a given term; number between brackets indicate results from an advance 
search string ("a given term AND nanotechnology"). Numbers in bold indicate regulatory agencies with highest 
hit for each keyword. Sources: scientific publications (TIM), regulatory authorities' websites, clinical trials 
(ICTRP)  
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3.2.2 Mapping of keywords in regulatory authorities' websites 
The number of documents extracted from 13 websites (Table 7) mentioning the 
keywords (hit counts) were quantified. 0 contains a summary table of the results of this 
mapping exercise.  
Table 7. Number of webpages crawled for this study per regulatory authority 
Regulatory authority  URL (English version) #documents 
retrieved 
Australian Government Department of Health www.tga.gov.au 6128 
Agência Nacional de Vigilância Sanitária, Brasil portal.anvisa.gov.br 472 
Health Canada www.hc-sc.gc.ca 15197 
Ministry of Health Labour and Welfare, Japan www.mhlw.go.jp/english/ 2248 
Ministry of Food and Drug Safety, Korea www.mfds.go.kr/eng/ 87 
Russian Federal Service for Surveillance in Health 
Care 
www.roszdravnadzor.ru/en 70 
Health Sciences Authority, Singapore www.hsa.gov.sg/content/hsa/en.html 487 
Swiss Agency for Therapeutic Products www.swissmedic.ch/index.html?lang=en 35368 
U.S. Food and Drug Administration www.fda.gov 76754 
Food and Drug Administration, Taiwan www.fda.gov.tw/EN/ 4052 
European Medicines Agency www.ema.europa.eu 4704 
European Commission, DG Grow ec.europa.eu/growth/index_en.htm 71783 
European Commission , DG Santé http://ec.europa.eu/health/index_en.ht
m 
3383 
This table shows the variation in the amount of information (in number of text documents), in English, 
extracted from the different bodies.  
3.2.2.1 Information on nanomedicine in the websites of regulatory agencies 
The first set of findings concerned the variability of the total information amount 
retrieved from each regulatory authority's English language version website. Using the 
metadata extracted from all crawled websites, a database comprising 220 733 
unstructured text documents was built. The number of documents extracted from each 
website using the WebCrawler software showed the variability of the information 
provided, ranging from thousands of text documents published by the FDA (76754) to a 
few dozen published by the Russian regulatory authority website (70). As the search was 
restricted to publications in English and there are significant differences between the 
types of products regulated by each authority, a quantitative comparison of the search 
results from the regulatory authorities' websites was not meaningful and this fact needs 
to be taken into consideration when interpreting the outcomes of this mapping. The 
translated websites tend to provide fewer documents such as the Russian Federal 
Service for Surveillance in Healthcare's (Roszdravnadzor) and the Korean Ministry of 
Food and Drug Safety's websites only 70 and 84 texts were extracted, respectively. In 
addition, some regulatory authorities are regulating different types of products which 
had an impact on the level of information provided in the website. Due to technical 
limitations the crawling could not filter only by the type of products (e.g. medicinal 
products and medical devices) resulting in an increase of documents providing 
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information about product types that are outside the scope of this report. For example, 
the FDA not only regulates drugs and medical devices but also regulates e.g. food 
products, cosmetics, and tobacco; the FDA had the highest number of documents 
retrieved as it is English mother tongue and regulates several different fields (76754). 
Other agencies that use English intensively, for example EMA, cover mainly one 
regulatory field, medicinal products, and therefore the total number of text documents 
extracted was significantly smaller (4704). Finally, the information architecture in the 
website could also explain the variation in number of documents retrieved from some 
regulatory authorities' websites. An example of this is Swissmedic, the Swiss Agency for 
Therapeutic Products, which is involved in the authorisation and monitoring of medicinal 
products and medical devices; even though English is not a primary language, the 
crawling exercise extracted 35368 text documents, almost tenfold difference compared 
to the number of documents provided by the EMA's website. This high number is 
attributed to the publishing of documents in several official languages (German, French 
and Italian), which were included in the English language webpage. Documents in 
languages other than English were also extracted from Health Canada's website, which 
also has French as an official language and from the Brazilian ANVISA (Agência Nacional 
de Vigilância Sanitária). 
Inter-agency variations in the number of terms matching the keyword set (Figure 10) 
were observed. All websites, except the Russian Roszdravnadzor English version, showed 
at least one term matching the nanomedicine keyword set. For example, the websites of 
the FDA, Health Canada (HC) and TFDA had a higher number of terms matching the 
keyword set, while the Brazilian ANVISA and the Korean MFDS had less than 5 terms 
matching the keyword set. The number of documents extracted from each regulatory 
authority website for each term of the keyword set was counted. After data 
consolidation, i.e. grouping counts of the singular and plural forms (when appropriate), 
this approach returned a total of 141 terms matching the keyword set (0). In general, 
approximately 80% of the terms from the keyword set were used by less than half of the 
regulatory agencies, and more than 40% of the terms were present only in 1 of the 
webpages surveyed. 
Figure 10. Total number of terms matching the nanomedicine keyword set in documents 
extracted from regulatory authorities' (RAs) websites.  
  
 
According to the text mining results, the FDA's website showed the highest number of 
terms (115) matching the keyword set. Since English is the main language used by the 
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FDA and this agency addresses many regulatory fields, this might be a reason for the 
higher number of informative documents at the website. 
This list included general terms such as nanohealth, nanopharmaceutical and nanodrug. 
General terms such as nanotechnology, nanomaterial and nanoparticle were the most 
frequently nano-prefixed terms matching the keyword set within this website. Regarding 
nanomedicine-specific terms, the FDA has the website using the highest number of 
terms to describe structural entities compared to other agencies. The list includes terms 
such as liposomes (in 150 documents), hydrogel (48), nanospheres (10), micelles (6) 
and dendrimers (5). A closer look to the type of documents mentioning these terms 
revealed the enrichment on information on science and research projects in the webpage 
from external sources (universities or research centres). This is also the case of the term 
nanomedicine that appeared only in 16 documents and it was also used mainly to 
describe names of academic departments or titles of research projects and publications 
from external sources. The FDA does not recognise the term nanomedicine to describe 
any type of medicinal or medical product; instead, the agency uses the general terms 
nanotechnology products, drug products that contain nanomaterials or products that 
involve the application of nanotechnology [31]. 
Health Canada is the second regulatory authority website matching a high number of 
nanomedicine-related terms (64) from the applied keyword set. Besides the term 
delivery system, words such as nanotechnology, nanomaterial and nanoscale were the 
most mentioned from the keyword set. Almost 43% of these terms described structural 
entities such as iron oxide, colloid, aerosol and hydrosol and these were the top 20 most 
frequent terms in this analysis of the data from Health Canada; the list also included 
terms such as quantum dot, liposome, SPIO (superparamagnetic iron oxide) and 
nanocarrier. The general terms nanomedicine and nanomedicines were also found in the 
matching list. Neither term was frequently used in the information extracted from the 
website; however, these terms were included in the informative webpage for Frequently 
Asked Questions Related to the Policy Statement on Health Canada's Working Definition 
for Nanomaterial. In this context, nanomedicine describes the application of 
nanotechnology to treat diseases or restore functions, and the term nanomedicine 
defines the resultant product of this application. The term nanomedicines in this text also 
denotes the application of nanotechnology for both pharmaceutical drugs and medical 
devices. 
Taiwan FDA (TFDA) returned a total of 59 terms matching the keyword set, and this was 
the third best terminology match for nanomedicine for regulatory authorities. General 
terms such as nanoparticle, nanomaterial, nanotechnology, nanoscale and nanostructure 
were the most frequently mentioned ones in the information extracted from this agency. 
The terms nanomedicine and theranostic were also found among TFDA website's 
metadata. Comparable to Health Canada, structural entities contribute to a significant 
percentage of the matching terms captured. The most frequent categories were 
nanoparticle, micelles, liposomes and quantum dots. Among the unique terms, the 
following were found: nanocarrier, metal nanoparticle and mesoporous silica. A closer 
look at the type of documents, however, indicated that these terms were used in 
citations from articles published in English. None of the terms mentioned in the English 
version of the TFDA's website had an associated definition.  
EMA's information texts matched 40 terms of the keyword set, from which the most 
frequent general terms were: nanomedicine, the plural form nanomedicines, tissue 
engineering, nanotechnology, and personalised medicine. The list of specific terms 
included keywords to identify structural entities such as nanocolloidal, or colloid, 
liposome or liposomal, micelle and virosome. A specific term extracted from EMA's 
website is nanosimilars used to describe the concept of nanomedicines that are claimed 
to be similar to a reference nanomedicine12. Another relevant term found, although not 
                                           
12 http://www.ema.europa.eu/ema/index.jsp?curl=pages/special_topics/general/general_content_000345.jsp& 
(retrieved 31/08/2017) 
 39 
 
 
exclusively for nanomedicine, is borderline product. This term is mainly used in a 
European context (by EMA, DG GROW, DG SANTE and Swissmedic).  
This mapping approach also revealed that certain terms were uniquely used by certain 
regulatory authorities. Two issues should be considered for a further discussion on 
terminology harmonisation: 1) the uniqueness of certain terms in this analysis, e.g. 
terms may be found in only one source illustrated by EMA being the only source using 
nanomedicines, and 2) the frequency of occurrence of texts mentioning a term in each 
regulatory authority. The first issue contributes to the extension of the vocabulary; the 
second may indicate the establishment of a term in the field and it might motivate the 
discussion on harmonisation of a specialised terminology. To detect those terms specific 
to an agency or regulatory body, the contribution of such terms was included in the 
analysis of the total dataset of extracted texts from the different websites. This approach 
allowed identifying those agencies that were the main contributors to the frequency of a 
specific term. This approach is relevant to understand the emerging nanomedicine terms 
that are regionally accepted but are not accepted by other regulatory bodies. 
A clear example of agency-related preference for terminology is the use of general key 
terms such as nanomedicines−in the plural form− and nanomaterial in the healthcare 
sector context. The plural form of the term nanomedicine is almost exclusively used by 
EMA (nanomedicines term frequency: 731 hits) to describe the application of 
nanotechnology to medicinal products. This use of the term nanomedicine may also 
explain the low number of documents retrieved from EMA with the term nanomaterial 
compared to the other regulatory bodies, in which the term nanomaterial is used to 
describe medicinal products, such as drug products containing nanomaterials, as in the 
FDA.  
Also Swissmedic rarely uses the term nanomedicines (4 hits) in the information 
provided, and shows a pattern similar to EMA’s for the term nanomaterial. The term 
nanomedicine is not adopted by Swissmedic for the description of drugs and devices; 
instead, the agency describes human medicines as products containing nanoparticles, 
where the particles have at least one nanoscale dimension (1-1000 nm) plus a function 
and/ or mode of action based on nanotechnology characteristics (in the form entitled 
Application for Authorisation/ Variation of human medicines [32]). 
 
RESULT 3: Mapping of keywords (n=383) in regulatory 
authorities' websites 
 
- Establishment of a database of 220733 unstructured text documents derived from 13 
websites of regulatory/legislative bodies 
- Variations between agencies matching the keyword set i.e. FDA=115 keywords   
- Nanotechnology, nanomaterial, nanoscale, and nanomedicine used by nearly every 
agency 
- The term nanomedicines is mainly used in European websites 
 
 
An analysis of the term frequency of these selected keywords ( 
Table 5) offers an initial assessment of the type and amount of information provided by 
the different regulatory sources on the topic of nanomedicine as well as the compilation 
of descriptions for future discussion of harmonising the terminology. 
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Figure 11 represents the frequency of the same nano-terms in the six websites of the 
regulatory agencies that had the most information in English on nanomedicine. The 
presented results showed that general terms such as nanotechnology, nanomaterial, 
nanoscale, and nanomedicine were mentioned in almost every website suggesting that 
information on the application of nanotechnology in the healthcare sector was being 
provided by the selected websites, whereas other terms were used almost distinctively in 
some regulatory agencies, as in the case of the above discussed term nanomedicines.  
Figure 11. Frequency of general terms in selected regulatory authorities' websites 
 
Analysis of most frequently used general terms in six of the most active regulatory agencies providing 
information on nanomedicine, analysed in this report. 
Specific terms, such as terms to define nanotechnology platforms used in nanomedicine, 
were selected by their frequency in the scientific publication review as well as by their 
presence in the mapping analysis of regulatory authorities' websites. The results of the 
matching documents with these terms (Figure 12) may provide an initial indication of 
the categories of nanomedicine products upcoming in the regulatory domain.  
There were significant differences in the use of the selected terms among the regulatory 
authorities. The results from term frequency analysis showed that nanoparticles and 
liposomes were the only specific terms mentioned in almost all the websites analysed 
followed by the terms micelle and colloid. The FDA agency showed the highest number of 
specific terms to describe nanoscale materials and formulations. A closer look at the type 
of documents including these terms revealed that many of these documents were related 
to information regarding research programmes. 
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Figure 12. Frequency of specific terms in selected regulatory authorities' websites 
 
 
Analysis of most frequently used specific terms in six of the most active regulatory agencies providing 
information on nanomedicine, analysed in this report. 
3.2.3  Mapping in clinical trial registries 
In 2013, Etheridge et al. [25] reviewed existing commercial and investigational 
nanomedicine products in order to describe the type of nanotechnology-based products 
currently in clinical development. The authors selected a number of representative terms 
(see 0) and identified 247 nanomedicine products approved or under clinical 
investigation. Also, De La Iglesia et al. [33] presented the first attempt to automatically 
identify information on nanodrugs and nanodevices in clinical trials using text-mining 
tools and aiming to distinguish clinical trials of nanotechnology-based products from 
clinical trials of conventional drugs. By applying a different keyword set, these authors 
identified 414 clinical trials involving nanotechnology products; however, a complete 
description of the terms and the products was not provided in the publication. Their 
results were valuable background information for this research, and terms proposed in 
these studies were also introduced in this keyword set. However, these papers had the 
objective to describe the type of nanotechnology-based products as well as the products 
themselves as reported in clinical registries, not the terminology. 
This study explored the variety of nanomedicine related terms in the clinical trials (CT) 
that were registered in the WHO clinical registry. The term frequency refers to the 
number of clinical trial summaries containing the term and provided in this database. 
In total 1230 CTs potentially related to the application of nanotechnology in medicinal 
products (drugs) and medical devices were captured. Terms defining product brands, 
company names, methodologies and metric variables that are unspecific in the field of 
nanomedicine were excluded resulting in total number of 722 CTs. The results were 
perfectly matching the list of clinical trials reported by De La Iglesia et al. [33]. 
3.2.3.1 Increase of nanomedicine terminology in clinical registries  
The increase of specific terms in the text of the summaries allowed monitoring the 
emergence of nanomedicines in CTs. The analysis indicated an increase of nanomedicine 
products in clinical trials as well as an increase of nano-prefixed terms describing these 
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products. Even if this study is not an exhaustive analysis of nanomedicine products 
currently in clinical development, the analysis demonstrates the expanding terminology 
in the field of nanomedicine.  
From 2004 to 2016 54% more nano-prefixed terms were used in the title of the 
retrieved CT summaries.  
The analysis of nanomedicine terms used in CT summaries revealed that the most 
retrieved CTs (53%) describe investigational health products are using the term 
nanoparticle (Figure 13). The majority of this use of the term nanoparticle were 
referring to CTs (n=117) related to the nanoparticle albumin-bound paclitaxel (nab-
paclitaxel) [34]. This subset represented however less than 50% of the CTs registered 
for nab-paclitaxel, and when searching by using the term nab-paclitaxel or the brand 
name Abraxane 630 CTs were identified. 
The selected terms listed in  
Table 5 were searched using the advance search engine of the WHO-ICTRP website. In 
comparison to the number of specific terms related to nanomedicine, the number of CTs 
mentioning general terms was rather low, and terms such as nanomedicine and 
nanomedicines were not mentioned in any of the CTs to describe the scientific field or 
formulations, neither other variants such as nanopharmaceutics or nanotherapeutics. 
Only few new terms and variants such as nanodiamond, nanomicellar, or nanofibrous 
were identified in this dataset.  
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Figure 13. Term frequency of nano-prefixed terms selected to describe the use of nanotechnology in clinical trials registries 
 
 
 
 
 
 
Source: ICTRP database (data retrieved in November 2016)
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3.2.4 Mapping in patents 
Patent databases are a valuable tool to understand the innovative potential of new 
technologies. As already described by Daim, 2006 [35], the analysis of patents can help 
with forecasting the impact and upcoming needs of products derived from emerging 
technologies. However, due to legal issues with patents, a clear understanding of the 
terminology among stakeholders is essential. Queries in the patent data base "EPO-
PATSTAT" using the search string "nanomedicine*" with TIM resulted in the identification 
of 40 patents. The number of patents increased to 116 and 255 when other keyword 
combinations such as (nanotech* AND medicine) and (nano* AND "medical device") 
have been used. The top 10 keywords extracted from these 40 patents included mostly 
general terms, applicable to other biomedical areas, such as invention, medicine, 
preparation methods, diagnostics, biocompatibility and therapeutic effects, and only few 
specific terms for nanomedicine such as nanoparticle and quantum dot. 
Patent officers examine and classify patents into the technology classes of the 
Cooperative Patent Classification (CPC) system (see examples in Table 8). The CPC is a 
common, internationally compatible classification system for technical documents, in 
particular patent publications; depending on the foresee applications of a patent, one 
patent can be classified in more than one class or subclass. TIM offers the possibility to 
extract information on CPC classification from the dataset, and map the co-occurrence of 
classifications in a network (Figure 14). The analysis of these data provided further 
information on the type of products and applications in the field of nanomedicine. The 
identified 40 patents belong to two major classes according to the cooperative patent 
classification system (CPC): A61K and B82Y. 
Table 8. Main Cooperative Patent Classification (CPC) subclasses found in the patents from the 
publications dataset. 
CPC_Class CPC_Subclass Title Definition statement 
B82Y  Specific uses or applications of 
nanostructures; measurement or 
analysis of nanostructures; 
manufacture or treatment of 
nanostructures 
Applications and aspects of 
nanostructures which are produced by 
any method, and is not restricted to 
those that are formed by manipulation 
of individual atoms or molecules. 
B82Y 5/00 Nanobiotechnology or 
nanomedicine, e.g. protein 
engineering or drug delivery 
Artificial structures, particles, etc. 
Although they may be of nanosize, 
liposomes and virus-like particles 
(VLPs) are not considered to be 
nanotechnology. 
B82Y 15/00 Nanotechnology for interacting, 
sensing or actuating, e.g. quantum 
dots as markers in protein assays 
or molecular motors 
Nanostructures used for sensing or 
actuating, wherein the nanostructure 
itself (e.g. quantum dot, nanotube) is 
at least part of the sensor or actuator. 
B82Y 30/00 Nanotechnology for materials or 
surface science, e.g. 
nanocomposites 
NA 
A61K  Preparations for medical, dental, or 
toilet purposes 
 
Preparations for dentistry; Cosmetic or 
similar toilet preparations; Medicinal 
preparations; Preparations for testing 
in vivo; Preparations containing 
radioactive substances for use in 
therapy or testing in vivo 
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Table 8 (cont.) 
CPC_Class CPC_Subclass Title Definition statement 
 A61K 47/00 Medicinal preparations 
characterised by the non-active 
ingredients used, e.g. carriers or 
inert additives; Targeting or 
modifying agents chemically bound 
to the active ingredient 
Pharmaceutical compositions 
characterised by the excipients, i.e. the 
non-active ingredients; New excipients 
per se. 
 
24 patents also covered applications such as medicinal preparations characterised by the 
non-active ingredients, classified as A61K 47/00. This categorisation included non-active 
ingredients being chemically bound to the active ingredients, e.g. polymer drug 
conjugates, and medicinal preparations containing organic active ingredients. Specific 
terms to describe the materials covered in this group were nanotubes, nano spheres, 
polymerosomes, liposomes, drug nanoparticles, nanocapsules, polymeric micelles or 
drug-nanoparticles conjugates. Also, three subcategories of B82Y were found in the 
dataset: 6 patents classified as B82Y 5/00 that includes patents describing technology 
such as nanocapsules for drug delivery, therapeutics, or radioactive pharmaceutical 
preparations, followed by 3 patents classified as B82Y 15/00 that includes patents of 
tools for measurement of physical, chemical and biological properties at surface with 
nm-resolution. Finally, 3 patents classified as B82Y 30/00, included materials such as 
nanoparticles, nanocomposites, dendrimers, nanotubes and fullerenes. 
Figure 14. Visualization of the CPC classification of the patents in this dataset.  
 
 
The network represents the classification numbers identified in the patents present in the publication dataset 
(40 patents), using nanomedicine* as string search. The size of the node reflects the number of patents 
identify within a class. The map shows a clear enrichment of patents classified as B82Y and A61K. Source: TIM 
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3.3 Step 3: Compilation of information and term descriptions 
3.3.1 Compilation of relevant documentation from regulatory 
sources  
Table 9 shows a compilation of documents with regulatory relevance retrieved in this 
study. The type of relevant documents includes e.g. simple consumer information, 
reflection papers to help industry and regulators to assess products, and various 
guidance documents aimed at industry, the general public or agencies' staff. The type of 
information in these documents included: 
 Working definitions or glossaries for relevant nanomedicine terms. 
 Information about the characteristics, uses, safety, and benefits of 
the application of nanotechnology in health products [36, 37]. 
 Information requirements to enable evaluation of health products in 
applications, e.g. declaration of ingredients considered 
nanomaterials, in drug products or veterinary medicines (Health 
Canada [38]; Swissmedic [32, 39]; EMA [40]); provision of 
description of nanomaterial quality attributes and structural 
characterization (e.g. size, charge, morphology, composition, and 
complexation)[31], provision of additional supporting data [41, 
42]; and special requirements for labelling [41]. 
 Reflection papers on nanomedicines providing guidance for industry 
and regulators on developing and evaluating nanomedicines [43]. 
Further text-mining of the dataset that was extracted from the regulatory authorities' 
websites allowed exploring the existing documentation to obtain information on the 
application of nanotechnology in the health sector and identify the type of terminology 
used and information provided. For example, since 2012 Swissmedic requires that 
nanoparticles are declared using the form entitled Application for Authorisation/ Variation 
of human medicines (VO Form) [32]. This form has a section for pharmaceuticals to 
provide other information, including if the drug contain synthetic nanoparticles, and to 
specify which components of the medicinal product contains nanoparticles. According to 
this document, particles that have at least one dimension in the nanoscale (1- 1000 nm) 
plus a function and/ or mode of action based on nanotechnology characteristics are 
nanoparticles. The webpage also highlights that this information must be provided for 
medicinal products containing innovative nanoparticles (for example, Aerosil, a silicon 
dioxide, is not considered to be innovative). Another example is EMA's pre-submission 
meeting request form, which aims to provide an overview of the most relevant topics 
that an applicant is advised to consider when preparing their upcoming application for 
initial marketing authorisation, and which can be discussed at a MAA (marketing 
authorisation application) pre-submission meeting. This document asks for information 
on whether the active substance applies nanotechnology. 
The FDA has recently released a Draft Guidance for Industry – Drug Products, Including 
Biological Products, that Contain Nanomaterials to share FDA’s current thinking for the 
development of human drug products, including those that are biological products, in 
which a nanomaterial is present in a finished dosage form. This FDA draft guidance lists 
a set of recommendations without a legal enforcement that discusses both general 
principles and specific considerations for the development of drug products containing 
nanomaterials, including considerations for establishing the equivalence of such products 
with other drugs. Considerations for quality, nonclinical, and clinical studies are 
discussed as they relate to drug products containing nanomaterials throughout product 
development and production. This guidance applies to drug products, including biological 
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products, in which nanomaterials may serve as active ingredients, carriers loaded with 
an active ingredient or inactive ingredients [31]. For medical devices, the FDA does not 
provide any specific document requiring information on the application of 
nanotechnology; however the agency has issued a final guidance document entitled 
Considering Whether an FDA-Regulated Product Involves the Application of 
Nanotechnology that describes FDA’s general approach to regulating products that utilize 
nanotechnology or contain nanomaterials and is applicable to all FDA-regulated products. 
FDA also accepts information provided in the Auditor and Technical Expert Competency 
Summary form developed by the Medical Device Single Audit Program (MDSAP) in which 
the expert should express whether medical devices are utilising nanomaterials 13. 
 
                                           
13 http://www.fda.gov/downloads/medicaldevices/internationalprograms/mdsappilot/ucm380005.doc. 
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Table 9. Summary of documents in English language on nanomedicine compiled from regulatory authorities' websites.  
Country Regulatory authorities 
Regulate or 
support 
regulation 
Primary legislation for 
medical products 
Regulatory and guidance documents related to application of nanotechnology in 
medical products 
Australia Therapeutic Goods 
Administration (TGA) 
Medicines 
Medical devices  
 
- Therapeutic Goods Act 1989 
- Therapeutic Goods 
Regulations 1990 
- Therapeutic Goods (Medical 
Devices) Regulations 2002 
- Under revision: Australian regulatory guidelines for medical devices (ARGMD) 
(2011) [44] 
- TGA webpage for consumer information [36] 
Brazil Brazilian Health Surveillance 
Agency (Anvisa) 
Drugs 
- Synthetic and semi-synthetic 
drugs (new, generics and 
similars); RDC 60/2014 
- Classification and 
Registration Requirements of 
Medical Products; RDC 
185/2001 (Medical devices) 
No specific information available 
Canada Health Canada, Health 
Products and Food Branch (HC) 
Drugs 
Health Products 
 
- Food and Drugs Act 
- Natural Health Product 
Regulations 
- Health Canada 3011: Drug Submission Application Form for Human, Veterinary or 
Disinfectant Drugs and Clinical Trial Application/Attestation  
- Guidance Document on Topical Anaesthetic, Analgesic or Antipruritic Labelling 
Standard [25] 
- Guidance for Completing the Drug Submission Application Form (Part 2- Drug 
Product Formulation Information)  
- Guidance Document: How to Complete the Application for a New Medical Device 
Licence [45] 
- Future revision of information requirements in Medical Devices Licence 
Application 
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Table 9 (cont.) 
Country Regulatory authorities 
Regulate or 
support 
regulation 
Primary legislation for 
medical products 
Regulatory and guidance documents related to application of nanotechnology in 
medical products 
Japan Ministry of Health, Labour and 
Welfare (MHLW) 
Pharmaceuticals 
Medical devices 
- The Pharmaceutical Affairs 
Law 
Two guidance documents on Management Guidance on Clinical Trial Notification: 
points to consider in the case of some nanotechnology-based medicines (Japanese 
only) 
- PFSB/ELD Notification No.05314 (2013) 
- PFSB/ELD Notification No.05318 (2013) 
- Joint MHLW/EMA reflection paper on the development of block copolymer 
micelle medicinal products14 
- Guideline for the Development of Liposome Drug Products (2016)15 
- Reflection paper on nucleic acids (siRNA)-loaded nanotechnology-based drug 
products (2016)16 
Pharmaceuticals and Medical 
Devices Agency (PMDA) 
Republic of 
Korea 
Ministry of Food and Drug 
Safety (MFDS) 
Drugs 
Medical devices 
- Pharmaceutical Affairs Act 
[Amended by Act No.14170, 
May 29, 2016] 
- Medical Device Act 2003 
No specific information available 
Russian 
Federation 
Roszdravnadzor (Federal 
Service for Control over 
Healthcare and Social 
Development) 
Medicines 
Medical devices 
Federal Law of 12 April, 
2010 
No specific information available 
 
 
 
 
                                           
14 Japan PMDA Nanomedicine Initiative WG (http://www.pmda.go.jp/english/rs-sb-std/standards-development/cross-sectional-project/0008.html; accessed April 2017) 
15 National Institute of Health Sciences. www.nihs.go.jp/drug/section4/160328_MHLW_liposome_guideline.pdf 
16 National Institute of Health Sciences. www.nihs.go.jp/drug/section4/160328_MHLW_siRNA_RP.pdf 
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Table 9 (cont.) 
Country Regulatory authorities 
Regulate or 
support 
regulation 
Primary legislation for 
medical products 
Regulatory and guidance documents related to application of nanotechnology in 
medical products 
Singapore Health Sciences Authority 
(HSA) 
Western 
medicine 
Medical devices 
Health Products Act 2007 Draft GN-17: Guidance on Preparation of a Product Registration submission for 
General Medical Devices using the ASEAN CSDT (HSA, 2014): request information 
on novel feature due to e.g. nanotechnology in product [46] 
Switzerland Swiss Institute of Therapeutic 
Products (Swissmedic) 
Medicinal 
products 
Medical devices 
Federal Act on Medicinal 
Products and Medical 
Devices (Therapeutic 
Products Act, TPA; SR 
812.21) 
- Application for Authorisation/ Variation of human medicines" (VO Form) 
(Swissmedic): Information request on drugs containing nanoparticles [32] 
- Informational sheet on First-in-Man clinical trials with nanomedicines [47] 
United States of 
America 
U.S. Food and Drug 
Administration (FDA) 
Drugs 
Medical devices 
 
 
- Federal Food, Drug, and 
Cosmetic Act 
- Public Health Service Act 
- Draft Guidance for Industry – Drug Products, Including Biological Products, that 
Contain Nanomaterials (2017)[31] 
- Final Guidance for Industry - Considering Whether an FDA-Regulated Product 
Involves the Application of Nanotechnology (2014) [48] 
European Union  The European Medicines 
Agency (EMA) 
European Commission, DG 
SANTE 
Medicinal 
products 
 
 Scientific Guidelines for nanomedicines (EMA): 
- Reflection Paper on Data requirements for intravenous iron-based nano-colloidal 
products developed with reference to an innovator medicinal product (2015) 
- Reflection Paper on Data requirements for intravenous liposomal products 
developed with reference to an innovator liposomal product (2013) 
- Reflection Paper on Development of block-copolymer-micelle medicinal products 
(2014) 
- Reflection Paper on Surface coatings: general issues for consideration regarding 
parenteral administration of coated nanomedicine products (2013) 
- Marketing Authorisation Application (MAA) Pre-submission meeting request 
form: Request information on topic for consultation 
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Table 9 (cont.) 
Country Regulatory authorities 
Regulate or 
support 
regulation 
Primary legislation for 
medical products 
Regulatory and guidance documents related to application of nanotechnology in 
medical products 
European Union Directorate General for 
Internal Market, Industry, 
Entrepreneurship and SMEs 
(DG Grow) 
Medical devices 
- Regulation (EU) 2017/745 
of the European Parliament 
and of the Council of 5 April 
2017 on medical devices 
- Regulation (EU) 
2017/746 of the European 
Parliament and of the 
Council of 5 April 2017 on in 
vitro diagnostic medical 
devices  
New regulation of medical devices:  
- Introduces of a definition for nanomaterials (based on EC Recommendation) 
- Special requirements for labelling 
- Direct classification for MDs incorporating nanomaterials (except when 
encapsulated or bound n such a manner that it cannot be released into the 
patient’s or user's body) 
- Opinion on the Guidance on the Determination of Potential Health Effects of 
Nanomaterials Used in Medical Devices (SCENIHR)[42] 
Taiwan Taiwan Food and Drugs 
Administration (TFDA) 
Human drugs 
Medical devices 
 
Cosmetics 
Food 
 
Organization Act of the Food 
and Drug Administration, 
Ministry of Health and 
Welfare (2013) 
- Reference guide for nano-medical devices identification (2014) 
- Draft template of EP/STED17 for dental composites with specifications for 
nanotechnology application 
- Draft guidance for technical review of CMC18:with adapted review checklist for 
nanotechnology-related pharmaceuticals [49, 50] 
- Draft Guidance for technical review of CMC screening standards for liposome 
drugs 
                                           
17 Essential Principles/Summary Technical Documentation 
18 Chemistry, Manufacturing, and Controls 
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3.3.2  Compilation of descriptions of relevant terms  
The reduced set of terms described in section 3.1.3 was used to compile descriptions in 
sources with regulatory relevance. Most of the descriptions collected were not legally 
binding or established regulatory definitions but recommendations, working definitions or 
definitions provided in a specific context.  
 
Table 10 indicates the regulatory authorities that provide a description of the general 
terms related to nanomedicine on their website. For specific terms for different types of 
nanomaterials the search failed to find descriptions in most of the regulatory sources 
explored and as alternative sources to direct regulatory documents, descriptions from 
international standards were retrieved; biomedical and nanotechnology-specialised 
ontologies and glossaries; peer-reviewed articles, selected according their relevance in 
the research field, and other documents with regulatory influence. Descriptions for 
general and specific terms are listed in Annex 5. 
 
Table 10 Authorities providing descriptions in English of selected general terms on their website. 
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3.4 Discussion on selected nanomedicine terms 
3.4.1 Nanomedicine 
The increasing interest in nanomedicine research is reflected by the number of articles 
having this term as a keyword attributed by the authors. From 1996 to 2006 the term 
nanomedicine appeared as an author keyword in 80 documents from the publications 
dataset (Step 1) and increasing to a total of 2320 documents over the following ten 
years (Figure 15). 
Figure 15 Use of the term nanomedicine as an author keyword in the publications dataset 
 
Annual contribution of the total number of publications extracted with the search string nanomedicine* (blue 
line) in the period of 1996-2016 and f the total number of publications mentioning nanomedicine as an author 
keyword (red bars) in the same period. Source: TIM (http://tech.timanalytics.eu) 
According to the bibliometric analysis the term nanomedicine appears for the first time in 
1998 in a publication title [51]; in 2001 this term appears as an author keyword in an 
article about future possibilities that nanotechnology will offer in the field of 
neurosurgery [19]. In 2004 eight publications have nanomedicine as an author keyword. 
These publications discuss a wide range of topics from the application of nanotechnology 
in diagnostics, drug delivery [20, 21] and molecular imaging applications [22], the 
possibilities offered by nanotechnology in the field of neurological surgery [23], 
investigation of nanorobotics system design in nanomedicine [24], to the potential social 
impact and ethical issues of the application of nanomedicine in health care [25]. The 
analysis of the term co-occurrence shows that in the scientific literature the most co-
occurring terms with nanomedicine, i.e. terms that appear together in more than 50 
publications, are drug delivery, nanoparticles, nanotechnology, cancer, 
nanobiotechnology, liposomes, or theranostics nanomedicine. 
Some authors have indicated that a (regulatory) definition of nanomedicine would have 
implications for many aspects of translational research, potentially influencing fund 
allocation, patents, drug regulatory review processes and approvals, ethical review 
processes, clinical trials and public acceptance [26]. Other authors have expressed 
reservations about the use of the term nanomedicine to refer to nanotechnology-enabled 
medicine or nanotechnology in different areas of medicine [27], considering 
nanomedicine as an academic term, while explaining that industry perceives it as 
another advanced medical technology. 
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The mapping shows that the term nanomedicine is used almost exclusively by certain 
regulatory authorities in their websites. There is no regulatory definition of 
nanomedicine. Some of the authorities consulted in this report propose working 
definitions; however, other sources, stakeholders and organisations have defined the 
term from their perspective. Table 20 in 0 lists descriptions of the term nanomedicine 
retrieved from regulatory sources. 
The term nanomedicine was mentioned in two clinical trials' summaries in the dataset: 
once as primary sponsor company name (Clene Nanomedicine), and once to identify the 
application of nanomedicine technology for diagnosis, referring to the gene expression 
profile evaluation as diagnosis tool in allographs recipients (WHO Clinical trial ID: 
NCT01929785). 
3.4.2 Nanomedicines 
Table 21 in 0 presents a list of descriptions of the term nanomedicines extracted from 
regulatory sources. 
The term nanomedicines in the literature appears for the first time in 2003 and it was 
used to describe a "nano-antifungal" product class [43]. In 2004, Alonso [44] used the 
term as an author keyword and in the article defined nanomedicines as [products] 
consisting of nanosystems that are able to deliver drugs to the right place, at 
appropriate times. 
During the identification of terms in the scientific literature metadata, the term 
nanomedicines was among the top 20 most frequently occurring author keywords, 
mentioned in 146 publications (Figure 16, green bars). In contrast to the term 
nanomedicine that broadly defines the application of nanotechnology to the health sector 
and therefore could imply a variety of products including pharmaceuticals as well as 
medical devices, an analysis of the publications retrieved with the plural variant 
suggested the association of this term to the description of nanotechnology-based 
pharmaceutical products. 
Figure 16 Use of nanomedicines term as an author keyword in the publications dataset 
 
Annual contribution of the total number of publications extracted with the search string nanomedicine* (blue 
line) in the period of 1996-2016 and f the total number of publications mentioning nanomedicines as an author 
keyword (green bars) in the same period. Source: TIM (http://tech.timanalytics.eu)  
The scientific literature also presents other terms and expressions which medicinal 
products containing nanoparticles, nanomedicines products, nanodrugs or 
nanopharmaceuticals as synonyms.  
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In the clinical trial registry, the applied search did not find any record when mapping the 
ICTRP for this term. 
3.4.3 Nanomaterial 
The scientific publications dataset consists only of publications in the field of 
nanomedicine and the term nanomaterial in this context is among the top 10 most 
relevant keywords in the established set. 
Figure 17 Use of nanomaterial term as an author keyword in a nanomedicine related dataset 
 
Annual contribution of the total number of publications extracted with the search string nanomedicine* (blue 
line) in the period of 1996-2016 and f the total number of publications mentioning nanomaterial as an author 
keyword (orange bars) in the same period. Source: TIM (http://tech.timanalytics.eu)  
In a regulatory context, the term nanomaterial is also one of the most frequent nano-
prefixed terms, both in terms of number of texts extracted from authorities' websites 
and in terms of number of distinct authorities using the term in their documents. A 
comprehensive comparison assessment of the key elements in regulatory and advisory 
definitions of the term nanomaterial already exists [52]; this report only included the 
descriptions that are relevant to health products applying nanotechnology or containing 
nanomaterials. Table 22 in 0 presents a list of descriptions of the term nanomaterial 
extracted from regulatory sources. 
Regarding the use of nanomaterial to describe materials containing or applying 
nanotechnology in the health sector, several publications and official documents used the 
term nanomaterial when referring to the type of material in the registration or 
authorisation forms for nanotechnology-based products. The Australian TGA has a 
general working definition for nanomaterial, which is applicable to several products, and 
TGA uses the term in the definition of nanomedicines as therapeutic products containing 
nanomaterials. The FDA uses the term nanomaterial in a general context; it has not 
established a regulatory definition of nanomaterial, but rather uses the term for ease of 
reference when generally referring to both materials in the nanoscale range and certain 
materials that otherwise exhibit related dimension-dependent properties or phenomena. 
The various Directorates of the European Commission use the term nanomaterial in 
relation to different sectors and products. The DG GROW's website mentions the term 
nanomaterial in documents involving the description of medical devices, which are 
described as medical devices containing nanomaterials. The DG SANTE's website uses 
the term nanomaterial to describe the use of nanotechnology in products other than 
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medicinal products (e.g. cosmetics). EMA does not describe or use the term 
nanomaterial in the information provided at its webpage, instead the agency uses the 
term nanomedicine to define the use of nanotechnology in medicinal products. 
This mapping exercise in clinical trials showed only one summary referring to the term 
nanomaterial to describe a clinical research on nanomaterial-based sensors. 
3.4.4 Nanotechnology 
The survey of scientific publications revealed that the term nanotechnology was one of 
the most frequently used author keywords in the nanomedicine publications dataset. The 
term appeared in the earliest publications, and modifications of the word such as cancer 
nanotechnology or pharmaceutical nanotechnology were introduced in recent years, with 
more than 50 composed terms. 
In general, there is no accepted regulatory definition of nanotechnology at international 
level. The definition of nanotechnology and its interpretation are essential elements in 
the definition of nanomedicine. Several guidance documents on requirements for 
marketing authorisation of drugs and health products indicate special requirement for 
nanotechnology–based products or they fall outside the scope of the guidance. Table 23 
in 0 lists the descriptions of the term nanotechnology provided in English language in the 
webpages and documents provided by regulatory sources. 
Two main elements were identified as critical in the retrieved descriptions of the term 
nanotechnology: the size and the exhibition of unique properties related to dimensions. 
In general, the size ranges from 1 to 100 nm but in some of the descriptions, this range 
is approximate and not always consistent, even in documents from the same source. 
Other sources only mention the term nanoscale to define the size (section 4.5.4). 
In some of these nanotechnology descriptions, a change of properties at the nanoscale in 
comparison to the non-nanoscale is indicated as a regular element of the description; 
whereas in others, this change of properties, either chemical, physical or even biological, 
is only a determining factor in the description of nanotechnology when the outcome of 
the technology is a structure larger than 100 nm. 
A number of clinical trials (14) and patents also mentioned the term nanotechnology in 
their descriptions. 
3.4.5 Nanoscale 
In a literature review on challenges facing the development of nanotechnology 
terminology and nomenclature in the field of nanotechnology [53], Klaessig et al. 
claimed that any new field derived from the application of nanotechnology methods and 
techniques is susceptible to the debate on the nanoscale size and how it affects the 
classification of the products enabled by these technologies and their regulation [53]. In 
nanomedicine, size is a key element which may warrant additional safety requirements 
or quality attributes. Klaessig et al. [53] referred to nanoscale as an example of a term 
that may have different meanings depending the regulatory context. The author notes 
that there is a tendency that those [unique properties] concerned with biological effects 
or behavioural differences have a more flexible range to define the term nanoscale, 
increasing the size range of the definition beyond 100 nm. Descriptions of the term 
nanoscale found in the regulatory authorities' (RAs) websites (0) were compiled. 
The keyword analysis of RAs' websites showed the use of the term nanoscale mainly as 
an adjective or as a synonym of the prefix "nano" in words related to health sector 
products differentiating them from their bulk equivalent, or to indicate the size of the 
molecular or structural entity or product (i.e., nanoscale materials, nanoscale self-
assembling peptide, nanoscale oil, nanoscale device, nanoscale ingredients, nanoscale 
crystals, nanoscale platforms or nanoscale therapeutics). In other cases, the term 
nanoscale is implicit in the use of the prefix "nano" for some terms to differentiate them 
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from the bulk equivalent or to indicate the application of nanotechnology methods or 
techniques. 
Almost all descriptions found in the explored regulatory sources indicated a size range 
that includes 1 to 100 nm for nanoscale. These descriptions might include the limits 
mentioned, leading to a more rigid application of nanoscale. Other descriptions use the 
words "around" or "approximately" allowing interpretation to consider products of larger 
sizes as well. 
Health Canada defines in its glossary the term nanoscale as "properties or phenomena 
as properties which are attributable to size and their effects; these properties are 
distinguishable from the chemical or physical properties of individual atoms, individual 
molecules and bulk material" [54].  
As for the application in nanomedicine, the nanoscale phenomena may also cover 
specific physiological interactions, transitions between molecular and microscopic scales, 
such as increase of drug availability due to an increase of the surface, or alteration in the 
pK [25]. This unique behaviour could occur for sizes larger than 100 nm, and it had been 
taken into consideration in some descriptions concerning nanomedicine terminology. For 
example, Swissmedic describes the upper limit size range to 1000 nm when defining 
nanoscale and FDA's overarching final guidance explains that when considering whether 
an FDA-regulated product involves the application of nanotechnology, FDA will consider 
whether a material or end product is engineered to exhibit properties or phenomena 
attributable to its dimensions up to 1000 nm. 
3.4.6 Nanostructure 
Table 25 presents a list of descriptions of the term nanostructure extracted from 
different sources. The only description found in a regulatory source for the term 
nanostructure was in the Government of Canada’s terminology and linguistic data bank 
Termium Plus. This term had been also described in the CPC to explain the classification 
for specific uses or applications of nano-structures. In the description of this class, other 
terms such as nanosize or nanoscale are also defined as relate[d] to a controlled 
geometrical size below 100 nanometres (nm) in one or more dimensions. 
In the dataset of clinical trial summaries, only one result was found to use this term to 
describe a clinical research project on a nanostructured lipid carrier.  
Concerning patents, 36 patents classified under the CPC as nanomedicine used the term 
to identify structures with a size range larger than 100 nm. In one patent, the term 
nanostructure was described as a structure having at least one region or characteristic 
dimension with a dimension of less than about 500 nm, e.g., less than about 200 nm, 
less than about 100 nm, less than about 50 nm, or even less than about 20 nm (Patent 
number: 9,598,287; Title: Method of synthesizing carbon nanorods and nanowires). In 
other patents, the size describing a nanostructure went beyond 1000 nm, where the 
nanostructure of claim, has a length of about 1 nm to about 1500 nm (Patent number: 
9,187,330; title: Tubular nanostructure targeted to cell membrane). 
3.4.7 Nanosimilars 
This term was initially proposed by EU regulators and it was described on the EMA 
website as nanomedicines that are claimed to be similar to a reference nanomedicine19.  
In the scientific literature, only 3 publications included the term in the author keyword 
list. In one of these publications, the term nanosimilars was explained as new medicinal 
outcomes combining the generic drugs and the nanocarrier as an innovative excipient, in 
                                           
19 Nanotechnology. European Medicines Agency webpage: 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/special_topics/general/general_content_000345.js
p& (Retrieved 9 March 2017) 
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order to evaluate them as final products [55]. Other terms or phrases, such as generic 
versions of nanomedicines or follow-on nanomedicines had been used to describe this 
concept in the scientific literature [56-58]. No results were found in the mapping of this 
term to the ICTRP clinical trials database. 
3.4.8 Nanodevice 
The only definition for this term was found in the glossary TERMIUM Plus® from the 
Government of Canada. In this source, nanodevice is defined as an artificial eutectic 
mechanical device that relies on nanometres-scale components [54]. The glossary also 
provides synonyms: nano-devices delivering drugs and devices incorporating 
nanotechnology. 
The National Cancer Institute Thesaurus (NCIT) gives more relevance to the chemical or 
biological part of the definition and defines this term as a functional macromolecule 
composed of nanoscale components. Other definitions focused on the engineering 
properties of the device, thus the NanoParticle Ontology (NPO) defines this term as an 
engineered nanomaterial which has an end-directed activity/function.  
3.4.9 Theranostic products (or theranostics), Combination 
products, and Borderline products  
3.4.9.1 Theranostic Products (or theranostics) 
In the literature, several authors define theranostics as the combination of disease 
diagnosis and therapy [59]: A term created from the words "therapeutic" and 
"diagnostics", it refers to a class of pharmaceuticals and their directly-related diagnostic 
accoutrements [60]. When applied to nanomedicine, a variety of synonyms had been 
used to describe the meaning including nanotheranostics, theranostic products or 
theranostic platforms. In these cases, the term refered to the combination of diagnostic 
and therapeutic properties within a single nanomedicine formulation [61]. 
The biomedical terminology of Medical Subject Headings (MeSH) included the term 
theranostic nanomedicine referring to an integrated nano-scale approach to medicine 
which involves concurrent diagnosis, drug delivery, therapy, and monitoring of 
therapeutic response [62]. 
3.4.9.2 Combination Products 
The term combination products is mainly used by the FDA, which defines it as: 
(1) A product comprised of two or more regulated components, i.e., drug/device, 
biologic/device, drug/biologic, or drug/device/biologic, that are physically, 
chemically, or otherwise combined or mixed and produced as a single entity; (2) 
Two or more separate products packaged together in a single package or as a 
unit and comprised of drug and device products, device and biological products, 
or biological and drug products; (3) A drug, device, or biological product 
packaged separately that according to its investigational plan or proposed 
labelling is intended for use only with an approved individually specified drug, 
device, or biological product where both are required to achieve the intended use, 
indication, or effect and where upon approval of the proposed product the 
labelling of the approved product would need to be changed, e.g., to reflect a 
change in intended use, dosage form, strength, route of administration, or 
significant change in dose; or (4) Any investigational drug, device, or biological 
product packaged separately that according to its proposed labelling is for use 
only with another individually specified investigational drug, device, or biological 
product where both are required to achieve the intended use, indication, or effect 
(21 Code of Federal Regulations 3.2(e)).   
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Also, Health Canada uses the term combination product in a similar concept: 
Is a therapeutic product that combines a drug component and a device 
component (which by themselves would be classified as a drug or a device), such 
that the distinctive nature of the drug component and device component is 
integrated in a singular product (Health Canada 2006). 
Inside this category, Health Canada indicated that nano-devices delivering drugs, fell 
between regulatory regimes (for drugs and medical devices) and thus required different 
regulatory approaches which could cause administrative delays in product reviews, and 
also result in inconsistencies across regulatory frameworks (Health Canada 2010). 
The Australian Therapeutic Goods Administration (TGA) proposes a new term to convey 
the potential regulatory uncertainty over this type of products: Device-medicine 
boundary products: […] therapeutic goods that are not readily identified as medicines or 
devices [63]. 
3.4.9.3 Borderline Products 
Like the Australian TGA, the EMA also uses borderline products as a term to indicate 
products with an unclear regulatory path, although there is no official definition for 
borderline products. In a report, the EMA Innovation Task Force (ITF) uses this term to 
describe also products that include combination of pharmaceuticals and device. […] 
products for which there is uncertainty over whether they fit the definition of a medicinal 
product or not. 
In the Manual on borderline and classification in the Community Regulatory framework 
for medical devices (version 1.17 of 09-2015)20, the European Commission provided an 
explanation of the meaning of borderline cases for medical devices:  
Borderline cases are considered to be those cases where it is not clear from the 
outset whether a given product is a medical device, an in vitro diagnostic medical 
device, an active implantable medical device or not. Or alternatively, borderline 
cases are those cases where the product falls within the definition of a medical 
device but is excluded from the Directives by their scope. Where a given product 
does not fall within the definition of medical device or is excluded by the scope of 
the Directives, other Community and/or national legislation may be applicable. 
                                           
20 Manual on borderline and classification in the Community Regulatory framework for medical devices (283 
KB) (version 1.17 of 09-2015) 
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4 Final remarks and conclusion 
A novel, growing scientific field is usually accompanied by the generation of a myriad of 
terms, concepts and definitions, which might be used ambiguously by the stakeholders 
with diverse interests and different backgrounds, as is the case for the application of 
nanotechnology in the healthcare sector.  
This report aims to support the establishment of a harmonised terminology, in English, 
for nanotechnology-based health products. Terminology related to the field of 
nanomedicine has been captured, mapped, and analysed. The terminology derived from 
different types of information sources commonly used in the regulatory framework for 
medical products: scientific articles, RAs' webpages, clinical trial registries and patents. 
This study contributes to the ongoing debate on terminology for nanomedicine, presents 
supporting information for obtaining an overview of the potential divergences that may 
appear in the use of terminology in a regulatory context, and discusses the challenges 
that may arise from the variety of definitions of the same (or very similar) terms.  
The major outcomes of this work are summarised here. 
 Presentation of a methodology to profile the basic terminology in the 
emerging field of nanomedicine and construct a specialised keyword set  
The tech and text mining tools used in this study were confirmed as suitable methods to 
obtain an objective picture of the terminology used and allowed extraction of relevant 
keywords within an evolving field such as nanomedicine. By combining text mining and 
bibliometric methodologies, a methodology has been developed which allowed to 
construct a keyword set which is sufficiently comprehensive to cover a wide range of 
concepts related to the field of nanomedicine as well as to identify the relevant 
information in different types of sources. 
Similar to earlier bibliometric analysis of nanotechnology-related publications [64], the 
analysis of keywords in the publications dataset identified an increase of the terminology 
associated to nanomedicine over the years, particularly in nano-prefixed terms, which 
can be interpreted as an increasing research activity in this field. The combination of an 
automatic term recognition approach, a specialised subset of publications and a simple 
literature review yielded a comprehensive list of general terms defining the principal 
areas of application of nanomedicine including therapeutics, diagnostics, drug delivery 
and devices incl. nanorobotics. Furthermore, specific terms that define the types of 
nanomaterials applied, such as dendrimers, nanocarriers, micelles, liposomes, and 
magnetic nanoparticles, were identified.  
Based on term frequency, as an indication of terminology consolidation within the field, 
and term relevance, which is a text-mining algorithm that identified candidate terms 
from specialised scientific publications considered to be highly relevant to a field, over 
four hundred keywords from scientific publications related to the field of nanomedicine 
were selected for the applied specific keyword set. The use of a specific keyword set was 
particularly useful to explore sources covering diverse themes, tailoring the mapping to 
specific information on nanomedicine and avoiding the inclusion of terms related to 
topics or products outside the scope of this analysis (e.g. cosmetics, food or pesticides). 
Based on its completeness and robustness, this keyword set is a valid tool to map other 
information sources on the topic of nanomedicine. 
 Mapping and analysis of the use of specialised nanomedicine terminology 
in relevant regulatory sources 
None of RAs have specific regulations for nanotechnology-based medical products. The 
regulation of these products is covered by the general legislation addressing the health 
sector and available procedures to ensure products' safety, quality and efficacy. 
However, the RAs are aware of the need for additional regulatory guidance, 
requirements and testing standards to address nanomedicine and support the approval 
of these products [10]. A way to adapt current regulation is through a number of 
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nanospecific requirements, and some medicine regulatory agencies are already 
requesting information to identify nanotechnology-based products and providing specific 
guidance on how to assess the quality or toxicity of certain materials used in 
nanomedicine [65]. 
Mapping different information sources with the specialised keyword set provided an 
overall picture on the use of terminology, especially in a regulatory context. The analysis 
of the type and frequency of nanomedicine-related terms was analogous to the one 
applied in bibliometric studies when exploring a common lexicon on nanotechnology in 
the scientific literature [17]. The initial assumption of the study was that the use of 
nanomedicine-related terms, including nano-prefixed and non nano-prefixed terms, 
reflects the sharing of information and interest of the RA regarding the application of 
nanotechnology in the health sector. Also, the identification of differences in the use of 
specific terminology among the RA could be used to indicate potential regional 
divergences and identify areas for future discussions towards terminology harmonisation.  
The analysis of the frequency of occurrence for general terms revealed an interesting 
trend in the use of certain terms. For example, to describe the application of 
nanotechnology in medicinal products, EMA uses the term nanomedicines, whereas 
nanomaterial is used by the FDA to describe drug products that contain nanomaterials.  
The terminology analysis of the RAs' websites provided insights into the differences in 
the amount of information as well as the number and type of terms used in regulatory 
documents to describe the advancements in the nanomedicine field. The type of 
information provided at these websites presented a wide range of subjects and 
document types, including product registration forms, guidance documents, product 
information factsheets, patient/consumer leaflets, assessment reports from regulatory 
agencies or information on safety of drugs. Regarding the total amount of information 
extracted from the webpages, a huge variability among the regulatory authorities was 
observed. For non-English webpages this variability could be partially explained by the 
limited number of webpages in English. When English is the primary language, this 
variability could be explained by the level of transparency to inform different 
stakeholders (consumers, practitioners, registrants). A confounding source of terms was 
the variety of products that a health authority may regulate, from food and cosmetics to 
tobacco products. Among the authorities analysed in here, the FDA, Health Canada and 
TFDA are agencies presenting more nanomedicine-related concepts in the information 
shared on their websites. In particular, an extensive list of specific terms related to 
nanomaterials at the FDA website in a specialised section on Science and Research gave 
a significant amount of information on basic and clinical research.  
Finally, the report describes interesting regional variants in the use of general terms 
indicating the need to establish clear terminology and definitions which would facilitate 
an effective communication among international stakeholders and foster a regulatory 
convergence for products that apply nanotechnology. An example is EMA's use of the 
plural form of the term nanomedicine that is almost exclusively used in the EU to 
describe the application of nanotechnology in medicinal products. Since EMA only works 
on medicinal products and biological products, the term nanomedicines, when used by 
EMA, should not be confused with other applications, such as medical devices. However, 
the term nanomaterial is used by EMA with a low frequency, and it is used more 
frequently in organisations outside the EU as a general term to refer to nanotechnology-
based products or materials (e.g. liposomes, dendrimers and metal nanoparticles). Some 
terms, identified as used by non-European agencies to describe nanomedicine products, 
are compound terms such as therapeutic products containing nanomaterials (Health 
Canada), nanotechnology-based medicines or nanosize drugs (PMDA, Japan), or drug 
products that contain nanomaterials, nanotechnology products or products that involve 
the application of nanotechnology (FDA). However, these terms might not be solely 
related to medicinal products (or drugs) but also refer to medical devices or combination 
products. Thus, an agreed set of terms and definitions, which describe the various 
applications of nanotechnology in medical products unambiguously, would improve 
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communication among stakeholders and contribute towards global regulatory 
convergence for such products. 
 Increased use of nanomedicine-related terms in clinical trials and 
patents 
As previously reported in [25], an increase of applications of nanotechnology in health 
products was also identified through the analysis of terminology in the international 
clinical trials registries database WHO-ICTRP. Due to the nature of the information 
reported (for example, type of material, processes or interventions, disease targeted or 
studied application), clinical trial registries and patents were interesting sources of 
information to assess the impact of application of nanotechnology in the health sector, 
and therefore useful sources of specialised terminology. Researchers, industry and 
policy-makers might benefit from the information provided in patents to identify 
potential solutions to technical problems, future commercial applications, and to drive 
innovation and regulatory preparedness to inform decision-making [18].  
In this study, the keyword set in clinical trials and patents as a proxy for the terminology 
used by researchers, clinicians and producers to describe the application of 
nanotechnology in medicinal products and medical devices in a specialised context other 
than scientific publications. This analysis did not aim to provide any categorisation of 
nanomedicines.  
Within the clinical trials registry, it was evident that materials, products and research 
protocols described would correspond exclusively to the health sector and the approach 
identified a wide range of terms describing the use of nanomaterials in the health sector. 
The fact that only few new terms were identified querying nano*, in comparison with the 
nano-prefixed terms already present in the keyword set, validated its extensiveness to 
be used for future evaluations of terminology in other sources. 
Similar to scientific publications, the clinical trials database was enriched in specific 
terms describing materials and formulations but showed scarce reference to general 
terms. The analysis of non nano-prefixed terms showed that liposomes, emulsions, 
aerosol, hydrogel followed by colloids were the most frequent terms used to report 
potential nanomedicine products. However, due to the lack of detailed size information, 
it was difficult to reliably assess whether the material is smaller than 1000 nm and 
whether the extracted clinical trial could be referring to an investigation of a product 
applying nanotechnology. Depending on the definition of nanomedicine or nanomaterial, 
a number of clinical trials extracted by querying these terms could be considered outside 
the scope of this study. For example, several products already approved and on the 
market involve drugs encapsulated in liposomes with a size of several micrometres, 
which in some scientific publications were labelled as nanopharmaceuticals based on its 
individual drug containing nano-sized chambers [66]. A similar trend was observed in 
patents; however, as some patents had a well-defined classification system that 
indicated whether nanotechnology was involved or were directly classified as 
nanomedicine, the uncertainty associated to the use of non nano-prefixed term to 
identify nanomedicine products was reduced. 
The increasing use of nano-prefixed terms for already existing concepts may suggest an 
effort to unambiguously identify the tested product as a nanotechnology-based product. 
However, the social aspect of using nano-prefixes to imply innovation or rebranding 
technology to receive funding had also been previously suggested as a relevant factor in 
the analysis of the lexicon evolution on nanotechnology [14]. Thus, the establishment of 
a clear terminology to describe materials and formulations applying nanotechnology or 
containing nanomaterials would contribute to developing a classification system for these 
products to strengthen the translation of research, increase transparency and enable 
informed decisions. 
 Compilation of relevant terms to describe the application of 
nanotechnology in the health sector and relevant documentation.  
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Finally, the report presents a compilation of descriptions of selected nanomedicine-
related terms provided in documents by RA or with regulatory relevance. Due to a 
general lack of information on terms related to materials and formulations within the 
RAs' websites, the descriptions were extracted from existing vocabularies, glossaries or 
available ontologies. Some of the selected terms were used also in other contexts; 
however, the extraction of descriptions was limited to documents that inform on the 
application of nanotechnology in the health sector.  
This compilation presents the variety of elements in the descriptions, which may 
contribute to the discussion, at scientific and/or regulatory level, on the need to clarify 
certain terms. It also points out the inconsistencies among RA in the descriptions of a 
certain term and provides the foundation to work towards a harmonised terminology in 
nanomedicine. 
In conclusion, the diversity of terms as well as their correlation and description highlight 
the challenges of communication in biomedical research and regulation of 
nanotechnology-based products. The mapping approach presented here is a first attempt 
to identify the key terms distinctly used by different health authorities to provide 
information on nanomedicine. These results show sectorial and geographical difference in 
the use of the key terms among authorities in different geographical areas. This diversity 
was also observed in the definitions extracted from regulatory sources, especially those 
concerning general terms. The results aim to provide a first basis for discussions towards 
a harmonised terminology in this area. In the future, an extension of this mapping 
approach to other relevant local, national and global health authorities, for example 
international organizations such as the World Health Organization and the World Trade 
Organization, may contribute to the effort to integrate terms and concepts across 
authorities covering the regulation of medical products applying nanotechnology. This 
work might provide necessary background information to allow the development of 
standards in the field of nanomedicines, which would stimulate innovation and foster 
industrial competitiveness. 
Finally, as this report has been underway for some time and as the preliminary outcomes 
were presented to the IPRF at several occasions, various websites of the RA have been 
modified. Given this dynamic nature of websites, it would not be possible to exactly 
replicate this study.  
4.1.1 Challenges and next steps 
This initial study has shown the feasibility of the methodology, which could thus be used 
in future research for example in studies with an enlarged number of RAs' websites. The 
present study focussed mainly on authorities from countries participating in the IPRF 
Nanomedicines Working Group.  
Since text-mining was performed over the total of information obtained from the 
regulatory agencies, the frequency analysis of the terminology might include documents 
from the application of nanotechnology in other fields, for example the use of 
nanoparticles in sun-screen products. This could have a significant impact in the number 
of documents extracted for certain terms, especially for general terms such as 
nanotechnology or nanoscale. In order to identify only health related documents, the 
current dataset needs to be further curated, and ways to systematically or 
(semi)automatically in-and exclude documents might be considered in future.  
Due to technical challenges, it was impossible to crawl some webpages, hence manual 
mapping using the website's search engine was performed. Therefore, the frequency 
analysis was not considered for these websites but the retrieval of term definitions was 
performed whenever possible (Step 3). A similar approach was used for clinical trials 
information. The presented results could therefore be considered as an analysis of trends 
rather than a report of exact frequency numbers. An automatic text-mining approach, 
using term variants, considering product brands or co-term analysis would have resulted 
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in a more accurate picture of the use of nanomedicine terminology in these information 
sources.  
The application of text mining and automatic term extraction as well as analysis of other 
relevant information sources that are representative of the translation of nanomedicine, 
e.g. automatic text mining of the clinical trials databases may provide sufficient and 
robust data for the analysis of the evolution of terminology in this emerging technology. 
Comparing the terminology used at different stages of translation (from research to 
commercialisation) could aid in understanding for example the maturity of the state of 
science, the level of integration between stakeholders and the consolidation of the 
terminology. A common understanding on terms relevant for innovative medical 
products will support a smooth translation of highly needed products from the laboratory 
environment to clinical applications where they are highly needed in order to adress 
unmet medical needs. Since most diseases are not region specific a harmonised 
terminology describing such emerging product class are of utmost importance to make 
them available to markets worldwide without unnecessary delay. 
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Annex 1 Description of bibliometric search engines 
A1.1  Automatic extraction with Tools for Monitoring Innovation 
(TIM) 
TIM is a platform being developed by the JRC's Competence Centre on Text Mining and 
Analysis at the European Commission, which applies text mining and computational 
linguistic techniques to monitor innovation through the analysis of documents on a 
specific topic. TIM technology editor allows its users to create and visualise datasets 
about specific technological issues. It gathers together datasets such as patents, 
scientific publications, and EU grants (http://timanalytics.eu/). 
This search engine provides a wide range of text-mining and visualisation tools 
interesting for this purpose, such as automated extraction of keywords, information on 
keyword occurrence and co-occurrence frequency (Figure 2) and the application of 
algorithms to rank keywords according their relevance on the document set retrieved for 
a given search string. 
A1.1.1.Keyword and topic visualisation 
TIM facilitates the visualisation of the keyword extraction results through word maps, 
also called keyword co-occurrence networks (KCO). KCOs use the most frequent author 
keywords of the documents to study the conceptual structure of a research field (Figure 
18). The size of the nodes is proportional to the respective keyword's frequency 
(number of documents mentioning a given author keyword); the thickness of the edges 
represents the co-occurrence of the linked nodes (number of documents sharing 
keywords. Author keywords listed in one paper are linked together because they are all 
terms that can be used to represent the core of a research paper and stronger 
interrelations can be expected. 
Figure 18 Visualisation of keyword frequency and co-occurrence in TIM  
 
This platform identifies and lists three categories of keywords: author, automatic and 
relevant keywords (Box 1). In general, the automatic keywords category of keywords 
contains general terms that are unspecific for the field of nanomedicine. For this reason, 
only author keywords and relevant keywords extracted with TIM were considered in the 
construction of the nanomedicine keyword set. 
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Keywords generated by TIM (Tools for Monitoring Innovation) 
language processing algorithms 
 Author Keywords are keywords chosen by authors of scientific papers to describe the 
topic of their paper and for indexing their paper. Author keywords are frequently 
included in the header information of a published journal article. This category only 
refers to terms found in the scientific literature (articles, reviews, conference 
proceedings and some book chapters) and no data consolidation has been performed in 
this set.  
 Automatic keywords are terms automatically extracted from the text using language 
processing algorithms. They are calculated by processing the title, abstract and author 
keywords. The Automatic keywords are extracted from all types of documents retrieved 
with this query, including patents and EU projects. The list of automatic keywords goes 
through a process of data consolidation, for that plurals and certain type of spellings are 
collapsed in one simple term; i.e. the term nanomedicine shows in the literature many 
spelling variants: Nanomedicine, nanomedicine, Nano Medicine, nanomedicines, or 
Nanomedicines. This process reduces redundancy and noise but in some cases may also 
omit relevant information, i.e. plurals of terms with specific meaning compared to their 
singular form. The system applies specific calculations to rank the relevance and results 
in a third type of keyword list called relevant keywords.  
Relevant keywords are terms ranked within the total of documents; these terms have 
associated a numerical score that measures the relevance of the keyword in the group of 
the total of identified terms of this dataset. TIM scores the relevance of the automatically 
extracted keywords within the pool of documents according their weight and uniqueness 
in this dataset. Thus, this score identifies those terms that are rarer and potentially more 
specialised or related to the field. This rank is calculated using the term frequency–
inverse document (TF-IDF) calculation, a numerical statistic that is intended to reflect 
how important a term is to a document by estimating the rarity of a term in the whole 
document collection. TIM designates this list of terms as relevant keywords (source: 
http://tech.timanalytics.eu/). 
A1.2  Automatic extraction with GoPubMed 
To automatically extract terminology on nanomedicine, another bibliographic tool, 
GoPubMed was used, to validate and complement the keyword set extracted with TIM. 
This publication search engine explores information from PubMed 
(https://www.ncbi.nlm.nih.gov/pubmed/), one of the most relevant biomedical literature 
databases. 
Like TIM, GoPubMed provides statistics on top terms and total publications hit counts. A 
particularity of GoPubMed is that this platform performs an ontology-based literature 
search, using hierarchically structured vocabularies, and therefore allows the extraction 
of terms found inside the same class. This web server uses background knowledge and it 
associates concepts with keywords which allows going from general terms to more 
specific ones on the searched topic [67]. These concepts categories come from 
biomedical specific vocabularies such as GeneOntology (GO) for molecular biology 
(www.geneontology.org), MeSH (Medical Subject Headings), SNOMED, or UMLS for the 
medical domain (umlsinfo.nlm.nih.gov). Each of these categories nests other specific 
concepts related with the searched keyword. 
100 top terms provided by the engine were selected and expert judgement were applied 
to exclude terms not specific for nanomedicine but used in the broader field of health 
care and toxicology (i.e. humans, cell line, culture, preparations, or temperature). In 
addition, to increase the specificity of the keywords retrieved selected terms were nested 
under certain general terms: nanoparticles, pharmaceutical preparations, drug delivery 
systems and nanostructures. 
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Annex 2 List of keywords automatically extracted with 
bibliometric search engines 
A2.1 List of keywords automatically extracted with TIM for 
nanomedicine 
The top 100 relevant keywords and author keywords retrieved by using TIM and 
(nanomedicine*) as search string creating a nanomedicine specific publication dataset. 
The keywords are sorted by relevance score (Table 11) and occurrence frequency, 
respectively. Some of the differences between the keywords is whether for example it 
starts with a capital letter or not (e.g. 1. Nanomedicine versus 4. nanomedicine), or 
whether it is plural or not (e.g. 1. Nanomedicine versus 12. Nanomedicines). Author 
keywords having the same frequency appear in random order. The abbreviations in this 
table are automatically assigned by TIM, and they do not always represent the ones 
commonly found in the literature.  
Table 11 Top 100 most relevant terms in TIM's nanomedicine* publications dataset 
Ranking Keywords Relevance Ranking Keywords Relevance 
1 nanomedicine  22492.08 51 nanotoxicity  471.94 
2 drug delivery (DD)  3734.26 52 cancer nanomedicine  470.67 
3 nanotechnology  3512.40 53 silver nanoparticle (SN)  465.71 
4 nanoparticle  3222.09 54 protein corona (PC)  461.46 
5 nanocarriers  1867.88 55 therapeutics  460.78 
6 theranostics  1535.91 56 reactive oxygen species' (ROS)  456.42 
7 liposomes  1494.18 57 paclitaxel  449.80 
8 nanomaterial  1467.77 58 cellular uptake  449.12 
9 quantum dot (QD)  1147.52 59 PEGylated  446.52 
10 polyethylene (PE)  1124.41 60 active targeting  436.10 
11 micelles  951.64 61 gene delivery  434.68 
12 cancer therapy  909.61 62 anticancer drug  430.30 
13 gold nanoparticle (GN)  903.87 63 cytotoxicity  429.12 
14 deoxyribo nucleic acid (DNA)  884.94 64 nanotheranostics  427.96 
15 dox  813.93 65 multifunction  427.39 
16 nanobiotechnology  803.07 66 drug carrier  419.96 
17 MRI 752.73 67 TEM 419.21 
18 dendrimer  751.93 68 nanoscale  416.70 
19 carbon nano tube (CNT)  750.77 69 theranostic nanomedicine  412.74 
20 biocompatibility  749.18 70 drug targeting  408.00 
21 nanorobotics  743.43 71 hydrolysis acidification (HA)  406.43 
22 magnetic nanoparticles (MN)  735.83 72 cancer cells  403.58 
23 nanotoxicology  743.43 73 FeO  399.90 
24 Manufactured nanoparticles (MNP)  710.97 74 photodynamic therapy  399.63 
25 biodistribution  664.92 75 nanotherapeutics  399.18 
26 photothermal therapy  655.71 76 nanoformulation  395.31 
27 targeted drug delivery  655.44 77 delivery system (DS)  384.98 
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Table 11 (cont) 
Ranking Keywords Relevance Ranking Keywords Relevance 
28 biomedic  642.26 78 nanocapsule  384.85 
29 targeted delivery  630.40 79 nanomedical  383.93 
30 quantum dots (QD)  607.94 80 nanosystem 374.68 
31 carbon nanotube (CN)  607.44 81 cancer  373.99 
32 inf  605.53 82 gene therapy (GT)  372.06 
33 doxorubicin  602.52 83 chitosan  369.73 
34 pH  565.24 84 iron oxide (IO)  368.92 
35 ML  555.56 85 nanogel  366.50 
36 solid lipid nanoparticles (SLN)  543.26 86 nanopharmaceutical  359.34 
37 tocopheryl polyethylene glycol 
succinate (TPGS)  
539.33 87 encapsulation  356.01 
38 tumor targeting  538.84 88 mesoporous silica (MS)  347.80 
39 poly lactic glycolic acid (PLGA)  538.38 89 nanostructure  344.79 
40 conjugation  532.21 90 nanodiamonds  338.84 
41 cancer nanotechnology  515.27 91 polymer therapeutics  338.09 
42 molecular imaging (MI)  509.78 92 super paramagnetic iron oxide 
nanoparticles (SPION)  
337.89 
43 delivery  509.48 93 sup  337.10 
44 nanos  507.13 94 contrast agent (CA)  333.95 
45 aunps  505.43 95 nanodrugs  333.87 
46 ribonucleic acid (RNA)  503.80 96 polycaprolactone (PCL)  332.56 
47 EPR effect  499.56 97 prodrugs  331.14 
48 Central nervous system (CNS)  485.71 98 drug load (DL)  328.52 
49 sirna  485.16 99 polymer 328.09 
50 self assembly (SA)  483.43 100 ptx  325.35 
 
 
     
Table 12 Top 100 most frequent author keywords in TIM's nanomedicine* publications dataset 
Ranking Keywords 
Frequency 
Number publications 
Ranking Keywords Frequency 
Number publications 
1 Nanomedicine 2087 51 Tissue engineering 45 
2 Drug delivery 604 52 Dendrimers 44 
3 Nanoparticles 594 53 Hyperthermia 43 
4 nanomedicine 504 54 Micelles 43 
5 Nanotechnology 414 55 Controlled release 43 
6 Cancer 218 56 Endocytosis 43 
7 Nanoparticle 207 57 Photothermal therapy 42 
8 drug delivery 171 58 siRNA 41 
9 nanoparticles 142 59 Inflammation 41 
10 Liposomes 133 60 Targeted delivery 40 
11 Cancer therapy 110 61 DNA 39 
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Table 12 (cont.) 
Ranking Keywords 
Frequency 
Number publications 
Ranking Keywords 
Frequency 
Number publications 
12 Nanomedicines 106 62 Polymeric nanoparticles 39 
13 Theranostics 95 63 Biomaterials 38 
14 Carbon nanotubes 93 64 Drug delivery system 38 
15 Imaging 92 65 Breast cancer 37 
16 Gold nanoparticles 89 66 Oxidative stress 37 
17 Cytotoxicity 86 67 Blood-brain barrier 36 
18 Quantum dots 85 68 Therapy 36 
19 Nanomaterials 82 69 Diagnosis 35 
20 Gene therapy 77 70 Active targeting 34 
21 Targeting 76 71 theranostics 34 
22 Magnetic nanoparticles 76 72 Tumor targeting 34 
23 Chemotherapy 73 73 PLGA 33 
24 Nanobiotechnology 71 74 Polymers 32 
25 Nanotoxicology 71 75 Nanocarrier 31 
26 Toxicity 69 76 Diagnostics 31 
27 nanoparticle 66 77 gold nanoparticles 30 
28 cancer 65 78 self-assembly 29 
29 Liposome 64 79 Atherosclerosis 29 
30 Self-assembly 63 80 Personalized medicine 28 
31 Drug targeting 63 81 cancer therapy 28 
32 Doxorubicin 63 82 liposomes 28 
33 Biodistribution 62 83 Polymeric micelles 27 
34 Biocompatibility 61 84 Theranostic 27 
35 nanotechnology 58 85 Protein corona 27 
36 MRI 55 86 Docetaxel 26 
37 Gene delivery 55 87 SiRNA 26 
38 Apoptosis 54 88 nanomaterials 26 
39 Molecular imaging 54 89 Polymer therapeutics 25 
40 Drug delivery systems 53 90 Biodegradable polymers 25 
41 Cancer nanotechnology 52 91 Polymer 24 
42 Photodynamic therapy 52 92 photothermal therapy 24 
43 Chitosan 50 93 Reactive oxygen species 24 
44 Magnetic resonance imaging 50 94 Targeted therapy 24 
45 Targeted drug delivery 48 95 drug targeting 23 
46 Paclitaxel 47 96 Bioavailability 23 
47 Pharmacokinetics 47 97 Dendrimer 23 
48 Silver nanoparticles 47 98 Alzheimer's disease 23 
49 Nanotoxicity 46 99 Regenerative medicine 23 
50 Nanocarriers 45 100 Surface modification 23 
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A2.2. List of keywords automatically extracted with TIM for 
nano and medical devices 
TIM top 100 relevant keywords and author keyword retrieved using (nano* AND 
"medical device*") as search string sorted by relevance score and occurrence frequency, 
respectively. Author keywords having the same frequency appear in random order. 
Table 13 Top 100 most relevant terms in TIM's (nano* AND "medical device*") publications 
dataset 
Ranking Relevant Keywords Relevance Ranking Relevant Keywords Relevance 
1 medical device (MD)  1991.14 51 nano scale  85.16 
2 silver nanoparticle (SN)  538.07 52 nanoskin  82.82 
3 nanotechnology  439.32 53 Food and Drug Administration(FDA)  79.37 
4 agnps  324.69 54 electrospinning  78.65 
5 implanted medical devices (IMD)  287.01 55 nanogenerator  78.49 
6 biocompatibility  271.37 56 scaffold  77.50 
7 biomaterials  253.26 57 polyurethane  76.99 
8 nanoparticle  236.30 58 polymer  76.34 
9 nanomaterial  213.66 59 bionanocomposite  75.96 
10 biomedic  209.71 60 silver ions  74.80 
11 nanosilver  209.47 61 mosquito lagoon (ML)  74.21 
12 nanomedicine  206.06 62 antibacterial property  73.58 
13 silver  202.61 63 catheter   73.11 
14 biofilm  201.13 64 titanium  72.99 
15 drug delivery (DD)  192.85 65 nanotopography  72.56 
16 active implanted medical devices 
(AIMD)  
188.47 66 nanobiotechnology  72.52 
17 carbon nano tube (CNT)  187.69 67 implantable device  72.43 
18 nanocomposites  168.98 68 nanostructured surface  71.86 
19 scanning electron microscope (SEM)  155.62 69 antimicrobial activity  71.18 
20 coating  152.96 70 antibacterial coating  71.16 
21 nanos  150.17 71 anti biofilm  70.29 
22 tissue engineering (TE)  147.60 72 surface modification  69.21 
23 bias competit (BC)  138.26 73 stent  67.94 
24 antimicrobial  135.37 74 x ray diffraction (XRD)  67.15 
25 inf   135.00 75 hydroxylapatite (HAP)  65.24 
26 biofilm formation (BF)  134.38 76 transmission electron microscopy (TEM)  64.49 
27 protein undernourished (PU)  132.27 77 biosensors  64.17 
28 carbon nanotube (CN)  131.35 78 block copolymer (BC)  63.89 
29 antibacterial  130.67 79 nanotube  63.53 
30 medical implants  129.65 80 blood compatibility  62.94 
31 medical application  123.87 81 orthopedic  62.86 
32 invention  120.93 82 ag nps  62.42 
33 cellulose  119.77 83 micro-Electro-Mechanical Systems (MEMS)  59.58 
34 polydimethylsiloxane (PDMS)  119.06 84 nanocellulose  59.39 
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Table 13 (cont.) 
Ranking Relevant Keywords Relevance Ranking Relevant Keywords Relevance 
35 regener medicin (RM)  112.36 85 thereof  56.74 
36 bacterial  112.00 86 biomimetic  56.32 
37 poss pcu  111.97 87 nanometer  56.31 
38 nanofiber  110.33 88 ag nanoparticle  55.91 
39 wound dressing (WD)  108.66 89 polymere  54.59 
40 nanostructure  108.38 90 staphylococcus aureus (SA)  54.54 
41 antibacterial activity (AA)  105.80 91 hydroxyapatite  54.53 
42 nanoscale  104.42 92 the coat (TC)  54.33 
43 hemocompatibility  101.19 93 cytotoxicity  54.30 
44 poly lactic glycolic acid (PLGA)  97.40 94 polylactic acid  54.21 
45 micro nano  93.74 95 chitosan  54.12 
46 protein adsorption  91.17242 96 atomic force microscopy (AFM)  53.14 
47 implantable  90.60061 97 nanocoating  53.13 
48 hydrogel  89.11189 98 nanopore membranes  52.82 
49 adhesic  88.4455 99 antibiofilm  52.43 
50 implants  86.3094 100 graphene  52.31 
Table 14 Top 100 most frequent author keywords in TIM's (nano* AND "medical device*") 
publications dataset 
Ranking Author Keywords Frequency 
Number publications 
Ranking Author Keywords Frequency 
Number publications 
1 Nanotechnology 47 51 Nanofibers 6 
2 Nanoparticles 41 52 Hydrogels 6 
3 Silver nanoparticles 41 53 Staphylococcus aureus 6 
4 Medical devices 37 54 Infection 6 
5 Biocompatibility 35 55 Stainless steel 6 
6 Medical device 27 56 silver nanoparticles 6 
7 Drug delivery 27 57 Osteoblasts 6 
8 Biomaterials 19 58 Polymers 6 
9 Silver 18 59 Hemocompatibility 6 
10 Nanoparticle 16 60 Pseudomonas aeruginosa 5 
11 Nanomaterials 16 61 Bionanotechnology 5 
12 Antibacterial 16 62 Bionanocomposites 5 
13 Nanomedicine 15 63 Mechanical properties 5 
14 Tissue engineering 15 64 Fibroblasts 5 
15 Biofilm 14 65 Nanoskin® 5 
16 Carbon nanotubes 13 66 POSS-PCU 5 
17 Antimicrobial 13 67 Collagen 5 
18 Regenerative medicine 12 68 MEMS 5 
19 Cytotoxicity 12 69 Biomedical 5 
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Table 14 (cont.) 
Ranking Author Keywords Frequency 
Number publications 
Ranking Author Keywords Frequency 
Number publications 
20 Antibacterial activity 12 70 Apoptosis 5 
21 Bacterial cellulose 12 71 Implant 5 
22 Nanocomposites 11 72 Hydroxyapatite 5 
23 Surface modification 11 73 Biosensors 4 
24 Silver nanoparticle 11 74 Titanium dioxide 4 
25 Electrospinning 10 75 Corrosion 4 
26 Titanium 10 76 Coatings 4 
27 Protein adsorption 10 77 Medical applications 4 
28 Toxicity 10 78 S. aureus 4 
29 Nanosilver 10 79 Chitosan 4 
30 Inflammation 9 80 Nanostructured materials 4 
31 Coating 9 81 Catheter 4 
32 Nanocomposite 9 82 medical device 4 
33 Antimicrobial activity 9 83 Film 4 
34 Controlled release 8 84 Biomedical application 4 
35 Biomaterial 8 85 Nanomaterial 4 
36 Cell adhesion 8 86 Self-assembly 4 
37 Surface functionalization 8 87 Scaffold 4 
38 Polymer 8 88 Bacterial adhesion 4 
39 Biofilms 8 89 DNA damage 4 
40 Nanoindentation 7 90 cytotoxicity 4 
41 Nanotopography 7 91 AFM 4 
42 biofilm 7 92 Carbon 4 
43 Biomedical applications 7 93 biocompatibility 4 
44 Scaffolds 6 94 Stem cells 4 
45 nanoparticles 6 95 Albumin 4 
46 Hydrogel 6 96 Nanotubes 3 
47 Biosensor 6 97 Tribology 3 
48 Composites 6 98 Thrombin 3 
49 nanotechnology 6 99 Gene therapy 3 
50 Nanobiotechnology 6 100 Nanofibers 3 
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A2.3 List of keywords automatically extracted with GoPubMed 
Table 15 GoPubMed top 100 "Top terms" sorted by keyword occurrence frequency 
− Nanoparticles 
− Humans 
− Pharmaceutical 
Preparations 
− Animals 
− Neoplasms 
− Therapeutics 
− Nanomedicine 
− Tissues 
− Mice 
− Evaluation Studies as Topic 
− Drug Delivery Systems 
− Nanostructures 
− Research Report 
− Proteins 
− Genes 
− Patients 
− Nanotechnology 
− Microscopy 
− Male 
− Female 
− Electrons 
− Polymers 
− Electronics 
− Particle Size 
− Oxides 
− Liposomes 
− Cell Line 
− Drug Carriers 
− Cell Line, Tumor 
− Membranes 
− Fluorescence 
− Polymerization 
− Culture 
− Peptides 
− X-Rays 
− Cell Survival 
− Medicalization 
− Immunization 
− Work 
− Antineoplastic Agents 
− Forecasting 
− Diagnosis 
− Lipids 
− DNA 
− Hydrophobic and 
Hydrophilic Interactions 
− Lung 
− Nanotubes 
− Stem Cells 
− Drug Therapy 
− Apoptosis 
− Membrane 
− Spectrum Analysis 
− Nature 
− Equipment and Supplies 
− Personal Autonomy 
− Physics 
− Serum 
− Polyethylene Glycols 
− Cells, Cultured 
− Immunity 
− Microscopy, Electron 
− Fees and Charges 
− Rats 
− Medicine 
− Technology 
− Intracellular 
− Adult 
− Apoptosis 
− Biological Availability 
− Safety 
− Environment 
− Metal Nanoparticles 
− Microscopy, Electron, 
Transmission 
− antigen binding 
− Temperature 
− Antibodies 
− Micelles 
− Macrophages 
− Cell Proliferation 
− X-Ray Diffraction 
− stem cell development 
− Magnetic Resonance 
Spectroscopy 
− Inflammation 
− Ligands 
− stem cell differentiation 
− Microscopy, Electron, 
Scanning 
− Oxygenators 
− Breast Neoplasms 
− Carcinoma 
− Binding 
− Nanotubes, Carbon 
− Survival 
− Hydrogen-Ion 
Concentration 
− RNA, Small Interfering 
− Doxorubicin 
− Pharmacokinetics 
− Wounds and Injuries 
− Transfection 
− Lasers 
− Permeability 
Source: GoPubMed (http://gopubmed.org/web/gopubmed/); search string nanomedicine* 
Table 16 List of synonyms linked to nanoparticles, pharmaceutical preparations, drug delivery 
systems and nanostructures.  
 Nanoparticles Pharmaceutical preparations Drug Delivery Systems Nanostructures 
− Carbon nanotubes 
− Metal Nanoparticles 
− Dendrimers 
− Quantum Dots 
− Nanocapsules 
− Magnetite Nanoparticles 
− Fullerenes 
− Nanoconjugates 
− Nanospheres 
− Nanoshells 
− Nanodiamonds 
− Calcifying Nanoparticles 
− Liposomes 
− Drug Carriers 
− Micelles 
− Dendrimers 
− Nanocapsules 
− Colloids 
− Hydrogels 
− Hydrogel 
− Prodrugs 
− Delayed-Action 
Preparations 
− Suspensions 
− Nanoconjugates 
− Emulsions 
− Excipients 
− Plant Extracts 
− Powders 
− Capsules 
− Dosage Forms 
− Drug Combinations 
− Liposomes 
− Drug carriers 
− Dendrimers 
− Nanocapsules 
− Nanoconjugates 
− Excipients 
− Drug implants 
− Unilamellar liposomes 
− Virosomes 
− Tablets 
− Insulin infusion systems 
− Nanoparticles 
− Nanostructures 
− Nanotubes Nanotubes, 
Carbon 
− Metal Nanoparticles 
− Dendrimers 
− Quantum Dots 
− Nanocapsules 
− Nanocomposites 
− Nanofibers 
− Magnetite Nanoparticles 
− Fullerenes 
− Nanoconjugates 
− Nanospheres 
− Nanopores  
− Nanoshells  
− Nanodiamonds 
− Nanowires 
− Calcifying Nanoparticles 
− Nanotubes, Peptide 
 
Source: GoPubMed (http://gopubmed.org/web/gopubmed/); search string nanomedicine*. These terms are 
sorted by term frequency (number of publications mentioning the term)  
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Annex 3 Description of nanomedicine materials and products in 
the literature 
The extracted categories derived from the scientitic literature review, by searching for 
the term nanomedicine. The 50 most cited scientific reviews on nanomedicine published 
until October 2016 were considered.  
Table 17 Summary of list of terms identified in the literature review 
Source Terms (not official categories) Reference 
 
  
U.S. Food and Drug Administration (FDA)  
 
List of terms applicable to nanomedicine 
Nanoparticle 
Polymeric nanoparticle platforms 
Dendrimer 
Liposomes 
Micelles 
Nanoemulsions 
Nanotube 
Superparamagnetic iron oxide 
Oral presentation 
Not official document [68] 
European Commission 
DG Research  
European Technology Platform on 
NanoMedicine 
 
Nanomedicine 
Liposomes 
Micellular and micro-emulsion Systems 
Liquid crystal based formulations 
Nanocrystals 
Antibodies and conjugates 
Naturally occurring proteins as delivery 
systems 
Polymer conjugates and bio-conjugates based 
on the conjugation of polypeptides and 
polymers 
Biodegradable nanoparticles/nanocapsules 
Virus-like particles for gene delivery 
Delivery of small nucleic acids or mimetics 
Delivery of vaccines 
Oral presentation 
Not official document [69] 
Taiwan 
 
Nanomaterial 
Liposome 
Micelle 
Nanocrystal 
Metal colloid 
Polymer-drug conjugate 
Solid nanoparticle 
Dendrimer 
Scientific article [49] 
Australia TGA 
 
Nanomedicines 
Liposomes 
Pegylated liposomes 
Pegylated proteins  
Protein-drug conjugate 
Nanocrystal 
Nanosuspension 
Emulsions 
Polymeric nanoparticles 
Metal/metal oxides 
Vaccines 
Monoclonal antibodies 
Oral presentation 
Not official document [70] 
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Source Terms (not official categories) (cont.) Reference 
Scientific publications (reviews)   
Nanopharmaceuticals 
(Weissig, 2014) 
Lipid-based (non-liposomal) formulations 
Pegylated proteins, polypeptides, aptamers 
Nanocrystals 
Polymer-based nanoformulations 
Protein–drug conjugates 
Surfactant-based nanoformulations 
Metal-based nanoformulations (SPION) 
Virosomes 
[71] 
Nanoformulation 
Drug nanoparticles 
(Wais, 2016) 
Liposomes 
Dendrimers 
Block copolymer micelles 
[72] 
Nanoparticle therapeutics 
(Miller, 2013) 
Liposome 
Albumin-bound nanoparticles 
Polymeric nanoparticles 
Dendrimers 
Metal nanoparticles 
[73] 
Nanotherapeutics or nanotherapeutic products 
(Hafner, 2014) 
Nanocrystal 
Nanoemulsions 
Polymeric drugs 
Liposomes 
Polymer-protein conjugates 
Nanoparticles 
Virosomes 
Polymeric drug 
Nanocomplex 
[74] 
Nanomedicine-related terms 
(Etheridge, 2013) 
Aerosol OR Nanoaerosol 
Colloid OR Colloidal OR Nanocolloid OR Nanocolloidal OR 
Nanosuspension OR Nanocoll 
Dendrimer OR Dendrimeric 
Emulsion OR Nanoemulsion 
Fleximer 
Fullerene 
Hydrogel 
Hydrosol 
Liposome OR Liposomal OR Nanosome OR Nanosomal 
Micelle OR Micellar 
Nano 
Nanobiotechnology 
Nanobottle 
Nanocapsule OR Nanoencapsulation 
Nanoceramic 
Nanocoating OR Nanocoated 
Nanocomposite 
Nanocrystal OR Nanocrystallite OR Nanocrystalline 
Nanodiamond 
Nanodrug 
Nano-Enabled 
Nanofiber OR Nanofilament 
Nanofilter or Nanomesh 
Nanogel 
Nanomaterial 
Nanomedicine 
Nanometer 
Nanoparticle OR Nanosphere 
Nanopore OR Nanoporous 
[25] 
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Source Terms (not official categories) (cont.) Reference 
Nanomedicine-related terms (cont.) 
(Etheridge, 2013) 
(cont.) 
Nanorod 
Nanoscaffold 
Nanoscale 
Nanosensor 
Nanoshell 
Nanosilver 
Nanostructure 
Nanotechnology 
Nanotherapeutic 
Nanotube 
Nanowire 
Quantum Dot 
Solgel 
Superparamagnetic OR Iron Oxide OR SPIO OR USPIO 
Virosome 
[25] 
Nanomedicines 
Nanocarriers 
(He, 2016) 
Polymeric nanoparticle 
Micelle 
Liposome 
Nanogel 
Mesoporous inorganic nanoparticles 
Metallic/metal oxide nanoparticle 
Carbon nanotube 
[75] 
Nanocarriers 
(Cho, 2008) 
Polymeric nanoparticles (polymer-drug conjugates) 
Polymeric micelles 
Dendrimers 
Liposomes 
Viral-based nanoparticles 
Carbon Nanotubes 
[76] 
Nanomedicinal products 
(Noorlander, 2015) 
Dendrimer/fleximer 
Emulsion  
Gold nanoparticle 
Iron nanoparticle 
Liposome 
Micelle 
Nanodispersion 
Polymer conjugate 
Polymeric nanoparticles 
Protein nanoparticle 
Virosome  
[77] 
Nanomedicine 
(Min, 2015) 
Liposome and Lipid-based nanomedicine 
Protein nanoparticles 
Polymer-drug conjugates 
Polymeric-micelles and nanoparticles: 
 Polymeric micelles 
 Dendrimers 
Inorganic Nanoparticles 
[78] 
Clinical applications 
(Riehemann, 2009) 
Lipid-based vehicles 
Liposomal drug carrier  
Polymer based delivery 
Metal nanoparticles 
Nanoshells 
Non-injectable nanovectors 
[79] 
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Source Terms (not official categories) (cont.) Reference 
Nanovectors 
(Bhattacharya, 2012) 
Liposomes 
Dendrimers 
Micelles 
Polymeric nanoparticles 
Solid lipid nanoparticles 
Other nanoparticles 
[80] 
Nanomedicine systems 
(Rizzo, 2013) 
Liposome 
Polymer 
Micelle 
Nanoparticle 
Antibody 
[61] 
Carrier systems in theranostic nanomedicines 
(Theek, 2014) 
Liposomes 
Micelles 
Polymers 
Dendrimers 
Proteins 
Nanoparticles  
Microbubbles 
Antibodies 
[81] 
Nanomedicines 
(Bremer-Hoffmann, 2015) 
Inorganic particles 
Polymer based nanocarrier 
Lipid based nanocarrier 
Virosome 
Protein conjugate 
[82] 
Nanotechnological platforms or nanocarriers 
(Aparicio-Blanco, 2016) 
Polymer-based nanocarriers: 
 Polymeric conjugates 
 Polymer nanoparticles 
 Polymeric micelles 
 Dendrimers 
Lipid-based nanocarriers: 
 Liposomes 
 Solid lipid nanoparticles 
 Lipid nanocapsules 
Metal-based nanocarriers: 
 Magnetite/Gold/Selenium nanoparticles 
[83] 
Nanomedicines (material category) 
(Bobo, 2016) 
Polymeric nanoparticles 
Polymeric micelles 
Liposomal nanoparticles 
Protein nanoparticles 
Inorganic nanoparticles 
Crystalline nanoparticles 
[84] 
Nanoparticles 
(Tatar, 2016) 
Organic: 
 Drug-polymer conjugate 
 Protein-polymer conjugate 
 Dendrimer 
 Polymeric nanoparticle 
 Liposome 
 Micelle 
Inorganic: 
 Carbon nanotube 
 Silica nanoparticle 
 Porous nanoparticle 
 Gold nanoparticle 
 Iron oxide nanoparticle 
[27] 
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Source Terms (not official categories) (cont.) Reference 
Nanoparticles (cont.) 
(Tatar, 2016) 
 Quantum dots 
Carbon nanotube 
cont. [27] 
Nanoplatform 
(Ma, 2016) 
Lipid-based nanoparticles 
 Liposomes 
 Nanoemulsions 
 Solid-lipid nanoparticles 
Polymeric nanocarriers 
 Polymer-drug conjugates 
 Dendrimers 
 Micelles 
 Polymersomes 
 Microbubbles 
 Protein nanoparticles: (virus nanoparticles) 
Inorganic platforms 
 Carbon-based theranostic platforms (fullerene, carbon 
nanotubes, graphene) 
 Metallic nanoparticles 
[85] 
Nanocarriers 
(Núñez, 2016) 
Micelleplexes: 
 Linear block copolymers 
 Star block copolymers 
 Self-Assembled Cationic Peptides 
Lipoplexes 
Dendrimers 
Cyclodextrins 
 Metallic and magnetic nanoparticles 
[86] 
Nanocarriers 
(Luo, 2015) 
Liposomes 
Polymer-conjugated drugs 
Polymeric nanoparticles 
Dendrimers 
Inorganic nanoparticles 
[87] 
Type of nanoparticles 
(Kompella, 2013) 
Polymeric nanoparticles 
Polymeric nanogels and hydrogels 
Liposomes 
Micelles 
Dendrimers 
Chitosan nanoparticles 
Protein nanoparticles 
[88] 
Nanomaterial type 
(Bregoli, 2016) 
Liposomes 
Albumin-based nanoparticles 
Micelles 
Polymeric nanoparticles 
Inorganic nanoparticles 
[89] 
Nanoscale therapies 
(Heath, 2009) 
Liposome 
Albumin-based 
Polymeric micelle 
Polymeric-drug conjugate 
Targeted liposome 
Targeted polymer-based particle 
Solid inorganic or metal particle 
Dendrimer 
[90] 
Nanotherapeutic platforms 
(Wicki, 2015) 
Lipid based nanocarriers: 
 Solid lipid nanoparticle 
 Stealth liposome 
 
[29] 
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Source Terms (not official categories) (cont.) Reference 
Nanotherapeutic platforms (cont.) 
(Wicki, 2015) 
 Liposome 
Drug conjugates: 
 Antibody-Drug conjugate 
 Polymer-Drug conjugate 
 Polymer-Protein conjugate 
Polymer based nanocarriers: 
 Polymeric micelles 
 Nanoparticle Albumin bound Technology (Nab) 
 Polymeric nanoparticle 
Inorganic nanoparticles: 
 Silica Nanoparticle 
 Metal Nanoparticle 
 Hafnium Oxide Nanoparticle 
Viral nanoparticle 
cont. [29] 
Nanoparticle strategies 
(Gupta, 2011) 
Liposomes 
Micelles 
Polymer nanospheres and nanoshells/nanocapsules 
Ultrasound-sensitive nanostructures 
Au nanospheres and nanoshells 
Dendrimer nanostructures 
Magnetically sensitive nanostructures 
 
Base nanoparticle : 
 Liposomes 
 Micelle 
 Polymer particle 
 Gold particle or shell 
 Ultrasound sensitive bubble 
 Dendrimer 
 Iron oxide particle 
 Quantum dot 
Hybrid constructs 
[91] 
Nanoparticles 
(Ozcelikkale, 2013) 
Polymer nanoparticle 
Liposome 
Polymeric micelle 
Carbon nanoparticle 
Quantum dot 
Gold nanoparticle 
Iron oxide nanoparticle 
[92] 
Nanomaterials 
(Zhao, 2011) 
Carbon black nanoparticle 
Carbon nanotube 
Cerium oxide 
Chitosan  
Cobalt  
Copper oxide  
Fullerene derivative  
Gold nanoparticle  
Multi walled nanotube 
Nanocarrier 
Nanoceramic 
Nanocomposite 
Nanofiber 
Nanomaterial 
Nanoparticle 
Nanorod 
Nanoscroll 
[93] 
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Source Terms (not official categories) (cont.) Reference 
Nanomaterials (cont.) 
(Zhao, 2011) 
Nanotube 
Nanowire 
Nickel nanoparticle 
Platinum 
Poly n isopropylacrylamide 
Polymer 
Quantum dot 
Silicon dioxide nanoparticle 
Silver nanoparticle 
Single walled nanotube 
Titanium dioxide 
Unclassified drug 
Zinc oxide 
Cont. [93] 
Nanoparticles 
(Zarbin, 2010) 
Carbon nanotube 
Dendrimer 
Fullerene 
Nanoceria 
Liposome 
Micelle 
Polyplex 
Dendrimer 
Gold nanoparticle 
Quantum dot 
Superparamagnetic iron oxide) 
Nanowires 
Nanostructured scaffolds (nanowires and other support matrices with 
defined nanoscale features). 
[94] 
Nanocarriers 
(Godin, 2010) 
Neutral liposomes 
Cationic liposomes 
Hemaglutin virus of Japan (HVJ) liposomes 
Perfluorocarbon nanoparticles 
Polyelectrolyte nanoparticles (RNA or polyvinyl sulfate with 
polyethylene imine/DNA complex) 
Polymeric (PLA or PLGA) 
Nanoparticles 
[95] 
Nanomedicine technologies taxonomy 
(Freitas Jr, 2005) 
Raw nanomaterials: 
 Nanoparticle coatings 
Nanostructured materials: 
 Cyclic peptides 
 Dendrimers 
 Detoxification agents 
 Fullerenes 
 Functional drug carriers 
 Nanobarcodes 
 Nanoemulsions 
 Nanofibers 
 Nanoparticles 
 Nanoshells 
 Carbon nanotubes 
[96] 
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Source Terms (not official categories) (cont.) Reference 
Nanomedicine technologies taxonomy (cont.) 
(Freitas Jr, 2005) 
 Noncarbon nanotubes 
 Quantum dots 
Nanopores: 
 Nanofiltration membranes 
Nanopores 
Cont. [96] 
Types of nanoparticles 
(Emerich, 2007) 
Ceramic nanoparticles 
Dendrimers 
Hydrogels 
Liposomes 
Micelles 
Nanocrystals 
Polymer nanoparticles 
Solid lipid nanoparticles 
[97] 
Nanosized oral lipid-based drug delivery 
systems 
(Dening, 2016) 
Nanosized oral lipid-based drug delivery systems. 
 Self-emulsifying formulations 
 Lipid-based micelles 
 Liposomes 
 Solid lipid nanoparticles (SNLs) 
 Mucoadhesive hydrogel 
 Nanostructured lipid carriers (NLCs) 
 PCL nanocapsules and submicron emulsions 
 Lipid nanovesicles 
Oral polymer-based nanocarriers. 
 Polymeric micelles 
 Polymeric nanoparticles 
[98] 
Types of nanoformulations 
(Moss, 2014) 
Inorganic nanoparticles 
Organic-inorganic nanoparticle 
Solid drug nanoparticle 
Dendrimer 
Nanoemulsion 
Liposomes 
[99] 
Nanomaterials (nanoparticles) 
(Abeer, 2012) 
Liposomes 
Polymer nanoparticles (nanospheres and nanocapsules) 
Solid lipid nanoparticles 
Nanocrystals 
Dendrimers 
Fullerenes 
Inorganic nanoparticles 
[100] 
Type of nanomedicines 
(Fattal, 2014) 
Lipids: 
 Liposome 
 Nanoemulsion 
 Solid lipid nanoparticles 
Polymers: 
 Nanosphere 
 Nanocapsule 
 Polymeric micelles 
[28] 
Nanodrugs 
(Markman, 2013) 
Lipid-based nanoparticles (liposomes) 
Polymer-conjugate 
Dendrimers 
Carbon-based nanoparticles 
Metallic and magnetic nanoparticles 
[101] 
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Source Terms (not official categories) (cont.) Reference 
Types of contrast agents 
(Mody, 2009) 
Liposomes 
Micelles 
Dendrimer 
Magnetic polymeric nanohybrids 
Fullerenes 
Nanotubes 
[102] 
Polymer-based nanomedicine 
(Park, 2008) 
Polymer-based nanomedicine 
 Polyethyleneimine (PEI) 
 Poly(L-lysine) (PLL) 
 Synthetic biodegradable polycations 
 Chitosan 
Polymeric micelles: 
 PEG– poly(amino acid) 
 PEG– polyester 
 PEG– lipid 
 Polysaccharides 
Others: 
 Liposomes 
 Microparticles 
 Self-aggregates 
 Nanoparticles 
Polymer–drug conjugates 
[30] 
Inorganic hollow nanoparticles and 
nanoparticles 
(Son, 2007) 
Carbon nanotube 
Hollow nanoshells 
Porous nanospheres 
Nanotube 
[103] 
Nanodrugs 
(Markman, 2013) 
Lipid-based nanoparticles (liposomes)Polymer-conjugate 
Dendrimers 
Carbon-based nanoparticles 
Metallic and magnetic nanoparticles 
[101] 
Nanomedicine 
(Martins, 2015) 
Nanoparticles 
Liposomes 
Polymeric Nanocarriers 
Albumin Bound Nanoparticles 
Metallic Nanoparticles 
Drug Conjugates 
[104] 
Theranostic nanomedicines 
(Lammers, 2011) 
Liposomes 
Polymers 
Micelle 
Nanoparticle 
Antibody 
[105] 
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Annex 4 Mapping regulatory authorities' websites 
Table 18 Number of regulatory authorities' webpages crawled for this study  
Authority  URL (English version) #Pages retrieved 
Australian Gov Dep of Health www.tga.gov.au 6,128 
Agência Nacional de Vigilância Sanitária portal.anvisa.gov.br 472 
Health Canada www.hc-sc.gc.ca 15,197 
Ministry of Health, Labour and Welfare, Japan www.mhlw.go.jp/english/ 2,248 
Ministry of Food and Drug Safety, Korea www.mfds.go.kr/eng/ 87 
Federal Service for Surveillance in Health Care www.roszdravnadzor.ru/en 70 
Health Sciences Authority, Singapore www.hsa.gov.sg/content/hsa/en.html 487 
Swiss Agency for Therapeutic Products www.swissmedic.ch/index.html?lang=en 35,368 
US Food and Drug Administration www.fda.gov 76,754 
Food and Drug Administration, Taiwan www.fda.gov.tw/EN/ 4,052 
European Medicines Agency www.ema.europa.eu 4,704 
European Commission, DG Growth ec.europa.eu/growth/index_en.htm 71,783 
European Commission , DG Health http://ec.europa.eu/health/index_en.htm 3,383 
Website crawling and data collection June 2016 
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Table 19 Keyword frequency (number of documents) of final keyword set analysis in the 
regulatory authorities' dataset.  
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aerosol  structural entity 48 4 5 323 1 50   2 182 51 666 9 
aggregation  characterisation 11  26 86 9 33 3  3 3 14 188 9 
borderline 
products  
general 5 1 4   4    8 1 23 6 
cancer 
nanomedicine  
characterisation    1        1 1 
cancer 
nanotechnology  
characterisation    2        2 1 
carbon black 
nanoparticle  
structural entity      4      4 1 
carbon nanotube  structural entity 1   10 3 4      18 4 
carbonbased 
nanoparticles  
structural entity    1        1 1 
cationic liposome  structural entity    2        2 1 
coating  chemical 
processing 
2485 2 8 323 9 147   1 89 19 3083 9 
colloid  structural entity 1 1 1 82  56 1   38 17 197 8 
colloidal gold  structural entity    4  2      6 2 
combination 
products  
general 4  20 48417 3 45 4   14 48 48555 8 
conjugate  chemical 
processing 
 14 50 279 8 33    12 46 442 7 
conjugation  chemical 
processing 
 1 1 31 10 33    11 5 92 7 
delivery system  general 3 3 1 427 10 53 2  5 233 35 773 10 
deliverysystem  general          2  2 1 
dendrimer structural entity 1   5        6 2 
dls  characterisation 3   8 1     13  25 4 
dustiness  characterisation 1           1 1 
dynamic light 
scattering  
characterisation    5 1       6 2 
emulsion  chemical 
processing 
4  23 146 14 23    658 24 892 7 
fullerene  structural entity    8 3       11 2 
functionalisation  chemical 
processing 
2           2 1 
gold nanoparticle  structural entity    10 3       13 2 
hafnium  structural entity 1           1 1 
hydrogel  structural entity    48  10    150 6 214 4 
hydrosol  structural entity    3        3 1 
iron oxide  structural entity 1   44  86   8 4 5 148 6 
iron oxide 
nanoparticle  
structural entity    4        4 1 
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Table 19 (cont.) 
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laser light scattering  characterisation    2 3       5 2 
lipid emulsion  structural entity    5  2    16  23 3 
lipid nanoparticle  structural entity    1        1 1 
liposome  structural entity   22 150 6 8    2 5 193 6 
magnetic iron oxide  structural entity      1      1 1 
magnetic nanoparticles  structural entity    2        2 1 
mean particle size  characterisation    1 3 1      5 3 
mesoporous silica  structural entity     2       2 1 
metal nanoparticle  structural entity     2       2 1 
metallic nanoparticle  structural entity    2   1     3 2 
micelle  structural entity 1  3 6 19 3    1 4 37 7 
microbubble  structural entity   1 16  2      19 3 
microemulsion  structural entity   2 4 6      1 13 4 
microparticle  structural entity    44 8 4    3 1 60 5 
nano  general 11 9  78 2 15   1 16 2 134 8 
nanobased  general  1 1 2  2      6 4 
nanobio  general    1        1 1 
nanobiophotonic  general    1        1 1 
nanobiotechnology  general    3        3 1 
nanobody  structural entity    1        1 1 
nanocapsule  chemical 
processing 
1    2     2  5 3 
nanocarrier  structural entity     1       1 1 
nanoceria  structural entity    2        2 1 
nanocolloidal  structural entity   11 1      48  60 3 
nanocomposite  structural entity 3   3        6 2 
nanocrystal  structural entity    3  2      5 2 
nanodispersion  structural entity    1        1 1 
nanodrug  general    1        1 1 
nanoemulsion  chemical 
processing 
1   1        2 2 
nanoenabled  general 3           3 1 
nanoengineered  general    6        6 1 
nanofilter  chemical 
processing 
   2        2 1 
nanogold  structural entity    3        3 1 
nanohealth  general    4        4 1 
nanohybrid  general    1        1 1 
nanoiron  structural entity    1 2       3 2 
nanoliposomal  structural entity    2        2 1 
 91 
 
 
Table 19 (cont.) 
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nanomaterial  general 277 39 2 127 16 41  1   3 506 8 
nanomedicine  general 2 1 8 16 2 2    9 2 42 8 
nanomedicines  general   713 2  1    4 1 721 5 
nanometre  general 1 2 3   8     4 18 5 
nanomicroarray  general    3        3 1 
nanoobject  structural entity 1   1        2 2 
nanoparticle  structural entity 11 13 8 110 38 21 1   50 26 278 9 
nanopharmaceutic  general    4        4 1 
nanoporous  structural entity    1        1 1 
nanoprobe  structural entity    1        1 1 
nanoproduct  general  2  1  2      5 3 
nanorelated  general     6       6 1 
nanorelease  characterisation      2      2 1 
nanosafety  general 1           1 1 
nanoscale  general 5 2 2 53 10 16    48 2 138 8 
nanoscience  general 2 3  4 2 4      15 5 
nanoscopy  general    1        1 1 
nanosensor  general 3   1 1       5 3 
nanosight  general    2        2 1 
nanosilver  structural entity  4  9 2 4      19 4 
nanosimilar  general   4         4 1 
nanosize  general    1       1 2 2 
nanosized  chemical 
processing 
 3 1 6 2 3     2 17 6 
nanosphere  structural entity    10        10 1 
nanostencil  structural entity    1        1 1 
nanostructure  general 5   10 6 2     1 24 5 
nanosurfaces  characterisation    1        1 1 
nanosuspension  chemical 
processing 
     2      2 1 
nanosystem  structural entity   1 1        2 2 
nanotechnology  general 141 45 711 360 18 80    76 13 1444 8 
nanotherapeutic  general   3 3        6 2 
nanotoxicity  general    15 6 2    1 2 26 5 
nanotube  structural entity 1   13 3 8      25 4 
nanowire  structural entity  1  1        2 2 
non biological complex 
drugs  
general    1        1 1 
particle size 
distribution  
characterisation 1   27 3 13    4 13 61 6 
personalized medicine  general 5  2 259 4 5    6  281 6 
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Table 19 (cont.) 
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photocatalytic 
activity  
characterisation  1    2      3 2 
polymer  structural entity 75 1 7 268 23 71 1   118 41 605 9 
polymer 
therapeutics  
structural entity   1         1 1 
polymeric 
nanoparticle  
structural entity     2      1 3 2 
prodrugs  general    6 4 1      11 3 
protein corona  characterisation    3        3 1 
protein 
nanoparticle  
structural entity    1        1 1 
quantum dot  structural entity 1   11 3 11     2 28 5 
regenerative 
medicine  
general 2  9 57  1   1 8  78 6 
silica nanoparticle  structural entity    1 2 1      4 3 
silver nanoparticle  structural entity  2  19 4 4      29 4 
solgel  structural entity 2           2 1 
solid lipid 
nanoparticle  
structural entity    1        1 1 
specific surface 
area  
characterisation 1     2      3 2 
stability in vitro  characterisation    1        1 1 
stealth liposome  structural entity    1        1 1 
superparamagnetic 
iron oxide  
structural entity    1  3      4 2 
surface 
characteristics  
characterisation 3 1  14      4  22 4 
surface 
modification  
characterisation     1      1 2 2 
surface 
morphology  
characterisation    3        3 1 
targeted delivery  general  1  7  1      9 3 
targeted drug 
delivery  
general    3        3 1 
targeting  chemical 
processing 
30 50 31 372 11 71 1  67 56 25 714 10 
theranostic  general 3  1 2 2     1  9 5 
theranostic 
nanomedicine  
general    1 2       3 2 
tissue engineering  general 2  710 40 3     61 3 819 6 
virosome  structural entity   3       25  28 2 
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Annex 5 Description of selected nanomedicine terms 
In this annex, descriptions of general and specific terms were presented and selected as 
a result of the bibliometric analysis, literature review and the mapping of different 
information sources.  
In order to compile descriptions of the selected terms several types of documents were 
considered, including (1) webpage: when the term is directly mentioned in webpage 
sections, with or without an explicit given definition (i.e., definitions given in the text 
context); (2) reports: when the term is mentioned in scientific or regulatory reports 
authored by the authority; (3) presentations authored by the regulatory authority. The 
content does not necessarily represent the official opinion of the institution itself; (4) 
glossaries or terminology: documents including glossaries or suggested terminologies; 
(5) official documents: this category includes legal texts, and (6) guidance documents 
authored by the regulatory authority and representing its official opinion. 
It is outside the scope of this report to propose an official terminology or establish an 
official nomenclature to describe materials or products used in the area of nanomedicine. 
A5.1  Nanomedicine 
Table 20 List of descriptions in English of the term nanomedicine 
Source Descriptions for the term nanomedicine Type of 
document 
Australia 
Therapeutic Goods 
Administration (TGA) 
(Australia) 
When used in therapeutics, nanotechnologies have been defined as the application of 
nanotechnologies (or nanomedicine) for making a medical diagnosis or treating disease.  
Webpage  
[36] 
Canada 
Parliament of Canada 
(House of Commons)  
Nanomedicine is the use of an intervention that is at a molecular scale of 1 to 100 
nanometres (nm) inclusive to treat a disease or restore function.  
Report 
[106] 
Canada 
Health Canada 
The Canadian Institutes of Health Research broadly defines nanomedicine as the 
specialized measurement or intervention - at a molecular scale - needed to treat 
disease or restore function. This definition is meant to be inclusive of techniques and 
methodologies relevant to health research that does not necessarily fit within the 
narrower definitions of nanotechnology or nanomaterials. Outside of assessing 
possible contaminants or by-products of manufacturing products, Health Canada does 
not regulate technologies, or whole areas of medicine, but focuses on its regulatory 
responsibilities regarding substances, products, and applications of technology. (Source: 
Canadian Institutes of Health Research) 
Webpage 
[107]  
Canada 
Government of 
Canada TERMIUM 
Plus®  
Description 1: Application of nanoscience and nanotechnologies techniques in the field 
of medicine.  
Description 2: Nanomedicine is the application of nanotechnology (the engineering of 
tiny machines) to the prevention and treatment of disease in the human body. This 
evolving discipline has the potential to dramatically change medical science. Established 
and near-future nanomedicine applications include activity monitors, chemotherapy, 
pacemakers, biochips, OTC [over-the-counter] tests, insulin pumps, nebulizers, 
needleless injectors, hearing aids, medical flow sensors and blood pressure, glucose 
monitoring and drug delivery systems.  
Glossary  
[54] 
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Table 20 (cont.) 
Source Descriptions for the term nanomedicine Type of 
document 
European Union 
European Medicines 
Agency  
Nanomedicine is defined as the application of nanotechnology in view of making a 
medical diagnosis or treating or preventing diseases. It exploits the improved and often 
novel physical, chemical and biological properties of materials at nanometre scale.  
Report 
[108] 
Nanomedicine, the application of nanotechnology to human healthcare, offers 
numerous potential pathways to improving medical diagnosis and therapy and even to 
regenerate tissues and organs. It can provide personalised yet more affordable 
healthcare while at the same time offering an improved quality of life for everyone.  
Report 
[109] 
France 
Agence Nationale de 
Sécurité du 
Médicament et des 
produits de Santé 
Nanomedicine is one of the most promising nanotechnological applications. It uses new 
physical, chemical and biological properties related to the nanoscale structures of 
nanomaterials.  
Report 
[110] 
Ireland 
Health Products 
Regulatory Authority 
Nanomedicine is defined as the application of nanotechnology to the prevention and 
treatment of disease in the human body. Nanomedicine, an offshoot of nanotechnology, 
refers to highly specific medical intervention at the molecular scale for curing disease or 
of repairing and replacing damaged tissue and cells.  
Newsletter 
[111] 
United Kingdom 
Medicines and 
Healthcare products 
Regulatory Agency 
Application of nanotechnology in healthcare and disease diagnosis and treatment and 
prevention of disease.  
Report  
[112] 
A5.2  Nanomedicines 
Table 21 List of descriptions in English of the term nanomedicines 
Source Descriptions for the term nanomedicines Type of 
publication 
Australia 
Therapeutic Goods 
Administration (TGA) 
Nanomedicines or Therapeutic products containing nanomaterials in the form of 
metal oxides, liposomes, polymer protein conjugates, polymeric substances and 
suspensions have been registered in Australia and/or marketed overseas in the United 
States or the European Union.  
Synonyms used in the TGA: nanotechnology-based drug. products 
Webpage 
[113] 
European Union 
European Medicines 
Agency 
Nanomedicines: The European Medicines Agency has established a working definition 
of nanomedicines defined as purposely designed systems for clinical applications [with] 
at least one component at nano-scale size [and] resulting in definable specific 
properties and characteristics. [Nanomedicines] are related to the specific technology 
application and characteristics for the intended use (route of admin, dose), associated 
with the expected clinical advantages of the nano-engineering (e.g. preferential 
organ/tissue distribution) and needs to meet definition as a medicinal product 
according to European legislation.  
Presentation  
[114] 
Other terms used in EMA's publications are: "medicinal products containing 
nanoparticles", "nanomedicinal products" or "nanotechnology-based medicinal 
products" 
Report  
[108] 
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Table 21 (cont.) 
Source Descriptions for the term nanomedicines Type of 
publication 
Other related terms   
Japan 
Pharmaceuticals and 
Medical Devices 
Agency, Japan (PMDA) 
Nanotechnology-based medicines are anticipating improving the benefit-risk balance 
of drugs. In this project, point to consider for regulatory requirements for 
nanomedicine development is discussed. 
Other terms used for defining nanomedicines in PMDA website are: nanodrug delivery 
systems, nanomedical devices, nanopharmaceuticals, or nanosized drug. 
Nanosized drug: Characteristic of the drug: a. Whether the characteristics of the drug, 
such as extended release or nanosized (physical/chemical property, biological activity, 
etc.), are similar to those of approved drugs. 
Webpage 
[115] 
United States 
U.S. Food and Drug 
Administration (FDA) 
Nano-sized drug products, such as nanoemulsions, protein-drug complexes and iron 
colloids, are complex drug products that require comprehensive physicochemical 
characterization to gain insight into product quality that can eventually affect in vivo 
performance. 
In June 2014, FDA issued final guidance for industry titled “Considering Whether an 
FDA-Regulated Product Involves the Application of Nanotechnology” [48]. As described 
in that guidance, at this time, when considering whether an FDA-regulated product 
involves the application of nanotechnology, FDA will ask: (1) whether a material or end 
product is engineered to have at least one external dimension, or an internal or surface 
structure, in the nanoscale range (approximately 1 nm to 100 nm); and (2) whether a 
material or end product is engineered to exhibit properties or phenomena, including 
physical or chemical properties or biological effects, that are attributable to its 
dimension(s), even if these dimensions fall outside the nanoscale range, up to one 
micro meter (1,000 nm). The agency will apply these considerations broadly to all FDA-
regulated products, including food substances. For purposes of this guidance, FDA used 
terms and phrases such as “nanotechnology products” or “products that involve the  
application of nanotechnology” to refer to products that contain or are manufactured 
using certain materials in the nanoscale range, as well as products that contain or are 
manufactured using certain materials that otherwise exhibit related dimension-
dependent properties or phenomena.” 
 
Webpage 
[116] 
 
 
Guidance 
 [48] 
Canada 
Government of Canada 
TERMIUM Plus®21 
Nanodrug: Nanotechnology has excellent potential in revolutionizing Health Care 
industries. The reduction in size of pharmaceutically active ingredients should increase 
the stability and bioavailability of the drug. The nanodrug delivery systems will have 
extraordinary features such as targeted ultracontrolled release of drugs vis-a-vis 
existing drug delivery systems. 
Glossary  
[54] 
  
                                           
21 The Government of Canada’s terminology and linguistic databank. 
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A5.3  Nanomaterial 
Table 22 List of descriptions in English of the term nanomaterial 
Source Descriptions for the term nanomaterial Type of 
document 
Canada 
Health Canada 
Health Canada has a working definition of nanomaterial. As stated in Health Canada 
webpage, this working definition is a tool to help the Department gather safety 
information about nanomaterials.  
Health Canada considers any manufactured product, material, substance, ingredient, 
device, system or structure to be nanomaterial if:  
 It is at or within the nanoscale in at least one spatial dimension, or;  
 It is smaller or larger than the nanoscale in all spatial dimensions and exhibits 
one or more nanoscale phenomena. 
For the purposes of this definition: 
 The term "nanoscale" means 1 to 100 nanometres, inclusive; 
 The term "nanoscale phenomena" means properties of the product, 
material, substance, ingredient, device, system or structure which are 
attributable to its size and distinguishable from the chemical or physical 
properties of individual atoms, individual molecules and bulk material; and, 
 The term "manufactured" includes engineering processes and control of 
matter and processes at the nanoscale.  
Health Canada adds an explanatory note on biological substances, structures and 
processes are at the nanoscale: "Materials that either naturally exist within the 
nanoscale size range, or exhibit nanoscale properties/phenomena in nature will not 
automatically be re-classified as nanomaterials (e.g. naturally occurring chemical or 
biological molecules like nucleic acids/DNA/proteins, micro-organisms or cell structures 
like flagella or ribosomes, etc.). Health Canada currently regulates some biotechnology-
based health products, and at this time, Health Canada has no reason to reconsider 
those products as nanomaterials if they simply fall within the nanoscale." It also 
specifies: "Biotechnology incorporates products that are biologically sourced or use 
biological systems in their manufacturing."  
Webpage  
 [117] 
Canada 
TERMIUM Plus® 
(Government of 
Canada) 
A material with any external dimension in the nanoscale or having internal structure or 
surface structure in the nanoscale range.  
Glossary 
 [54] 
European Union The European Commission has provided an advisory definition of nanomaterial that 
contemplates special circumstances for medicinal products and medical devices. 
Commission Recommendation on the definition of Nanomaterial: ‘nanomaterial’ 
means a natural, incidental or manufactured material containing particles, in an 
unbound state or as an aggregate or as an agglomerate and where, for 50 % or more of 
the particles in the number size distribution, one or more external dimensions is in the 
size range 1-100 nm. Fullerenes, graphene flakes and single-wall carbon nanotubes with 
one or more external dimensions below 1 nm shall be considered as nanomaterials. 
 
Official 
document 
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Table 22 (cont.) 
Source Descriptions for the term nanomaterial Type of 
document 
European Union (cont.) 
The legal text of this recommendation indicates that: (16) It may in some cases be 
necessary to exclude certain materials from the scope of application of specific 
legislation or legislative provision even if they fall within the definition. It may likewise 
be necessary to include additional materials, such as some materials with a size smaller 
than 1nm or greater than 100 nm in the scope of application of specific legislation or 
legislative provisions suited for a nanomaterial. Regarding the pharmaceutical sector 
the recommendation text indicates that (17) Given the special circumstances prevailing 
in the pharmaceutical sector and the specialised nano-structured systems already in use, 
the definition in the Recommendation should not prejudice the use of the term 'nano' 
when defining certain pharmaceuticals and medical devices*. 
*Medical devices: 
The new Regulation of the European Parliament and of the Council on medical devices 
(EU) 2017/745, and amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and 
Regulation (EC) No 1223/2009 states that: In order to ensure a high level of health 
protection, free movement of goods and legal certainty for manufacturers, it is 
necessary to introduce a uniform definition for nanomaterials based on Commission 
Recommendation 2011/696/EU of 18 October 2011 on the definition of nanomaterial, 
with the necessary flexibility to adapt this definition to scientific and technical progress 
and subsequent regulatory development at Union and international level.  
The definition provided in the new legal text is: ‘nanomaterial’ means a natural, 
incidental or manufactured material containing particles in an unbound state or as an 
aggregate or as an agglomerate and where, for 50 % or more of the particles in the 
number size distribution, one or more external dimensions is in the size range 1-100 
nm; Fullerenes, graphene flakes and single-wall carbon nanotubes with one or more 
external dimensions below 1 nm shall also be deemed to be nanomaterials; 
The use of nanomaterials in medical devices would have also a direct impact in the 
classification of devices: unless the nanomaterial is encapsulated or bound in such a 
manner that cannot be releases, devices incorporating nanomaterials will be in class III 
(Chapter 3, 6.7 Specials rules). 
Official 
document 
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Table 22 (cont.) 
Source Descriptions for the term nanomaterial Type of 
document 
United States 
U.S. Food and Drug 
Administration (FDA) 
FDA has no regulatory definition for nanomaterial. 
FDA states in the final guidance titled “Considering Whether an FDA-Regulated Product 
Involves the Application of Nanotechnology”: “when considering whether an FDA-
regulated product contains nanomaterials, or otherwise involves the application of 
nanotechnology, FDA will ask:  
(1)  Whether a material or end product is engineered to have at least one external 
dimension, or an internal or surface structure, in the nanoscale range (approximately 1 
nm to 100 nm); 
 and  
(2) Whether an material or end product is engineered to exhibit properties or 
phenomena, including physical or chemical properties or biological effects, that are 
attributable to its dimension(s), even if these dimensions fall outside the nanoscale 
range, up to one micrometer (1,000 nm).”   
This final guidance also set forth a rationale for each element within these two points 
FDA will consider. 
In this final guidance for industry, FDA uses the term “nanomaterial” generally to refer 
to both materials in the nanoscale range and certain materials that otherwise exhibit 
related dimension-dependent properties or phenomena. Use of the term “nanomaterial” 
is for the purpose of communicating FDA’s current thinking elaborated in this document 
only and does not establish a regulatory definition.  
Guidance  
[48] 
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A5.4  Nanotechnology 
Table 23 List of descriptions in English of the term nanotechnology 
Source Descriptions for the term nanotechnology Type of 
documents 
Australia 
Australian Therapeutic 
Goods Administration 
(TGA) 
The term nanotechnology is used to describe a wide range of methods involved in the 
production and engineering of structures and systems by controlling size and shape at the 
nanometre scale. When used in therapeutics, nanotechnologies have been defined as the 
application of nanotechnologies (or nanomedicine) for the purpose of making a medical 
diagnosis or treating disease.  
Webpage  
[36] 
Canada 
Health Canada (HC) 
Nanotechnology is a field of science and technology that involves the manipulation of 
matter at a very small scale, the nanoscale. At the nanoscale (where 1 nanometre is only a 
billionth of a metre) matter exhibits chemical and physical properties which differ from the 
properties of bulk materials and single atoms or molecules.  
Webpage  
[118] 
Nanotechnology is the application of scientific knowledge to manipulate and control 
matter in the nanoscale to make use of size- and structure-dependent properties and 
phenomena distinct from those associated with individual atoms or molecules or with bulk 
materials. The term "nanoscale" is defined as 1 to 100 nanometers (nm) inclusive.  
Webpage  
[37] 
A precise molecule-by-molecule control of products and by-products in the development 
of functional structures. From the Latin nanus = "dwarf", so it literally means "dwarf 
technology". The word was originally coined by Norio Taniguchi in 1974, to refer to high 
precision machining. However, Richard Feynman and K. Eric Drexler later popularized the 
concept of nanotechnology as a new and developing technology in which humans 
manipulate objects whose dimensions are approximately 1 to 100 nanometers. 
Theoretically, it is possible that in the future a variety of human-made "nano-assemblers" 
(that is, tiny [molecular] machines smaller than a grain of sand) could manufacture those 
things that are produced in factories today. For example, enzyme molecules function 
essentially as jigs and machine tools to shape large molecules as they are formed in 
biochemical reactions. The technology also encompasses biochips, biosensors and 
manipulating atoms and molecules in order to form (build) bigger, but still microscopic 
functional structures and machines.  
Webpage  
[119] 
European Union 
European Medicines 
Agency (EMA) 
Nanotechnology is the use of tiny structures - less than 1,000 nanometres across - that are 
designed to have specific properties. Nanotechnology is an emerging field in science that is 
used in a wide range of applications, from consumer goods to health products.  
Webpage 
[43] 
Nanotechnology is defined as the production and application of structures, devices and 
systems by controlling the shape and size of materials at nanometre scale. The nanometre 
scale ranges from the atomic level at around .2 nm (2 Å) up to around 100 nm.  
Report  
[12] 
France 
Agence nationale de 
sécurité du médicament et 
des produits de santé  
Nanotechnology refers to the manipulation and control matter on a nanoscale to make 
use of size- and structure-dependent properties and phenomena distinct from those 
associated with individual atoms, molecules or bulk materials. The terms "manipulation 
and control" include material synthesis. Nanotechnologies therefore involve the 
production of structures, devices and systems using processes that allow the material to 
be structured on a nanoscale. 
Report 
[110] 
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Table 23 (cont.) 
Source 
Descriptions for the term nanotechnology Type of 
documents 
United States 
U.S. Food and Drug 
Administration (FDA) 
FDA has not established regulatory definitions of “nanotechnology,” “nanomaterial,” 
“nanoscale,” or other related terms. 
Nanotechnology is an emerging technology that can be used in a broad array of FDA-
regulated products, including medical products (e.g., to increase bioavailability of a drug), 
foods (e.g., to improve food packaging) and cosmetics (e.g., to affect the look and feel of 
cosmetics). Materials in the nanoscale range (i.e., with at least one dimension in the size 
range of approximately 1 manometer (nm) to 100 nm) can exhibit different chemical or 
physical properties, or biological effects compared to larger-scale counterparts. 
 
Guidance 
[48] 
 
A5.5  Nanoscale 
Table 24 List of descriptions in English of the term nanoscale 
Source Descriptions for the term nanoscale Type of 
documents 
Health Canada 
 
TERMIUM Plus® 
(Government of Canada)® 
Means 1 to 100 nanometres, inclusive.  
 
A size range of approximately 1 to 100 nm.  
Webpage 
[120] 
Glossary 
[54] 
European Union 
European Medicines 
Agency (EU) 
The nanometre scale ranges from the atomic level at around 2 nm (2 Å) up to around 100 
nm.  
Report  
[12] 
Switzerland 
Swissmedic 
The term nanoscale is defined within the description of nanoparticles: The particles have 
at least one dimension on the nanoscale (1-1000 nm) plus a function and / or mode of 
action based on nanotechnology characteristics.  
Official 
document  
[39] 
United Kingdom 
The Royal Society & The 
Royal Academy of 
Engineering 
Nanoscale (which was defined to be from 100 nm down to the size of atoms 
(approximately .2nm)) because it is at this scale that the properties of materials can be 
very different from those at a larger scale.  
Report 
[121] 
United States 
U.S. Food and Drug 
Administration (FDA) 
Materials in the nanoscale range (i.e., with at least one dimension in the size range of 
approximately 1 nanometer (nm) to 100 nm) can exhibit different chemical or physical 
properties, or biological effects compared to larger-scale counterparts.  
Guidance 
[48,] 
 
U.S. Patent and Trademark 
Office: Cooperative Patent 
Classification (CPC) 
On B82, classification for nano-technology: 
"nano-scale" relate to a controlled geometrical size below 100 nanometres (nm) in one or 
more dimensions. 
Website 
[122] 
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A5.6  Nanostructure 
Table 25 List of descriptions in English of the term nanostructure 
Source Descriptions for the term nanostructure Type of 
document 
Canada 
TERMIUM Plus® 
(Government of Canada) 
Having an internal or surface structure in the nanoscale range. (Reference number ISO/TS 
80004-4:2011(E)) 
Glossary 
[54] 
Cooperative Patent 
Classification (CPC) 
On B82, classification for nano-technology: 
"nano-structure" means an entity having at least one nano-sized functional component that 
makes physical, chemical, or biological properties or effects available, which are uniquely 
attributable to the nano-scale. 
Website  
[122] 
A5.7  Nanosimilars 
This term was initially proposed by EU regulators and it is referred in the EMA website as 
nanomedicines that are claimed to be similar to a reference nanomedicine22.  
A5.8  Nanoparticle 
Table 26 List of descriptions for the term nanoparticle 
Source Descriptions for the term nanoparticle Type of 
document 
Regulatory Authorities   
Australia 
Therapeutic Goods 
Administration (TGA) 
A nanoparticle is a particle within the nanoscale range of 1 to 100 nanometres in size; a 
nanometre is one millionth of a millimetre. (Original source: Referenced OECD 
definition).  
Webpage  
[123] 
Canada 
TERMIUM Plus® 
(Government of Canada) 
A nano-object with all three external dimensions in the nanoscale. 
In biomedical applications nanoparticles are used as drug carriers or imaging agents. For 
this purpose the nanoparticle may have a hollow structure providing a central reservoir 
that can be filled with anticancer drugs, detection agents, or chemicals, known as 
"reporters," that can signal if a drug is having a therapeutic effect. The surface of a 
nanoparticle can also be adorned with various targeting agents, such as antibodies, 
drugs, imaging agents, and reporters. Most nanoparticles are constructed to be small 
enough to pass through blood capillaries and enter cells.  
Glossary  
[54] 
European Union 
European Medicines 
Agency 
No description found for nanoparticle. 
[Public summary of opinion on orphan designation on Nanoparticle albumin-bound 
paclitaxel for the treatment of pancreatic cancer]: the paclitaxel is attached to a human 
protein called albumin in tiny particles known as ‘nanoparticles’.  
Report  
[124] 
 
 
 
 
                                           
22 European Medicines Agency webpage: 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/08/news_detail_001
875.jsp&mid=WC0b01ac058004d5c1 (Retrieved 10 April 2018) 
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Table 26 (cont.) 
Source Descriptions for the term nanoparticle Type of 
document 
France 
National Agency for the 
Safety of Medicine and 
Health Products 
A nanoparticle is a nano-object with three external dimensions on a nanoscale. 
Nanoparticles are not all spheres but may have the shape of needles, extended rods, 
spring structures, etc.  
Report  
[110] 
Switzerland 
Swissmedic: Swiss Agency 
for Therapeutic Products 
(Synthetic nanoparticles) The particles have at least one dimension on the nanoscale (1-
1000nm) plus a function and / or mode of action based on nanotechnology 
characteristics. 
This definition is included in the form "Application for authorisation / Variation of human 
medicines", in which the applicant should declare whether the medicinal product 
contains nanoparticles.  
Official 
document [39] 
Other sources   
ISO 
Nanoparticle: nano-object23 with all three external dimensions in the nanoscale 
NOTE If the lengths of the longest to the shortest axes of the nano‑object differ 
significantly (typically by more than three times), the terms nanorod or nanoplate are 
intended to be used instead of the term nanoparticle. [DD CEN ISO/TS 27687:2009, 4.1] 
Updated to ISO/TS 80004-2:2015. 
Standard 
terminology 
Taiwan 
Taiwan Food and Drug 
Administration 
Description of nanoparticle in the CMC technical review checklist proposal: 
Nano-object with all three external dimensions at the nanoscale that is the size range 
from approximately 1 nm to 100 nm. Polymeric nanoparticle platforms are 
characterized by their physicochemical structures including solid nanoparticles, 
nanoshell, dendrimer, polymeric micelle, and polymer-drug conjugates. [49] 
Peer-reviewed 
article  
 
BioPortal NCIT: A small, stable particle whose size is measured in nanometers. These particles are 
used in various biomedical applications in which they can be utilized as drug carriers or 
imaging agents. Various targeting agents, such as antibodies, drugs, imaging agents, and 
reporters can be attached to the surface of a nanoparticle. 
[Nanoparticle Type]: The classification of discrete nanoparticle entities. 
[Nanoparticle Topology]: The structural motif of a nanoparticle that is defined by the 
spatial relationship of the constituent atoms. 
[Nanoparticle Complex]: A nanoparticle bound to another moiety of interest via a 
chemical or physical interaction. 
 
Webpage 
 [126] 
 
 
 
 
 
                                           
23 nano-object: material with one, two or three external dimensions in the nanoscale. NOTE Generic term for all 
discrete nanoscale objects. [DD ISO/TS 80004-1:2010, 2.5] 
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Table 26 (cont.) 
Source Descriptions for the term nanoparticle Type of 
document 
BioPortal (cont.) 
(Cont.) 
[Nanoparticle Application]: The utilization of small (<100 nm), stable particles in a 
variety of technologies. Based on an understanding of chemical, biological and physical 
phenomena at the nanoscale level, processes are employed to create new nanoparticle 
technologies. 
MeSH: Nanometer-sized particles that are nanoscale in three dimensions. They include 
nanocrystalline materials; nanocapsules; metal nanoparticles; dendrimers, and 
quantum dots. The uses of nanoparticles include drug delivery systems and cancer 
targeting and imaging.  
Any crystalline structure possessing dimensions measured in terms of nanometers. 
Nanometer-sized particles that are nanoscale in three dimensions. They include 
nanocrystalline materials; nanocapsules; metal nanoparticles; dendrimers, and quantum 
dots. The uses of nanoparticles include drug delivery systems and cancer targeting and 
imaging. 
NPO: A primary particle which has an average size in the nanoscale range; which has an 
identifiable and definite chemical composition, property or function that uniquely define 
the nanoparticle's type as known; and, which may or may not exhibit a size-intensive 
property. Definition is partly based on ASTM E 2456-06 (Terminology for 
Nanotechnology). 
The type of nanoparticles mentioned in this ontology are: fluorescence NP (nanoparticle 
which has fluorescence property), fluorescent NP, doxorubicin-loaded NP, 
hydroxyapatite NP, core-shell NP, metal NP, polymeric NP, one-dimensional NP, 
tamoxifen-loaded NP, chitosan NP, biopolymer-coated NP, water-soluble NP, 
etoposide-loaded NP, NP characterization, bimetallic NP, gelatin NP, lipid NP, PLGA NP 
(nanoparticle which is basically composed of poly(lactic-co-glycolic acid) polymer), 
superparamagnetic NP, drug-loaded NP, lipid-coated NP, paclitaxel-loaded NP, two-
dimensional NP, PEGylated NP (a nanoparticle which has a coating agent composed of 
polyethylene glycol.), methotrexate-loaded NP, hydrogel NP (nanoparticle which exists 
while dispersed in a hydrogel), polymer-coated NP, gadolinium-loaded NP, three-
dimensional NP, gold NP, silver NP, carbohydrate-coated NP, spherical NP, or 
biodegradable NP. 
[nanoparticle component]: A chemical component which is identified as a nanoparticle 
based on its structure, chemical composition or function. 
[nanoparticle imaging] NIFSTD: An imaging assay that makes use of the unique 
properties of nanoparticles to elucidate specific targets in an image. 
Webpage 
 [126] (cont.) 
A5.9  Magnetic nanoparticles (SPIO, SPION, USPION) 
Table 27 List of descriptions for the term magnetic nanoparticles 
Source Descriptions for the term magnetic nanoparticles Type of 
document 
BioPortal NCIT: Superparamagnetic iron oxide nanoparticle (SPIO or SPION). Nanoparticles that 
have been functionalized with chemical amine groups and dextran. These particles have 
been utilized as magnetic resonance imaging agents and as probes to investigate 
thrombosis and tumor vasculature in conjunction with a CREKA peptide (cys-arg-glu-lys-
ala). Synonym: Amino Dextran-Coated Iron Oxide Particle. 
Webpage 
[126] [127] 
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Table 27 (cont.) 
Source Descriptions for the term magnetic nanoparticles Type of 
document 
BioPortal (cont.) NPO: An iron oxide nanoparticle which has superparamagnetic property. 
MeSH: Ferumoxsil. A large superparamagnetic iron oxide colloid; a miscible darkening 
agent; see also the dextran-coated superparamagnetic iron oxides - ferumoxides and 
ferumoxtran. 
Webpage 
[126] [127] 
Scientific literature Paramagnetic particles are important tools for cell sorting, protein separation, and single-
molecule measurements. The particles used in these applications must meet the following 
requirements: uniform in size, highly paramagnetic, stable in physiological salt buffer, 
functionizable, and 100-1000 nm in size. [128] 
Peer-reviewed 
article 
 
Synonyms Metal-based nanoformulations. Ultrasuperparamagnetic iron oxide nanoparticles 
(USPION) 
 
A5.10  Metal nanoparticles 
Table 28 List of descriptions for the term metal nanoparticles 
Source Descriptions for the term metal nanoparticles 
Type of 
document 
BioPortal MeSH Definition: Nanoparticles produced from metals whose uses include biosensors, 
optics, and catalysts. In biomedical applications the particles frequently involve the noble 
metals, especially gold and silver. 
NPO Definition: A nanoparticle which is basically composed of a metal. 
 
Webpage 
[126] 
A5.11  Polymer therapeutics 
Table 29 List of descriptions for the term polymer therapeutics 
Source Descriptions for the term polymer therapeutics Type of 
document 
Scientific literature 
The term “polymer therapeutics” was coined to describe polymeric drugs, polymer 
conjugates of proteins, drugs and aptamers, together with those block copolymer micelles 
and multicomponent non-viral vectors which contain covalent linkages. These often 
complex, multicomponent constructs are actually “drugs” and “macromolecular prodrugs” 
in contrast to drug delivery systems that simply entrap (non-covalently) therapeutic 
agents. 
Polymer–drug conjugates are drug delivery technologies in which a drug is covalently 
bound to a polymeric carrier, normally via a biodegradable linker. 
Types: Polymeric drugs (dendrimers); Polymer-Protein conjugate; Polymer-drug 
conjugates. 
Peer-reviewed 
article 
[129] 
Synonyms Polymeric conjugates, polymer-based nanomedicines, polymer-drug conjugates, polymer 
therapeutics, polymer-protein conjugates, polymer-drug conjugates, Polymer based 
delivery.  
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A5.12  Polymeric nanoparticle 
Table 30 List of descriptions for the term polymeric nanoparticle 
Source Descriptions for the term polymeric nanoparticle Type of 
document 
ISO polymer nanoparticle dispersion: mixing of nanoparticles (2.6) into a liquid polymer matrix 
which is solidified to produce a polymer matrix nanoparticle composite (ISO/TS 80004-
8:2013(en), 6.5.12) 
Standard 
BioPortal NPO Definition: A nanoparticle which is basically composed of polymer. (National Cancer 
Institute 2016 
Webpage 
Scientific literature Polymeric therapeutics: Describe polymeric drugs, polymer-drug conjugate, polymer-
protein conjugates, polymeric micelles to which drug is covalently bound and those multi-
component polyplexes with covalent linkages being developed as non-viral vectors.  
The authors state that to coin biomaterials (as proteins) and non-covalent drug delivery 
systems as polymer therapeutics is a misguided step in the Regulatory Authority 
positioning. [130]  
Polymer nanoparticles are perhaps the most influential biodegradable and biocompatible 
carriers. They have good surface modification potential, provide excellent pharmacokinetic 
control and are suitable for the entrapment of a wide range of therapeutics. Several 
formulations exist including those made from PLGA, PLA, PGA, gelatins, and chitosan. 
Some polymers exhibit cytotoxicity due to cell internalization and breakdown. Large-scale 
manufacturing is difficult and expensive but FDA-approved products exist including 
Abraxane. [97]  
Biodegradable polymer nanoparticles include chitosan nanoparticles, poly(ethylene glycol) 
(PEG) nanoparticles, and polylactide-co-glycolic acid (PLGA) nanoparticles. [128]  
Polymer nanoparticles Solid nanoparticles that consist of natural or synthetic polymers 
(Size: 100–1,000 nm). [131]  
Polymeric nanoparticles (polymer-drug conjugates): Drugs are conjugated to the side 
chain of a linear polymer with a linker (cleavable bond). [76] 
Peer-reviewed 
article 
 
 
 
 
 
 
 
 
A5.13  Polymeric micelle (block copolymer micelle) 
Table 31 List of descriptors for the term polymeric micelle 
Source Descriptions for the term polymeric micelle Type of 
document 
Regulatory Authorities 
  
European Union 
European Medicines 
Agency  
Block copolymer micelles: 
Block copolymer micelles are self-assembled micelles, and they are typically prepared from 
AB block copolymers. […] An active substance can be incorporated into the inner core of 
the block copolymer micelle product by chemical conjugation or by physical entrapment.  
Block copolymers with amphiphilic character spontaneously assemble into polymeric 
micelles in aqueous media, hydrophobic interactions typically drive this self-association. 
However, other driving forces may be used to promote micelle formation and enhance 
micelle stability. 
Report 
[132] 
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Table 31 (cont.) 
Source Descriptions for the term polymeric micelles Type of 
document 
Other sources 
  
BioPortal PDQ (Physician Data Query Terminology): 
Paclitaxel-loaded polymeric micelle: A biodegradable poly(ethylene glycol)-poly(D,L-
lactide) copolymer micelle nanoparticle-entrapped formulation of paclitaxel with 
antineoplastic properties. Paclitaxel promotes microtubule assembly and prevents 
depolymerization, thus interfering with normal mitosis. The copolymer residue increases 
the water-solubility of paclitaxel and allows delivery of higher doses than those achievable 
with paclitaxel alone. 
Webpage 
[126] 
Scientific literature Block copolymer micelles OR polymeric micelles: 
Micelles are biocompatible nanoparticles varying in size from 50 to 200 nm in which poorly 
soluble drugs can be encapsulated, which represents a possible solution to the delivery 
problems associated with such , and could be exploited to target the drugs to particular 
sites in the body, potentially alleviating toxicity problems. [128] 
 A block copolymer contains hydrophilic compartments (such as polyethylene glycol (PEG), 
polyacrylic acid (PAA)) and a hydrophobic compartment (such as polystyrene (PS), 
polybutylene (PB), polylactic acid (PLA)), which induces the controlled aggregation of block 
copolymers due to hydrophobic interactions in aqueous media. The polymeric building 
blocks can assemble into various architectures, including micelles of different sizes and 
shapes, and vesicles, which are of great interest in theranostics, because the chemical 
composition, total molecular weight and the block length ratios can be fine-tuned to 
produce well-defined nanocarriers with certain size and morphology. [85]  
Polymeric micelles consist of self-assembled polymeric amphiphiles tailored for controlled 
delivery of hydrophobic drugs. Through careful design of the hydrophobic/hydrophilic 
balance in the amphiphile, the size and morphology of the assembled micelles can be 
controlled. The internal core is hydrophobic and can be used to encapsulate poorly water 
soluble drugs, whereas the exterior surface is polar enough to allow dissolution in aqueous 
solution. The use of block copolymers as the amphiphiles has led to lower critical micelle 
concentration (CMC) and thus higher stability in comparison to traditional surfactant-based 
micelles. [84] 
Block copolymers are a type of macromolecule of chemically different segments 
connected via their terminal groups. There exist three basic structural types for block 
copolymers (Fig. 9). The first is the A–B structure, so-called diblock, with A and B being two 
different repeating units. A block of repeating units A is thereby connected to a block of 
units B. The second type is an A–B–A or A–B–C structure, called a triblock. A block of B is 
enclosed between blocks on either side. The third type is a multiblock in the style of (A–
B)n, where blocks of A and B are repeated to form areas of repeating units A and B. A 
special sub-group of block copolymers are radial block-copolymers. These are formed by 
two or more block copolymers radiating out from a central hub, forming star-shaped 
macromolecules with a pre-designed symmetry. In comparison to random copolymers, 
block copolymers exhibit well defined structures and their synthesis requires sequential 
architecture. [72]  
Supramolecular aggregates composed of amphiphilic block copolymers that self-assemble 
into aqueous media; inner core typically serves as a container for hydrophobic drugs (Size: 
20–80 nm). [131] 
 
Peer-reviewed 
article 
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Table 31 (cont.) 
Source Descriptions for the term polymeric micelles Type of 
document 
Scientific literature 
Polymeric micelles are nanoparticles formed upon self-assembly of amphiphilic (block co-
)polymers in aqueous solutions. The resulting structure is a usually spherical nanoparticle 
with a hydrophobic core acting as a reservoir for poorly soluble active pharmaceutical 
ingredients (APIs) and a hydrophilic shell which provides colloidal stability and limits 
protein adsorption and opsonisation, resulting in long-circulation times. [133] 
Amphiphilic block copolymers assemble and form a micelle with a hydrophobic core and 
hydrophilic shell. [76] 
Peer-reviewed 
article 
 
A5.14  Solid lipid nanoparticle 
Table 32 List of descriptions for the term solid lipid nanoparticle 
Source Description for the term solid lipid nanoparticle Type of 
document 
Scientific literature SLNs comprise a solid hydrophobic core of lipids, such as mono-, di- and triglycerides or 
fatty acids with a monolayer of phospholipid coating (Kaur et al., 2008). Like polymeric 
nanoparticles, they are capable of controlled release of up to several weeks and can also 
be coated or grafted with ligands for drug targeting (Kaur et al., 2008). They are also stable 
and biodegradable under physiological conditions (Barbu et al., 2009) with a high drug 
loading capacity for both hydrophilic and lipophilic drugs (Yadav et al., 2014). 
Peer-reviewed 
article 
[134] 
A5.15  Albumin-bound nanoparticle 
Table 33 List of descriptions for the term albumin-bound nanoparticle 
Source Description for the term albumin-bound nanoparticle Type of 
document 
Scientific literature The nanoparticle albumin-bound (nab) platform uses albumin to shuttle hydrophobic 
therapeutics. Albumin is a ubiquitous serum protein that naturally carries molecules in the 
bloodstream, attached by reversible noncovalent binding. 
Peer-reviewed 
article  
[73] 
A5.16  Liposome 
Table 34 List of descriptions for the term liposome 
Source Descriptions for the term liposome Type of 
document 
Regulatory Authorities 
  
European Union 
European Medicines 
Agency (EMA)  
Liposomes are classically described as artificially prepared vesicles composed of ions or more 
concentric lipidic bi-layers enclosing one or more aqueous compartments. They include, but 
are not limited to, moni- and multi-lamellar liposomes, multi-vesicular-liposomes and 
polymer-coated liposomes.  
Nanoliposomes: In this medicine, irinotecan is contained within tiny fat particles called 
‘nanoliposomes’.  
Report 
[135] 
[54, 136] 
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Table 34 (cont.) 
Source Descriptions for the term liposome Type of 
document 
Regulatory Authorities 
  
Canada 
TERMIUM Plus® 
 (Government of 
Canada) 
A vesicle formed by the homogenization (emulsification) of phospholipids in dilute salt 
solutions. Most are uniform-sized spheres of lipid bilayers that can be isolated from the 
suspending solution as a clear, separate phase. Liposomes are the prototypes of membrane-
bound biologic structures.  
Webpage 
[54] 
FDA Liposome drug products (LDP) contain drug substances encapsulated in lipid bilayer 
microvesicles designed for prolonged release and/or targeted delivery of drugs. (Center for 
Drug Evaluation and Research; Research Programs).  
Webpage 
[137] 
Taiwan 
Taiwan Food and Drug 
Administration 
Vesicles composed of one or more bilayers of amphiphatic lipid molecules enclosing one or 
more aqueous compartments.  
Peer-
reviewed 
article 
[49] 
Other sources 
  
British Standards 
Institution 
Stealth Liposome: liposome that has been specially designed to avoid detection by body's 
immune system. Note 1 Stealth liposomes are particularly designed to avoid detection within 
the reticuloendothelial system. Note 2 Detection avoidance is commonly achieved by the 
studding of the outside of the membrane with polyethylene glycol (PEGylation) which is inert in 
the body and so permits a longer circulation for drug delivery. [PAS 131:2007, 4.27]  
Terminology 
[138] 
BioPortal MeSH: Artificial, single or multilaminar vesicles (made from lecithin or other lipids) that are 
used for the delivery of a variety of biological molecules or molecular complexes to cells, for 
example, drug delivery and gene transfer. They are also used to study membranes and 
membrane proteins. 
NCIT: Substances composed of layers of lipid that form hollow microscopic spheres within 
which drugs or agents could be contained for enhanced safety and efficacy [139]. 
NCI-GLOSS: A very tiny, fat-like particle that is made in the laboratory. In medicine, liposomes 
containing drugs or other substances are used in the treatment of cancer and other diseases. 
Drugs given in liposomes may have fewer side effects and work better than the same drugs 
given alone. 
CRISP: single or multilaminar vesicles (made from lecithin or other lipids) that can be used for 
the delivery of a variety of biological molecules or molecular complexes to cells, for example, 
drug delivery and gene transfer; also used to study membranes and membrane proteins. 
NPO: A supramolecular structure which is a closed vesicle that forms on hydration of dry 
phospholipids above its transition temperature. This definition is also used in eNanoMapper 
ontology. 
Webpage 
[126] 
Scientific literature The sealed concentric microscopic shells formed when certain lipid substances are in an 
aqueous solution. [See also micelles.] [140] 
Liposomes are self-assembled lipid bilayer vesicles, with 20-150 nm diametres for Small 
Unilamellar Vesicles (SUVs) to a few micrometres in diameter for Large Multilamellar Vesicles 
(LMVs). [91]  
Peer-
reviewed 
articles 
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Table 34 (cont.) 
Source Descriptions for the term liposome Type of 
document 
Scientific literature 
(cont.) 
(cont.) 
Liposomes are concentric bilayered vesicles with an aqueous interior surrounded by a 
phospholipid. The amphiphilic nature, ease of surface modification, and good biocompatibility 
profile has made them attractive for increasing the circulating half-life of proteins and 
peptides. Liposomes can be made to stick to a cell to deliver its drug or deliver it via 
endocytosis. Despite a relatively long history of investigation liposomes exhibit limited 
stability and have not made significant medical impact. [97] 
Liposomes are stable microscopic vesicles of natural or synthetic lipids (usually phospholipids). 
Liposomes are formed when amphipathic lipids spontaneously assemble in layer form in 
aqueous medium. Depending on the conditions, multilayer or monolayer vesicles are formed. 
In multilayer vesicles, lipids are either ordered in circular rings with a head-to-tail structure 
with aqueous compartments in between or in a tail-to-tail arrangement with an aqueous 
internal part. The ability to enclose water soluble and lipophilic drugs in the lipid layers as well 
as encompass drugs with intermediate log[thin space (1/6-em)]P makes liposomes ideal 
candidates for drug delivery. In drug delivery by liposomes, cell entry is not happening by 
plasma clearance or tissue disposition, but by fusion or endocytosis, which increases the 
success rate of drug delivery to cells. This trait makes liposomes highly attractive not only for 
drug delivery but also as carriers for enzymes and other proteins into the inner part of the cell. 
Surface charge, hydrophobicity, size, fluidity and packing of lipid layers heavily influence the 
stability and type of protein for binding of liposomes. [72] 
Liposomal formulations […] are spherical, layered vesicles that self-assemble when placed in 
water. They range in size from 50 nm to micrometers, which permits loading with a variety of 
therapeutics, including simultaneous small molecules and macromolecules. Liposomes are 
classically eliminated by the MPS system; however, PEG can be added to the liposome surface 
and significantly enhance circulation half-life, which allows for increased tumor accumulation. 
[73] 
Peer-
reviewed 
articles 
A5.17  Dendrimer 
Table 35 List of descriptions for the term dendrimer 
Source Descriptions for the term dendrimer Type of 
document 
Regulatory Authorities 
  
Canada 
TERMIUM Plus® 
(Government of Canada) 
Complex nanomolecules called dendrimers can be used to map circuits. Developed at the 
Michigan Molecular Institute (MMI) and sold commercially through its affiliate company 
Dendritech, dendrimers are nested molecular spheres. Each layer has a unique 
composition, depending on the dendrimer's function and--most critically for circuit design 
purposes--dendrimers are produced in discrete sizes. [54] 
Glossary 
[54] 
FDA Repeatedly branched, roughly spherical large molecules (FDA-TRACK Research Glossary).  
 
Glossary 
[141] 
Taiwan Food and Drug 
Administration (journal 
article) 
Definition in the CMC technical review checklist: 
A polymer in which the atoms are arranged in many branches and sub-branches along a 
central backbone of carbon atoms. [49] 
Peer-reviewed 
article 
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Table 35 (cont.) 
Source Descriptions for the term dendrimer Type of 
document 
Other sources 
  
ISO Dendrimer: molecule comprising a multifunctional core molecule with a dendritic wedge 
of highly branched monomers regularly attached to each functional site, leading to a 
monodisperse, tree-like, or generational structure (ISO 18115-1:2013(en), 4.159) 
 
British Standards 
Institution 
Repeatedly branched macromolecule.  
NOTE Dendrimers can be configured as a sphere, partial sphere or wedge structure (i.e. 
dendritic wedge). [PAS 136:2007, 5.2] 
Dendritic particle: particle with a highly branched structure.  
NOTE Also referred to as a branched-chain aggregate. [derived from PAS 71:2005, 
definition 3.6]  
Dendron: dendrimer containing a single chemically addressable group. 
NOTE: The single chemically addressable group is known as the focal point. 
Glossary 
[142] 
BioPortal MeSH: Tree-like, highly branched, polymeric compounds. They grow three-dimensionally 
by the addition of shells of branched molecules to a central core. The overall globular 
shape and presence of cavities gives potential as drug carriers and contrast agents. 
Synonyms: Dendritic compounds, dendritic polymers, dendrimers, dendrons, dendrimer, or 
dendritic macromolecule. 
NCIT: A polymeric molecule which has a highly-branched, three-dimensional architecture. 
Dendrimers are synthesized from monomers and new branches are added in discrete 
steps to form a tree-like architecture. A high level of synthetic control is achieved through 
step-wise reactions and purification at each step to regulate the size, architecture, 
functionality and monodispersity of the molecules. These polymers have desirable 
pharmacokinetic properties and a polyvalent array of surface groups that make them 
potential drug delivery vesicles. This definition is shared by NPO, ENM,  
CHEBI: A highly branched macromolecule. This definition is shared in NBO and 
BIOMODELS. 
[Dendritic polymer]: A polymer substance composed of dendritic macromolecules. 
Webpage 
[126] 
Scientific literature Dendrimers are artificial, polymer-based molecules formed from monomers such that 
each layer of branching units doubles or triples the number of peripheral groups (i.e. they 
look like a foam ball). The void area within a dendrimer, its ease of 
modification/preparation, and size control offer great. Potential for targeted gene and 
drug delivery. Improvements in cytotoxicity profiles, biocompatibility and biodistribution 
are needed [97]. The first description the term dendrimer and the method of preparation 
of poly(amidoamine) dendrimers [143]. 
Dendrimers, hyper-branched polymers of the twenty-first century, are described as three-
dimensional polymers, which are organized into very symmetrical and mono-dispersed 
arrays. [144] 
There are various types of dendrimers: 
 Poly(amidoamine-organosilicon) dendrimers (PAMAMOS) 
 Poly(amidoamine) dendrimers (PAMAM) 
 Poly(propylene imine) dendrimers (PPI) 
 Chiral dendrimers 
 Liquid crystalline dendrimers 
 Tecto dendrimers 
 Hybrid dendrimers 
 Micellar dendrimers 
Peer-reviewed 
articles 
 111 
 
 
A5.18  Carbon nanotube 
Table 36 List of descriptions for the term carbon nanotube 
Source Descriptions for the term carbon nanotube Type of 
document 
Regulatory Authorities 
  
Canada 
TERMIUM Plus® 
(Government of Canada) 
A tube-shaped material, made of carbon, having a diameter measuring on the nanometer 
scale. Carbon nanotubes have many structures, differing in length, thickness, type of 
helicity, and number of layers. Although they are formed from essentially the same 
graphite sheet, their electrical characteristics differ depending on these variations, acting 
either as metals or semiconductors. 
Original source: Internet. [http://www.nanocyl.com]. Nanocyl. The Carbon Nanotube 
Specialist. FAQS. "What is a carbon nanotube?" (20120213) 
Webpage 
[54] 
Other sources 
  
ISO nanotube (2.6) composed of carbon (ISO/TS 80004-3:2010(en), 4.3)  
British Standards 
Institution 
Nanotube consisting of carbon. Note: This term is commonly used to refer to a seamless 
tube constructed from graphene that can be either a single-wall carbon nanotube 
(SWCNT), comprising a single layer of carbon atoms 
Terminology 
BioPortal NCIT: Fullerene-like nanostructures that consist of graphene cylinders. The ends of the 
construct are closed with pentagonal-shaped rings. 
Single-Walled Nanotube: A carbon nanotube comprised of a single layer of graphitic 
carbon. These tubes may be metallic or semi-conducting depending on the chirality of the 
tube. 
Double-Walled Nanotube: A carbon nanotube comprised of two layers of graphitic 
carbon. 
Webpage 
[126] 
Scientific literature Refers to any tiny tube composed of carbon, whose diameter is measured in nanometers. 
There are several potential applications for the utilization of carbon nanotubes (CNTs) 
within fields of biotechnology. [60] 
Peer-reviewed 
article 
A5.19  Micelle 
Table 37 List of descriptions for the term micelle 
Source Descriptions for the term micelle Type of 
document 
Regulatory Authorities 
  
Canada 
TERMIUM Plus® 
(Government of Canada) 
Aggregation of surfactant molecules dispersed in a liquid. Note 1: The surfactants 
molecules are often sequestered into hydrophilic and hydrophobic regions. Note 2: 
Micelles are commonly spherical but can also be branched, rods and worm-like. 
Webpage 
[54] 
Taiwan Food and Drug 
Administration 
Vesicles composed of one or more bilayers of amphiphatic lipid molecules enclosing one 
or more aqueous compartments [49]. 
Peer-reviewed 
articles 
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Table 37 (cont.) 
Source Descriptions for the term micelle Type of 
document 
Other sources 
  
ISO Micelle: An aggregate made up of molecules and/or ions, which is formed above a 
certain critical concentration in solutions of surface active agents. (ISO 862:1984(en), 37) 
Reverse micelle process: synthesis of nanoparticles (2.6) in solution using reagents in the 
presence of reaction stopping ligands that attach to the nanoparticle surface and inhibit 
further growth. (ISO/TS 80004-8:2013(en), 6.4.4) 
Standard 
Terminology 
British Standards 
Institution 
Aggregation of surfactant molecules dispersed in a liquid. Note 1 The surfactant 
molecules are often sequestered into hydrophilic and hydrophobic regions. Note 2 
Micelles are commonly spherical but can also be branched, rods or worm-like. [PAS 
131:2007, 4.10]  
Terminology 
[142] 
BioPortal 
NCIT: A multimolecular colloid particle, usually formed by amphipathic molecules in 
solution with the polar group toward the solution and the hydrophobic group toward the 
interior. 
NCI-GLOSS: A tiny particle made of substances that are soluble in water and that come 
together to form a ball-like shape. These particles can carry other substances inside 
them. In medicine, micelles are made in the laboratory and are used to carry drugs to 
body tissues and cells. 
MeSH: Particles consisting of aggregates of molecules held loosely together by secondary 
bonds. The surface of micelles is usually comprised of amphiphatic compounds that are 
oriented in a way that minimizes the energy of interaction between the micelle and its 
environment. Liquids that contain large numbers of suspended micelles are referred to 
as emulsions. 
CRISP: Aggregate of lipids in which the polar head groups face outward and the 
hydrophobic tails face inward. 
NPO: A supramolecular structure which is an aggregate of amphiphilic molecules in a 
polar solvent. 
Webpage 
[126] 
A5.20  Quantum dot 
Table 38 List of descriptions for the term quantum dot 
Source Descriptions for the term quantum dot Type of 
document 
Regulatory Authorities 
  
Canada 
TERMIUM Plus® 
(Government of Canada) 
A crystalline nanoparticle that exhibits size-dependent properties due to quantum 
confinement effects on the electronic states [54]. ISO/TS 27687:2008 
Webpage 
[54] 
Other sources 
  
ISO Quantum dot (QD): crystalline nanoparticle that exhibits size-dependent properties due 
to quantum confinement effects on the electronic states. [SOURCE: ISO/TS 27687:2008, 
definition 4.7] 
Standard 
terminology 
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Table 38 (cont.) 
Source Descriptions for the term quantum dot Type of 
document 
ISO Quantum dot: nanoparticle or region which exhibits quantum confinement in all three 
spatial directions [ISO/TS 80004-13:2017(en), 3.1.1.6] 
Quantum dot: nanoparticle or region which exhibits quantum confinement in all three 
spatial directions [ISO/TS 80004-13:2017(en), 3.1.1.6] 
Standard 
terminology 
British Standards 
Institution 
Discrete nanoscale semiconductor or metal structure that exhibits size-dependent 
electronic and optical properties due to quantum confinement [derived from 
Occupational Ultrafine Aerosol Exposure Characterization and Assessment] [PAS 
131:2007; 4.9]. 
Webpage 
[142] 
British Society for 
Nanomedicine 
Nanometer-sized semiconductor crystals, or electrostatically confined electrons. 
Something (usually a semiconductor island) capable of confining a single electron, or a 
few, and in which the electrons occupy discrete energy states just as they would in an 
atom (quantum dots have been called "artificial atoms"). [CMP] Other terminology 
reflects the preoccupations of different branches of research: microelectronics folks may 
refer to a "single-electron transistor" or "controlled potential barrier," whereas quantum 
physicists may speak of a "Coulomb island" or "zero-dimensional gas" and chemists may 
speak of a "colloidal nanoparticle" or "semiconductor nanocrystal." All of these terms 
are, at various times, used interchangeably with "quantum dot," and they refer more or 
less to the same thing: a trap that confines electrons in all three dimensions. [from 
Hacking Matter: Levitating Chairs, Quantum Mirages, and the Infinite Weirdness of 
Programmable Atoms. Wil McCarthy. February 2003] 
Quantum Dot Nanocrystals (QDNs): used to tag biological molecules, and "measuring 
between five and ten nanometres across, are made up of three components. Their cores 
contain paired clusters of atoms such as cadmium and selenium that combine to create a 
semiconductor. This releases light of a specific colour when stimulated by ultraviolet of a 
wide range of frequencies. These clusters are surrounded by a shell made of an inorganic 
substance, to protect them. The whole thing is then coated with an organic surface, to 
allow the attachment of proteins or DNA molecules. By varying the number of atoms in 
the core, QDNs can be made to emit light of different colours." [From The Economist 
print edition]  
Webpage 
[145] 
BioPortal MeSH: Nanometer sized fragments of semiconductor crystalline material which emit 
photons. The wavelength is based on the quantum confinement size of the dot. They can 
be embedded in microbeads for high throughput analytical chemistry techniques. (2004).  
Synonyms: Nanocrystals, Semiconductor; Semiconductor Nanocrystal; Dot, Quantum; 
Semiconductor Nanoparticles; Semiconductor Nanocrystals; Nanoparticles, 
Semiconductor; Semiconductor Nanoparticle; Nanocrystal, Semiconductor; Dots, 
Quantum; Nanoparticle, Semiconductor; Quantum Dot 
NCIT: Nanometer-sized semiconductor particles made of cadmium selenide (CdSe), 
cadmium sulfide (CdS) or cadmium telluride (CdTe) with an inert polymer coating. The 
semiconductor material used for the core is chosen based upon the emission wavelength 
range being targeted: CdS for UV-blue, CdSe for the bulk of the visible spectrum, and 
CdTe for far red and near-infrared. The size of the particle determines the exact color of a 
given quantum dot. The polymer coating protects cells from cadmium toxicity but also 
facilitates the attachment of a variety of targeting molecules, including monoclonal 
antibodies directed to tumor-specific biomarkers. Because of their small size, quantum 
dots can function as cell- and even molecule-specific markers that will not interfere with 
the normal cellular functions.  
Webpage 
[126] 
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Table 38 (cont.) 
Source Descriptions for the term quantum dot Type of 
document 
BioPortal 
(cont.) 
CHEBI: A nanometre sized semiconducting particle, whose excitons (electron-hole pairs) 
are confined in three spatial dimensions. This definition is shared by NBO and BIOMODELS 
ontologies. 
NPO: A three-dimensional nanoparticle which is made of material that exhibits quantum 
effects. Types described in this ontology: cadmium selenide QD, zinc sulphide QD, and 
gold QD. 
Webpage 
[126] 
Scientific literature QDs composed of semiconductor elements, e.g. CdSe, CdS, CdTe, PbS, PbSe, PbTe, SnTe, 
InAs and InP. [146] 
Quantum dots are nanoscale crystals of semiconductor material that glow or fluoresce 
when excited by a light source such as a laser. QD nanocrystals of cadmium selenide are 
200-10000 atoms wide and coated with zinc sulphide. [128] 
Peer-reviewed 
article 
A5.21  Colloid 
Table 39 List of descriptions for the term colloid 
Sources Descriptions for the term colloid Type of 
document 
Regulatory Authorities 
  
Taiwan Food and Drug 
Administration 
Metal colloid: Metal nanoparticles in colloidal systems where the term colloidal refers to 
a state of subdivision. This implies that the molecules or polymolecular particles are 
dispersed in a medium and have at least in one direction a dimension roughly between 
or, in a system, have discontinuities at distances of that order. For example, silver, gold, 
titanium dioxide, zinc oxide, and iron oxide. [49] 
Peer-reviewed 
article 
Other sources 
  
ISO Colloid: heterogeneous substance consisting of a liquid (dispersion medium) in which 
nanoscale (1 nm to 100 nm) particles are uniformly retained in suspension by their 
electrical charge, and which exhibits Brownian movements and is subject to cataphoresis 
(ISO/TR 13014:2012(en), 2.4) 
Standard 
Terminology 
BioPortal NCIT: A mixture of microscopic particles suspended in some sort of liquid medium. 
CRISP: two-phase systems in which one is uniformly dispersed in another as particles 
small enough so they cannot be filtered or will not settle out; the dispersing or 
continuous phase or medium envelops the particles of the discontinuous phase; all three 
states of matter can form colloids among each other. 
Synonym: ferrofluid, magnetic colloid 
MeSH: Two-phase systems in which one is uniformly dispersed in another as particles 
small enough so they cannot be filtered or will not settle out. The dispersing or 
continuous phase or medium envelops the particles of the discontinuous phase. All three 
states of matter can form colloids among each other. 
NPO: A suspension of particles (dispersed phase) in a liquid medium (dispersion medium 
or continuous phase). 
Webpage 
[126] 
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A5.22  Fullerene 
Table 40 List of descriptions for the term fullerene 
Sources Descriptions for the term fullerene Type of 
document 
Regulatory Authorities 
  
Canada 
TERMIUM Plus® 
(Government of Canada) 
Compound composed solely of an even number of carbon atoms, which form a cage-like 
fused-ring polycyclic system with twelve five-membered rings and the rest six-membered 
rings. 
Webpage 
[54] 
Other sources 
  
ISO Fullerene: molecule composed solely of an even number of carbon atoms, which form a 
closed cage-like fused-ring polycyclic system with 12 five-membered rings and the rest 
six-membered rings (ISO/TR 14786:2014(en), 3.2) 
Standard 
terminology 
British Society for 
Nanomedicine 
Fullerenes: Fullerenes are a molecular form of pure carbon discovered in 1985. They are 
cage-like structures of carbon atoms, the most abundant form produced is 
buckminsterfullerene (C60), with 60 carbon atoms arranged in a spherical structure. 
There are larger fullerenes containing from 70 to 500 carbon atoms.  
Webpage 
[145] 
 
BioPortal NCIT: One of three known pure forms of carbon that exhibits a spherical shape with a 
hollow interior. The number of carbon atoms comprising fullerenes is variable and several 
stable spherical carbon structures containing 70 or more atoms have been documented. 
CHEBI: A compound composed solely of an even number of carbon atoms, which form a 
cage-like fused-ring polycyclic system with twelve five-membered rings and the rest six-
membered rings. The term has been broadened to include any closed cage structure 
consisting entirely of three-coordinate carbon atoms. Other ontologies adopting this 
definition are ENM, NBO, BIOMODELS and SOPHARM. 
SIO: fullerene is a carbon allotrope which takes the form of a hollow sphere, ellipsoid, or 
tube. 
NPO: A fullerene refers to any cagelike, hollow molecule composed of hexagonal and/or 
pentagonal groups of carbon atoms, and it is regarded as the third form of carbon after 
diamond and graphite. 
MeSH: A polyhedral CARBON structure composed of around 60-80 carbon atoms in 
pentagon and hexagon configuration. They are named after Buckminster Fuller because 
of structural resemblance to geodesic domes. Fullerenes can be made in high 
temperature such as arc discharge in an inert atmosphere. 
Webpage 
[126] 
Synonyms bucky-ball, buckeyball, buckey-ball, buckminsterfullerene, footballene C60  
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A5.23  Nanocrystal 
Table 41 List of descriptions for the term nanocrystal 
Source Descriptions for the term nanocrystal Type of 
document 
Regulatory Authorities 
  
Canada 
TERMIUM Plus® 
(Government of Canada) 
Molecular-sized solids formed with a repeating, 3D pattern of atoms or molecules with an 
equal distance between each part. Internet. Original source: [http://www.nanohand.eu]. 
Glossary. (20080207) 
Nanocrystals are aggregates of anywhere from a few hundred to tens of thousands of 
atoms that combine into a crystalline form of matter known as a 'cluster'. Typically 
around 10 nm in diameter, nanocrystals are larger than molecules but smaller than bulk 
solids and therefore frequently exhibit physical and chemical properties somewhere in-
between. Nanocrystals are believed to have potential in optical electronics because of 
their ability to change the wavelength of light. [http://www.nanohand.eu]. Original 
source: Glossary. (20080207) 
Nanocrystalline metal: Magnetic Properties of Nanocrystalline Metals. Nanocrystalline 
materials represent one form of grain boundary engineering which increases the 
intercrystalline volume fraction of a material. It has been shown that this can affect 
mechanical, chemical, magnetic, kinetic and electrical properties. Nanomaterials 
produced by electrodeposition are porosity free and therefore yield their true intrinsic 
properties. However when assessing the intrinsic properties of nanocrystalline 
electrodeposits, microstructural and texture differences must be taken into 
consideration. Original source: (Department of Materials and Metallurgical, Engineering, 
Queen's University, Kingston, ON, Canada), (Department of Metallurgical Engineering, 
McGill University, Montreal, Que, Canada). 
Webpage 
[54] 
Taiwan Food and Drug 
Administration  
Nanoscale solid formed with a periodic lattice of atoms, ions, or molecules. [49] Peer-reviewed 
article 
Other sources 
  
ISO Nanocrystal: nano-object (3.1.3) with a crystalline structure (ISO/TS 20477:2017(en), 
3.1.7) 
Standard 
terminology 
British Standards 
Institution  
nanoscale solid formed with a periodic lattice of atoms, ions or molecules] [PAS 131:2007; 
4.13][142]. This definition is also adopted by the British Society for Nanomedicine. 
Terminology 
BioPortal CHEBI: Crystalline aggregates of atoms (100-10,000 atoms) with a diameter of 
approximately 10 nm. Type of nanocrystals mentioned in the ontology: gold nanocrystal, 
magnesium oxide nanocrystal, and cadmium telluride nanocrystal. This definition is also 
used in the NBO and BIOMODELS. 
Webpage 
[54]  
Scientific literature Nanocrystals are aggregates of molecules that can be combined in a crystalline form of 
the drug surrounded by a thin surfactant coating. High dosages can be achieved and 
poorly soluble drugs can be formulated for improved bioavailability. Both oral and 
parenteral delivery is possible and the limited carrier in the formulation reduces potential 
toxicity. Limitations include poor drug stability. [97] 
Nanoscopic crystal of a hydrophobic parent drug (Size: 50-1000 nm). [131] 
A term that is utilized to refer to any crystalline structure possessing dimensions (e.g. 
overall width) measured in terms of nanometers. [60] 
Peer-reviewed 
articles 
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A5.24  Nanocarrier 
Table 42 List of descriptors for the term nanocarrier 
Source Description Type of 
document 
ISO Nano-object24 or objects which are at larger scale but which carry nanoscale25 payloads 
able to transport a diagnostic or therapeutic agent either on its surface, within its bulk 
structure or within an internal cavity. Note 1: Transport might be target a specified, precise 
location. Note 2: Includes transport of medical payloads to specific cells and tissues, for 
example, anticancer agent, antibiotic, other drug release, or for imaging and sensing 
functions (ISO/TS 80004-7:2011(en), 4.4) 
Standard 
terminology 
A5.25  Nanocapsule 
Table 43 List of descriptors for the term nanocapsule 
Source Description Type of 
document 
ISO nano-object with more than one chemically or structurally distinct wall layer enclosing a 
hollow or solid core and which is designed to carry analytical, therapeutic or image 
enhancing components (ISO/TS 80004-7: 2011-10) 
Standard 
Terminology 
BioPortal MeSH: Nanometer-sized, hollow, spherically-shaped objects that can be utilized to 
encapsulate small amounts of pharmaceuticals, enzymes, or other catalysts (Glossary of 
Biotechnology and Nanobiotechnology, 4th ed). 
NBO: A three-dimensional nanoparticle which consists of a shell and a space, in which 
desired substances may be placed. It can be cylindrical or spherical in shape. 
Webpage 
[126] 
A5.26  Nanoemulsion 
Table 44 List of descriptors for the term nanoemulsion 
Source Description Type of 
document 
Regulatory Authorities 
  
Canada 
TERMIUM Plus® 
(Government of Canada) 
A fluid nanodispersion with at least one liquid nanophase (International Organization for 
Standardization (ISO)).  
Webpage 
[54] 
 
  
 
                                           
24 Nano-object (ISO definition): material with one, two or three external dimensions in the nanoscale. Note: 
generic term for all discrete nanoscale objects. 
25 Nano-scale: size range from approximately 1 nm to 100 nm. Note 1: Properties that are not extrapolations 
from a larger size will typically, but not exclusively, be exhibited in this range. For such properties the size 
limits are considered approximate. The lower limit in this definition (approximately 1 nm) is introduced to 
avoid single and small groups of atoms from being designated as nano-objects or elements of 
nanostructures, which might be implied by the absence of a lower limit. 
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Table 44 (cont.) 
Source Description Type of 
document 
Other sources 
  
ISO 
Nanoemulsion: nanodispersion (2.79) with a liquid matrix and at least one or more liquid 
nano-objects (2.82) (ISO 18451-1:2015(en), 2.80) 
Standard 
Terminology 
BioPortal The National Centre for Biomedical Ontology: Nanoemulsion: A mixture of two 
immiscible substances in which the sizes of the particles in the dispersed phase are 
defined as less than 1000 nm. 
Webpage 
[126] 
Scientific literature Emulsions are formed from two immiscible phases by energy input (e.g. stirring, 
homogenization) and the presence of surfactants to reduce surface tension and stabilize 
the droplets. Emulsions are thermodynamically unstable. As such, phase separation 
occurs in an emulsion, giving back two immiscible phases. [72] 
Oil nanodroplets dispersed within aqueous continuous phase suitable for entrapment of 
hydrophobic drugs (Size: 20–200 nm). [131] 
Peer-reviewed 
article 
A5.27  Nanosuspension 
Table 45 List of descriptors for the term nanosuspension 
Source Description Type of 
document 
Regulatory Authorities 
  
Canada 
TERMIUM Plus® 
(Government of Canada) 
A fluid nanodispersion where the dispersed phase is a solid. The use of the term 
"nanosuspension" carries no implication regarding thermodynamic stability. 
Webpage 
[54] 
ISO Nanosuspension: heterogeneous mixture of materials comprising a liquid and finely 
dispersed solid nano-objects (2.82) (ISO 18451-1:2015(en), 2.86) 
Standard 
terminology 
United States Patent and 
Trademark Office 
Nanosuspensions are dispersions of nanosized drug particles prepared by bottom-up or 
top-down technology and stabilised with suitable excipients. (US PATENT: 9,775,818) 
US patent 
A5.28  Nanocomposite 
Table 46 List of descriptors for the term nanocomposite 
Source Description Type of 
document 
British Standards 
Institution 
Multiphase structure in which at least one of the phases has at least one dimension in the 
nanoscale 
Terminology 
ISO Nanocomposite: solid comprising a mixture of two or more phase-separated materials, 
one or more being nanophase (ISO/TR 18401:2017(en), 3.12). 
Standard 
Terminology 
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Table 46 (cont.) 
Source Description Type of 
document 
BioPortal MeSH: Nanometer-scale composite structures composed of organic molecules intimately 
incorporated with inorganic molecules. Glossary of Biotechnology and Nanobiotechology 
Terms 
NCI Thesaurus: Heterogeneous materials comprised of nanoparticles and plastic resin to 
provide added strength and desirable thermal attributes. Nanocomposites are a class of 
compounds with unique performance profiles with respect to rigidity and transparent 
barrier properties. 
Webpage 
[126] 
A5.29  Nanoaerosol 
Table 47 List of descriptors for the term nanoaerosol 
Source Description Type of 
document 
Regulatory Authorities   
Canada 
TERMIUM Plus® 
(Government of Canada) 
A fluid nanodispersion with a gaseous matrix and at least one liquid or solid nanophase. 
(International Organization for Standardization (ISO)). Glossary [54] 
Nano-aerosol: term related to a category of nanostructured materials, fluid 
nanodispersions. 
Webpage 
[54] 
Other sources   
ISO Nanoaerosol: solid or liquid nano-objects in dispersion in a gaseous medium (ISO 
4618:2014(en), 2.163). 
Standard 
terminology 
Scientific literature Nano-aerosols are nanoparticles suspended in a gas. These nanoparticles could be liquid 
droplets but are usually solid particles with at least one dimension being less than 100 
nm. Most researchers consider nanoaerosol as another name of ultrafine aerosol or 
ultrafine particulate matter. [148] 
Nanoaerosols are defined here as being aerosols comprised of particles that are less than 
200 nm in diameter [149]. In comparison, aerosol particles created by a standard 3-jet 
Collison nebulizer are usually between 1 and 5 μm in diameter. [150] 
Peer-reviewed 
article 
A5.30  Nanobody 
In the EMA webpage two entries were found using the term nanobody for human 
medicinal products. In this document nanobody, is defined as a very small antibody (a 
type of protein)26 . This term is associated to the description of nanomedicine and it 
could be discussed because its biological origin. 
This term has not been mentioned in any other medicine agency webpage, only as part 
of FDA publication references. In this report, nanobodies are used to target lentivirus 
that would transduce to dendritic cells and macrophages (use as immunotherapeutic). 
The debate lies in the classification of this product as nanomedicine or simply as 
biological product.  
                                           
26 European Medicines Agency. Committee for Orphan Medicinal Products. Public summary of opinion on orphan 
designation (2009) 
http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2009/10/WC500006257.p
df 
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Table 48 List of descriptors for the term nanobody 
Source Description Type of 
document 
Scientific literature Refers to the smallest possible portion of an antibody which will bind to an 
antigen/hapten. Although nanobodies are not made naturally (i.e., the body always makes 
complete/full-size antibodies), nanobodies [approximately 120 amino acids in length] can 
be made via genetically engineered cells grown via cell culture. [60] 
Nanobodies, derived from naturally occurring single-chain antibodies, are the smallest 
fragments of naturally occurring heavy-chain antibodies that have evolved to be fully 
functional in the absence of a light chain. [128] 
One order of magnitude smaller that their parent molecules, conventional monoclonal 
antibodies, and thus have a greater stability as well as a reduced chance of causing 
immunogenic response in vivo. [151] 
Nanobodies are the smallest fragments of naturally occurring heavy-chain antibodies that 
have evolved to be fully functional in the absence of a light chain. [152] 
Nanobodies® (Ablynx) are among the smallest known antigen-binding antibody fragments, 
and are derived from the heavy-chain only antibodies that occur naturally in the serum of 
Camelidae. [153] 
Peer-reviewed 
article 
A5.31  Virosome 
Table 49 List of descriptors for the term virosome 
Source Description Type of 
document 
BioPortal NCIT: Virosomes are reconstituted influenza virus (A/Singapore) envelopes. The 
membrane of these vesicles consists of a spherical, unilamellar lipid bilayer. Purified 
influenza envelope glycoproteins (hemagglutinin HA and neuramindase NA) are inserted 
into the lipid bilayer. Virosomes with a bilayer consisting of neutral phospholipids can be 
used as an unspecific or a specific drug carrier system, while positively charged vesicles 
can be used as a transfer system for any genetic materials. 
MeSH: Semi-synthetic complex derived from nucleic-acid free viral particles. They are 
essentially reconstituted viral coats, where the infectious nucleocapsid is replaced by a 
compound of choice. Virosomes retain their fusogenic activity and thus deliver the 
incorporated compound (antigens, drugs, genes) inside the target cell. They can be used 
for vaccines (VACCINES, VIROSOME), drug delivery, or gene transfer. 
Webpage 
[126] 
Scientific literature Reconstituted virion-like lipid bilayer vesicle that contains integrated surface glycoproteins 
that are derived from viruses (Size: 20–150 nm). [131] 
Virosomes were developed from liposomes by combining liposomes with fusogenic viral 
envelope proteins. Unlike viruses, virosomes are not capable of replication but are pure 
fusion-active vesicles. Due to the presence of specialized viral proteins on the surface of 
virosomes, they can be applied to the active targeting and delivery of their content at the 
target site. [154] 
 Protein cages, which are multivalent, self-assembled structures. 
Peer-reviewed 
article 
Synonyms Virus-like particles for gene delivery, Viral nanoparticles.  
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